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Abstract 
Mycobacterium tuberculosis is the causative agent of tuberculosis disease which is a global 
health emergency. Lengthy treatment is required due to the intrinsic resistance of M. 
tuberculosis to most classes of antibiotics and continued survival of drug tolerant persisting 
populations. This tolerance and persistence may be because of pre-existing populations of 
bacteria recalcitrant to treatment through phenotypic mechanisms such as slow growth or non-
replicating persistence; or through genotypic alterations resulting in resistance phenotypes. In 
order to improve treatment, effective in vitro modelling of these populations and factors 
affecting efficacy is essential.  
Cell density, growth rate and growth phase were all found to affect the efficacy of isoniazid and 
rifampicin in this study. M. tuberculosis grown at a high cell density was shown to be less 
susceptible to antibiotic exposure, this was particularly true for rifampicin. Growth phase was 
also considered, in the host, a bacterium is likely to encounter nutrient depletion and enter 
stationary and non-replicating phases. Isoniazid and rifampicin were both less effective the 
longer M. tuberculosis was in culture. This work demonstrated the need for consideration of 
multiple factors when designing and modelling treatment of tuberculosis. 
Using continuous culture M. tuberculosis was grown at a fast (23.1 hours) and slow (69.3) 
doubling times, with and without isoniazid exposure aiming to elucidate the different responses 
these populations may have to antibiotic. Genotypic analyses showed that slow growing bacilli 
developed resistance to isoniazid through mutations specifically in katG codon Ser315 which are 
present in approximately 50–90% of all isoniazid-resistant clinical isolates. The fast growing 
bacilli persisted as a mixed population with katG mutations distributed throughout the gene. 
Phenotypic differences were detected between the populations at the two growth rates 
including expression of efflux mechanisms and the involvement of antisense RNA/small RNA in 
the regulation of a drug-tolerant phenotype.  
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1. Introduction 
Mycobacterium tuberculosis is the causative agent of tuberculosis diseases and is a global health 
emergency. A treatment is available but consists of at least four antibiotics and is lengthy due 
to the intrinsic resistance of M. tuberculosis to most classes of antibiotic, resistance is further 
compounded due to non-compliance. Populations of bacteria may be recalcitrant to treatment 
through phenotypic mechanisms such as slow growth or genotypic alterations resulting in 
resistance. In vitro modelling of these populations and factors affecting efficacy of this treatment 
is essential in order to improve the current treatment regime and evaluate novel antibiotics.  
1.1 Introduction to Mycobacterium tuberculosis 
Mycobacterium tuberculosis is an aerobic, pathogenic, slow growing bacilli. Humans are the only 
reservoir for M. tuberculosis and Robert Koch discovered in 1882 it is the causative agent of 
tuberculosis (TB). M. tuberculosis infection usually affects the lungs leading to pulmonary 
tuberculosis and has been described throughout history, having been referenced by Hippocrates 
as ‘phithsis’. The symptoms of active tuberculosis disease are a persistent cough, fever, weight 
loss, heavy night sweats, fatigue and loss of appetite, TB Alert recommends if a person has 3 or 
more of these symptoms that they should visit their doctor (TBAlert, 2010). Among the infected 
individuals, most do not develop active disease; their immune systems fail to eradicate the 
bacteria, which remain in a dormant state in granulomas for life (Józefowski et al., 2008) . Latent 
tuberculosis infection is defined as infection with M. tuberculosis as manifested by a positive 
immunological test result but without evidence of active disease including symptoms, 
progressive radiographic changes or microbiological evidence of replicating organisms (Lobue 
and Menzies, 2010). This latent phase of tuberculosis can develop into active disease at any 
point and around 10% of people with a dormant tuberculosis infection develop active disease 
and become sources of new infections, infecting on average 10-15 people per year. The 
progression of disease varies according to numerous factors (figure 1.1) and the importance of 
an intact immune response in eradicating the infection cannot be ignored, whether this is 
through age or due to co-infection with other agents.  
Tuberculosis was the principal cause of death by the end of the 19th and beginning of the 20th 
century throughout the world (Ducati et al., 2006). In the twentieth century chemotherapy for 
tuberculosis became available, beginning with the discovery of Para-amino salicylic acid (PAS) 
and thiosemicarbazone in 1943 leading to a treatment for TB; although these agents turned out 
to be bacteriostatic rather than bactericidal. The year 1944 resulted in the use of streptomycin 
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which was the first antibiotic and first bactericidal agent effective against Mycobacterium 
tuberculosis. These advances were swiftly followed by the introduction of isoniazid and the 
rifamycins in the 1950s leading to the closure of most of the sanatoria used for the treatment of 
tuberculosis in the past.  In the late 1970s and early 1980s, tuberculosis rates were declining and 
became regarded by many as a conquered disease (Harries, 2008). 
Today tuberculosis is a global health emergency, there were 6 million new TB cases notified to 
national laboratories in 2014 although it was estimated 9.6 million fell ill with the disease and 
1.5 million people died as a result of TB disease; more than 2 billion people, equal to one-third 
of the world’s population, are infected with TB bacilli and the lifetime risk of developing active 
tuberculosis once infected is around 10% (WHO, 2015). Currently, at least one-third of the 35.3 
million people living with HIV worldwide are infected with latent tuberculosis and persons co-
infected with tuberculosis and HIV are 29.6 times more likely to develop active tuberculosis 
disease than persons without HIV. Tuberculosis Is the most common presenting illness and 
leading cause of death in persons living with HIV  (WHO, 2013) and HIV co-infection is the most 
powerful known risk factor of progression of M. tuberculosis to active disease and increases the 
risk of latent TB reactivation 20-fold (Pawlowski et al., 2012). Cell mediated immunity, including 
CD4+ T-cells, has been shown to be essential for control of M. tuberculosis infection on humans 
and mice after experimental infection (Cooper, 2009) and along with tumour necrosis factor 
(TNF) have been shown to be important in maintaining granuloma organisation. Depletion of 
CD4+ cells is a main feature of  acquired immune deficiency syndrome (AIDs) and granuloma 
formation may fail in individuals with such a compromised immune system (Diedrich and Flynn, 
2011), containment of infection is therefore reduced leading to an increased risk of 
extrapulmonary TB with diffuse lesions across multiple organs. 
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Figure 1.1 Progression of M. tuberculosis infection. Adapted from (Sharma and Mohan, 
2013) 
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1.2 Treatment of Tuberculosis 
1.2.1 Current Regimes 
Mortality rates from tuberculosis infection significantly declined from the early to mid-20th 
century but funding for research dwindled and between 1970 and 1990, drug and vaccine 
developments slowed. With the onset of an AIDs pandemic and resistant strains emerging the 
rates of tuberculosis began to rise and with it, a renewed interest in research and drug 
development (Fogel, 2015). Today the standard chemotherapy for tuberculosis infection 
consists of at least four drugs prescribed for six to nine months (Vilcheze et al., 2007). In the first 
two months of treatment isoniazid, rifampicin, pyrazinamide and ethambutol are prescribed 
followed by a further 4 months of just isoniazid and rifampicin. This regime has not changed for 
decades although the Directly Observed Treatment Short-Course (DOTS) was introduced in 1998 
to address multi-drug resistant tuberculosis (Comas and Gagneux, 2009), the treatment 
algorithm set by the CDC is shown in figure 1.2 demonstrating the use of a combination of 
antibiotics for at least 6 months. 
Currently the standard course of treatment for latent tuberculosis infection is 9 months of 
isoniazid or rifampicin mono treatment for 4 months when the strain is shown to be resistant to 
isoniazid. A course of isoniazid and rifampicin combined for 3 months has been shown to be 
superior to the 9 month isoniazid mono therapy regime with excellent treatment compliance 
(Spyridis et al., 2007). Chemotherapy has two aims, to prevent the emergence of drug resistance 
and to shorten the period of treatment by killing the bacterial population quickly (D. A. 
Mitchison, 2000), this is complicated in M. tuberculosis due to its physiology the in vivo 
environments in which it can survive, it has been speculated that at least four significant 
subpopulations of bacteria exist.  
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These sub-populations include active growers that may be killed by isoniazid, those with 
sporadic metabolic bursts that could be killed by rifampicin, a population with low metabolic 
activity that is considered likely to experience acidic surroundings and hypoxia that may be 
susceptible to pyrazinamide and finally dormant bacilli that are not killed by any current agents 
(Dover and Coxon, 2011). 
1.2.1.1 Isoniazid 
Isoniazid (INH) enters the cell through passive diffusion and kills only dividing bacteria, its action 
is bacteriostatic for the first 24 hours after which the action becomes bactericidal (Jindani et al., 
2003). In the same time frame the mycobacterium cells lose their acid fastness and 
morphological changes such as loss of internal structure, appearance of surface wrinkles and 
bulging occur (Vilcheze et al., 2007) 
Isoniazid is a prodrug that is activated by the catalase-peroxidase enzyme (KatG) encoded by the 
katG gene (Zhang et al., 1992) that generates a range of highly reactive species which then attack 
multiple targets in M. tuberculosis. The reactive species produced by KatG mediated isoniazid 
activation include both reactive oxygen species such as superoxide, peroxide and hydroxyl 
Figure 1.2 The treatment algorithm for active tuberculosis used by the Centers for Disease 
Control and Prevention (CDC) (Centers for Disease Control and Prevention, 2003). CXR – Chest 
X-Ray, AFB – Acid Fast Bacilli, INH – Isoniazid, RIF – rifampicin, PZA – pyrazinamide. 
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radical, nitric oxide and reactive oxygen species such as isonicotinic-acyl radical or anion and 
cation electrophilic species. The primary target of isoniazid inhibition is thought to be the InhA 
enzyme (enoyl-acyl carrier protein reductase), involved in elongation of fatty acids in mycolic 
acid synthesis. The active species (isonicotinic-acyl radical or anion) derived from KatG-mediated 
INH activation reacts with NAD(H) to form an INH-NAD adduct and then attacks InhA (Zhang and 
Yew, 2009)(figure 1.3) 
 
 
  
 
 
Isoniazid is most active within the first 2 days of treatment when treating active disease, it 
appears that isoniazid works most effectively against ‘fast growing’ actively dividing populations. 
When the disease being treated was in a more ‘chronic’ stage with a higher proportion of slow 
Figure 1.3. Mechanism of action of INH in M. tuberculosis. INH is activated by KatG to form 
the INH-NAD adduct. The adduct inhibits InhA, the enoyl-ACP reductase of the fatty acid 
synthase type II system (FASII), which synthesizes mycolic acids (representation of three 
mycolic acid classes). This inhibition results in the inhibition of mycolic acid biosynthesis and 
ultimately cell death. (Vilcheze et al., 2007) 
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growing bacilli, the early bactericidal activity of isoniazid was reduced and the kill prolonged 
(Mitchison 2000). This decline in isoniazid activity after 2 days of exposure was presumed to be 
due to the depletion of the exponentially growing population which isoniazid is most active 
against. Gumbo et al tested this hypothesis and found that the cessation of isoniazid activity was 
due to emergence of resistance to isoniazid not depletion of the exponentially growing 
population. In the guinea pig model of tuberculosis infection it was hypothesised that the 
biphasic killing and decline in early bactericidal activity was due to the emergence of drug 
tolerant persisters and not genotypically mutated bacilli (Ahmad et al., 2009) 
1.2.1.2 Rifampicin 
Rifampicin was introduced as a treatment for tuberculosis in 1968 and greatly shortened the 
duration of the treatment regimen.  Rifampicin diffuses freely into tissues, living cells, and 
bacteria, making it extremely effective against intracellular pathogens like M. tuberculosis.  
The bactericidal activity of rifampicin stems from its interaction with the β-subunit of the RNA 
polymerase enzyme from prokaryotic organisms to inhibit transcription. This interaction 
physically blocks the elongation of the RNA chain (Hartmann et al., 1967) 
Rifampicin is used alongside isoniazid as a bactericidal treatment and is a key anti-mycobacterial 
in the regimen due to its activity against both growing and stationary phase bacilli with low 
metabolic activity, the latter activity is related to its high sterilising activity in vivo correlating 
with its ability to shorten treatment from 12-18 months to 6-9 months (Zhang and Yew 2009). 
The activity of rifampicin is concentration dependent and is strongly time dependent, the early 
bactericidal activity is less than isoniazid but rifampicin is responsible for sterilisation throughout 
the course of treatment (de Steenwinkel et al 2010). As discussed, the activity of isoniazid 
decreases after the first two days of treatment hypothesised to be due to the emergence of 
phenotypic and genotypic isoniazid resistance. The inclusion of rifampicin, with its continuing 
sterilising activity, is to prevent the emergence of resistance by killing the sub-populations of 
isoniazid mutants arising after the initial bactericidal response. 
1.2.1.3 Pyrazinamide and Ethambutol 
The activity of pyrazinamide, unlike any other anti-tuberculosis drug, is low against rapidly 
growing bacilli but increases as the metabolic activity of the bacilli decreases (Mitchison and 
Coates 2004). Pyrazinamide has very good sterilizing activity in vivo but is not active against M. 
tuberculosis under normal culture conditions at close to neutral pH. The pH has to be acidic 
(Zhang and Mitchison, 2003) therefore making studies investigating the efficacy in vitro difficult. 
Pyrazinamide is converted to the active form, pyrazinoic acid and it was widely accepted that 
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both pyrazinamide and pyrazinoic acid did not have a specific target but rather that cellular 
acidification causes inhibition of major processes. Recent studies have shown that both 
pyrazinamide and pyrazinoic acid have several different targets interfering with diverse 
biochemical pathways, especially in the NAD+ and energy metabolism (Stehr et al., 2015) and 
inhibition of the recycling of stalled ribosomes (Shi et al., 2011) 
Ethambutol is a drug that was initially reported to have activity against M. tuberculosis in 1961; 
similar to isoniazid, ethambutol primarily kills actively multiplying bacilli but has very poor 
sterilising activity. The main target of ethambutol appears to be the arabinogalactan 
biosynthesis pathway through inhibition of cell wall arabinan polymerisation (Mikusova et al., 
1995) and has also been reported to inhibit other pathways which include RNA metabolism, 
transfer of mycolic acids into the cell wall and phospholipid synthesis (Kolyva, Anastasia and 
Karakousis, 2012). The bacteriostatic nature of the activity of ethambutol means that it is mainly 
included within the treatment regimen to prevent emergence of resistance to other drugs. 
1.2.1.4 Drug development 
The current regime is far from ideal, with lengthy treatment times, non-compliance and a range 
or side effects and antagonism with therapies for other diseases. The TB drug development 
pipeline is active with a number of strategies including re-evaluation of existing TB drugs to 
optimize their utility; repurposing of drugs registered for non TB indications as components of 
TB drug combinations; development of improved analogues of compounds or drugs with some 
known but limited value for TB; and development of novel chemical entities with new modes of 
action against TB (Mdluli et al., 2015). A new regimen would ideally show rapid bactericidal 
activity and achieve stable cure through potent sterilisation in a shorter time frame than the 
typical 6 months of the current situation. The differing sub-populations present in an M. 
tuberculosis infection, due to differing replication rates, should all be killed. Novel modes of 
action may need to be incorporated to ensure effectiveness against strains that are currently 
resistant to existing drugs. It is also important that any new antibiotics introduced into the 
regime be compatible with anti-HIV agents and remain low cost to be accessible to all high 
burden countries. 
Currently the quinolone class of antibiotics is present in numerous clinical trials, moxifloxacin 
and gatifloxacin are being investigated in Phase III clinical trials as part of a 4 month regime for 
drug sensitive tuberculosis. Ciprofloxacin has demonstrated early bactericidal activity and is 
used in the treatment of multi-drug resistant tuberculosis (MDR-TB) however moxifloxacin has 
a superior activity against pulmonary TB and is less likely to select for resistance, leading to 
further evaluation in clinical studies (O’Sullivan, Hinds, et al., 2008; Wiles et al., 2010)   The 
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quinolones target DNA gyrase in M. tuberculosis, an enzyme required for important cellular 
processes such as replication and transcription, resulting in lethal double stranded DNA breaks. 
Bedaquiline along with a nitroimadazole, delamanid are being evaluated as additions to 
background therapy for MDR-TB. Both these classes of drugs are also in trials with pyrazinamide 
against sensitive and MDR-TB tuberculosis (Mdluli et al 2015). There has also been interest in 
the rifamycin class of antibiotics of which rifampicin is a member. Currently there is a lack of 
compounds entering phase I of the clinical trial process and several target areas have been 
identified including iron acquisition and storage, cholesterol metabolism, central carbon 
metabolism and reactive oxygen species (ROS) generation. The area of ROS is of particular 
interest when considering the persister populations in disease, it has been reported that a small 
change in dissolved oxygen can affect killing of bacterial persisters. The bacteria can be 
phenotypically resistant to most antibiotics but still sensitive to high quantities of radicals which 
is critical within the hypoxic core of the granuloma environment (Grant et al 2012) 
1.2.1.5 Focus on Isoniazid and Rifampicin 
Isoniazid and rifampicin are the two ‘frontline’ antibiotics against M. tuberculosis, present in 
treatment regimens for at least 6 months. This is due to the fact that isoniazid reduces the 
bacterial load by around 95% over the first 2 days of treatment, essential for decreasing the risk 
of transmission of tuberculosis. Isoniazid has excellent early bactericidal activity but its 
effectiveness decreases after this initial period. Rifampicin then becomes important and is 
thought to be active against sporadically active M. tuberculosis, an action crucial for preventing 
relapses; the continued presence of isoniazid serves to limit the emergence of rifampicin 
resistance (Dover and Coxon 2011; Mitchison 2000). 
Pyrazinamide is important within the regimen as it has an ability to kill a subset of bacteria not 
killed by other drugs, those bacteria that are subject to a hypoxic and possibly acidic 
environment. The inclusion of pyrazinamide has shortened the length of treatment from 9 
months to the current 6 months. There is no denying the importance of this drug but it is difficult 
to model in vitro due to the acidic conditions necessary in order for it to become active. 
The high bactericidal activity of isoniazid and rifampicin and the subsequent resistance has made 
these two drugs particularly important, in order to further understand how to treat tuberculosis 
either with novel therapies or existing ones these two antimicrobials need to be understood. 
This study focusses on isoniazid and rifampicin for that reason and the difficulties in working 
with pyrazinamide.  
The differing modes of action between isoniazid and rifampicin are highlighted in sections 
1.2.1.1 and 1.2.1.2. 
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1.3 Physiology of M. tuberculosis and intrinsic antibiotic resistance 
The current inefficient treatment regime available reflects the intrinsic ability of M. tuberculosis 
to resist most common antibiotics. The intrinsic properties of M. tuberculosis leads to drug 
tolerance which is the ability to evade the bactericidal activity of antimicrobial drugs with the 
hallmark of tolerance being bacteriostasis with reduced and delayed bactericidal activity (Wallis 
et al., 1999). The persistence of tuberculous disease and likelihood of relapse may in part be 
determined by drug tolerance. Drug tolerance in M. tuberculosis has traditionally been 
attributed to the impermeability of the cell wall however the situation is more complex.  
1.3.1 The Mycobacterial cell wall 
The mycobacterial cell wall is unique and its low permeability cannot be ignored and 
undoubtedly contributes to the intrinsic resistance.  The exterior of the cell wall is comprised of 
a network of glycopeptidolipids and trehalose dimycolates.  
The cell wall comprises of peptidoglycan as in many bacterial species but with a linked 
arabinogalactan layer and this arabinogalactan layer could serve to limit entry to hydrophobic 
molecules. A bilayer of lipophilic mycolic acid is covalently linked to the arabinogalactan layer, 
mycolic acids are C60-C90 long chain carboxylic acids and this layer limits the penetration of 
hydrophilic molecules. Beyond the hydrophobicity of the mycolic acids, their unusual length and 
characteristic unsaturations of the alkyl chain also contribute to the permeability barrier along 
with unusual cross-linking in the peptidoglycan layer. The different types of unsaturation, which 
may vary across species, likely contribute to the higher or lower permeability of the cell walls of 
different mycobacteria (Wivagg et al., 2014). 
The cell wall cannot be entirely impermeable as nutrients need to enter the cell and waste 
products be excreted meaning there must be other mechanisms being used. Hydrophobic 
compounds penetrate by dissolving into and through the lipophilic cell wall but are slowed by 
the low fluidity and unusual thickness of the unique cell wall (Sarathy et al., 2012). It has been 
hypothesised that this leaves time for activation of resistance related genes (Nguyen and 
Thompson, 2006) 
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Porin like channels are present in the mycobacterial cell wall for nutrient uptake and waste 
excretion, these channels have emerged convergently across mycobacterial species, specific to 
the nature of the organism. These porins have also been shown to be important in transport of 
antibiotics. In Mycobacterium tuberculosis, porins limit the growth rate and therefore antibiotic 
transport, the transport of hydrophilic compounds is also largely facilitated by porins (Sarathy 
et al., 2012). A porin encoding gene from M. smegmatis, mspA, has been shown to increase 
sensitivity to isoniazid, ethambutol and β-lactams when expressed in M. tuberculosis (Stephan 
et al 2004).   
Along with the unique structure of the cell wall, important enzymes are also present, M. 
tuberculosis has strong constitutive β-lactamase activity which combined with the highly 
Figure 1.4 Schematic structure of mycobacterial cell wall, and the synergy of cell wall 
exclusion and internal defence mechanisms in controlling intrinsic antibiotic resistance in 
mycobacteria. Intercalation of hydrophilic arabinogalactan and hydrophobic mycolate 
containing layers creates an extremely impermeable envelope for antibiotic penetration. 
Small molecules and nutrients are transported through porin channels that are deposited   
through these layers. Taken from (Nguyen and Pieters, 2009) 
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impermeable cell wall results in a high resistance to this class of widely used antibiotics. It has 
been shown however that if meropenem is combined with the β-lactamase inhibitor clavalanate 
some activity is evident (Wivagg et al 2014), opening up this class of antibiotics would be 
particular useful in treating drug resistant M. tuberculosis. There is also evidence of efflux pumps 
which use β-lactams as their substrate in M. tuberculosis (Almeida Da Silva and Palomino, 2011) 
1.3.2 Efflux pumps 
Efflux pumps are also a widely studied mechanism for intrinsic and acquired drug resistance in 
both prokaryote and eukaryote species. In M. tuberculosis the role of efflux pumps in intrinsic 
resistance varies depending on antibiotic, around 30% of isoniazid resistant clinical isolates 
cannot be explained compared to 5% of rifampicin resistant isolates (da Silva et al., 2011). Not 
all currently available anti-tuberculous drugs are considered as substrates of efflux mechanisms 
which have a narrow spectrum in M. tuberculosis. This substrate range is however something 
that can rapidly change due to point mutations, as seen in Bacillus subtilis (Klyachko and 
Neyfakh, 1998). Bioinformatic data, particularly transcriptional studies, has shown that some 
efflux pumps are over-expressed in the presence of drugs such as isoniazid and rifampicin (Jiang 
et al., 2008). Simultaneous expression of multiple genes involved in efflux of isoniazid, 
ethambutol and streptomycin signalled probable importance in multi drug resistant tuberculosis 
(Gupta et al., 2010) and these expression profiles have aided in the association of specific efflux 
pumps with their substrates  .  
1.3.3 Antibiotic modification 
Mycobacteria are able to inactivate antibiotics through chemical modifications. The 
aminoglycosides are a group of antibiotics that includes streptomycin. Aminoglycosides can be 
modified using phosphotransferases, nucleotidyltransferases and acetyltransferases, which are 
present across mycobacterial species including M. tuberculosis. Rifampicin can also be 
inactivated by many actinobacteria through glycosylation, phosphorylation and ribosylation 
(Nguyen and Pieters, 2009). Protection against oxygen toxicity through oxidative stress in most 
bacteria is provided by a reducing thiol, glucathione. Actinobacteria produce mycothiol and this 
appears to be unique to this order of bacteria, mycothiol provides resistance to several 
antibiotics such as vancomycin, rifamycin, macrolides, and β-lactams, which is hypothesised to 
be through direct interaction (Buchmeier et al., 2003; Rawat et al., 2002) 
Modification of antibiotic targets has been reported in M. tuberculosis, macrolides such as 
erythromycin and lincosamide antibiotics inhibit bacterial protein synthesis. M. tuberculosis has 
a methyl transferase that methylates the 23S rRNA and lowers the affinity of the antibiotic for 
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ribosomes (Buriánková et al., 2004) causing an intrinsic resistance to these classes of antibiotic. 
Mimicry of an antibiotic target has been highlighted as a mechanim that has potential to lower 
the efficacy of the fluoroquinolone class of antibiotics, MfpA is a molecule that resembles DNA 
and could serve to sequester fluoroquinolones and protect mycobacterial DNA from attack. 
Fluoroquinolones are an entirely synthetic antibiotic and this discovery provides a striking 
example of how evolution has provided bacteria with a perfect adaptability to environmental 
pressures, including human interventions (Nguyen and Pieters, 2009).  
1.3.4 Growth rate and growth phase 
One of the important factors in how M. tuberculosis has become a formidable pathogen is the 
inherent slow growth rate. Doubling times of 16 hours are achievable in optimal laboratory 
conditions but in reality doubling times vary depending on the site and stage of infection, often 
being much slower (Beste et al., 2009). Since virtually all antibiotics preferentially kill rapidly 
replicating bacteria, a slow growth rate poses a problem for treatment. When the cell wall itself 
contains the primary target for drug action a reduction in the relative abundance of the target 
material may reduce the overall susceptibility of the cells. Altering the porin availability of the 
cell wall through reduced growth rate can also slow down the transport of hydrophilic agents 
(Brown et al., 1990). Slowing down replication is an effective way to induce drug tolerance 
against many of the antibiotics that target cell division and cell wall synthesis. 
Tuberculosis has two distinct phases, an acute phase in which bacteria are actively growing and 
a persistent phase in which the bacteria are very slow growing or in a non-replicating state. M. 
tuberculosis can remain in this dormant state for many years leading to latent disease. The 
mechanism behind the ability of M. tuberculosis to remain in a host with a competent immune 
system for decades had puzzled researchers for many years, the observation in mouse models 
that the bacteria causing infection were replicating very slowly or not replicating at all supported 
the hypothesis that it is persistent non-replicating organisms that cause latent tuberculosis 
disease (Rees and Hart, 1961). In this state, the organism is refractory to immune clearance but 
primed for reactivation; treatments are largely inactive against this population of non-dividing 
bacteria allowing the disease to become latent. After reactivation this population becomes 
infectious once again. It has been shown that switching from fast to slow growth is a carefully 
controlled process  in mycobacteria involving a unique set of genes and not simply acceleration 
or deceleration of the same cellular processes (Beste et al., 2009) 
Growth phase can also affect the efficacy of antibiotic in similar ways to the growth rate. Bacteria 
that are exponentially growing and actively dividing are generally the most susceptible phase to 
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antibiotics with cell wall and replication based targets. As populations enter stationary and then 
death phase the proportion of the population that is rapidly dividing or dividing at all decreases 
and therefore the antibiotic susceptibility decreases. In vitro experiments have demonstrated 
that the number of persister cells in a population is directly proportional to the number of 
stationary phase cells inoculated into the culture (Balaban et al., 2004), giving some indication 
as to the importance of the growth phase of an organism when studying antibiotic effects. 
Stationary phase cells of M. tuberculosis have been shown to reduce the sterilising activity of 
isoniazid nearly 1000 fold (Wallis et al., 1999) and whilst rifampicin tends to be more active than 
isoniazid against this population the rates of killing are slowed (Paramasivan et al., 2005). 
1.4 Tolerance and persistence  
There is variability in patient response to therapy even when drug sensitive bacteria are isolated; 
some are cured quickly but in others viable organisms persist in sputum for many months. This 
persistence is despite drug susceptibility in vitro and the risk of relapse is increased in people in 
which sputum sterilisation is delayed (Wallis et al., 1999).  
Antibiotic resistance results in the need for a higher concentration of antibiotic to prevent 
growth; that is, the minimum inhibitory concentration (MIC) is increased. Once the higher 
concentration is achieved, growth of the organisms will cease and killing will begin.  
Tolerant organisms show only small or no changes in MIC but upon exposure to a higher than 
MIC concentration of antibiotic, viability is lost only very slowly (Handwerger and Tomasz, 1985). 
Drug tolerant bacteria respond to an otherwise bactericidal antibiotic as though it were 
bacteriostatic. In the presence of antibiotic the tolerant bacteria cease growing, they do survive 
and can initiate replication once the antibiotic is removed (Levin and Rozen 2006). M. 
tuberculosis has an intrinsic tolerance to most available drugs, using drug degradation and 
modification (e.g. β-lactamases), target modification (methyl-transferases) and target mimicry 
(MfpA resembles DNA and could sequester fluroquinolones) along with the unique cell wall 
structure which functions as an effective barrier (Nguyen and Pieters 2009) as discussed in 
section 1.3. 
1.4.1 Persistence 
Persistence is a non-inherited resistance and the term ‘microbial persistence’ describes a 
phenomenon whereby microorganisms which are drug-susceptible when tested outside the 
body are nevertheless capable of surviving within the body despite intensive therapy with the 
appropriate antimicrobial drug (McDermott, 1958). The rate and extent of killing of bacteria 
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depend on the genetic constitution of the bacterium and also the physiological state (e.g. growth 
rate) of the cells at the time the encounter the antibiotic (Handwerger and Tomasz 1985).  
Persister cells do not remain persisters indefinitely but can spontaneously switch back to the 
normal, non-persistent state and regain the usual sensitivity to antibiotics. Upon switching back, 
they appear, according to previous experimental data to be indistinguishable from normal cells 
(Kussell et al., 2005). It is thought that persistence may be a type of bacterial ‘insurance policy’ 
against stress. In a stressful environment the population either risks proliferation and then death 
or the option to suppress growth and be protected, for example in the presence of isoniazid. 
Reversible adoption of a slowly growing or non-growing state is regarded as a general strategy 
for persistence, this adaptation has been shown at the single cell level in M. tuberculosis 
(Wakamoto et al., 2013). Intrinsic factors such as noisy expression of genes influencing cell fate 
under antibiotic stress such as katG in M. tuberculosis may influence persistence, along with 
extrinsic factors such as oxidative stress due to reactive oxygen species (Balaban, Gerdes et al. 
2013) 
The assumption that persisters are pre-existing in a population before antibiotic exposure is 
based on a single example in E. coli (Balaban et al., 2004) where it was hypothesised that there 
are two types of persister cells. Type I are non-growing cells generated in stationary phase and 
are pre-existing, these persister cells have a negligible spontaneous switching rate from wild 
type to persister during exponential growth. In a batch culture it is thought that the number of 
persister cells is directly proportional to the number of stationary phase cells inoculated into the 
culture. Type II persisters do not originate from passage through stationary phase and the 
number of persisters is determined by the total number of cells and not by the size of the 
inoculums from stationary phase (Balaban et al., 2004).  
If this hypothesis is true in M. tuberculosis populations, both types of persisters will be present, 
the combination of type I and type II ensures a continuous generation of persisters in the wild 
type population during exponential phase and an increase in number after passage through 
stationary phase. Bacteria exit lag phase asynchronously therefore populations will also include 
a subset of cells that have not begun to replicate, bacteria that are in the process of repairing 
DNA damage do not divide whilst the repair processes are underway (Levin and Rozen, 2006). 
This is another source of cells that may be able to persist through stress despite being 
genotypically drug sensitive. 
A small persister sub-population within the larger antibiotic susceptible population has been 
shown to have differential susceptibility to oxidative stress, and was able to be eradicated 
through stimulation of reactive oxygen species (Grant et al., 2012). This work demonstrates that 
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efforts are being made to study and also combat these persisting populations, if successful, the 
length of treatment along with the number of antibiotics required could be reduced. 
Inherent tolerance to many classes of antibiotic make M. tuberculosis difficult to treat which is 
further compounded by its ability to lay dormant in a persistent state brought about by a 
decrease in growth rate and changes in the environment, metabolism and cell wall. Genetic 
resistance to frontline and emerging treatments is also a challenge and focus of much research 
which complicates the development of new therapeutics and regimes. 
 
1.5 Resistance to frontline treatments 
The regime to treat tuberculosis is complex consisting of multiple antibiotics over a long time 
period. Most common antibiotics are ineffective against M. tuberculosis, due to the bacterium 
being naturally resistant to many antibiotics and chemotherapeutic agents. These include β-
lactams, owing to the presence of hydrolytic and drug modifying enzymes such as periplasmic 
β-lactamases and amino glycoside acetyltransferases, drug efflux systems and a hydrophobic 
cell wall that acts as a barrier, making treatment more difficult (Ducati et al, 2006) 
Unlike the situation in other bacteria where acquired drug resistance is generally mediated 
through horizontal transfer by mobile genetic elements, in M. tuberculosis acquired drug 
resistance is caused mainly by spontaneous mutation in chromosomal genes producing the 
selection of resistant strains during sub-optimal therapy (Almeida Da Silva and Palomino, 2011). 
Despite drug susceptibility testing being part of the protocol for tuberculosis case management, 
resistance is still occurring due to previous treatment, non-compliance and improper or 
inadequate regimens. In 2013 3.5% of new and 20.5% of previously treated tuberculosis cases 
were caused by MDR-TB (WHO, 2014) and extensively drug resistant tuberculosis (XDR-TB) has 
been reported by 100 countries, on average 9% of people with MDR-TB have XDR-TB.  
In 2012 it was estimated that less than 25% of MDR-TB cases were detected worldwide (WHO 
2013). Further understanding of the mechanisms behind resistance is not only key to 
understanding the bacterium and developing alternative regimes and treatments but also to 
increase detection of resistant isolates so that they can be properly managed. 
 
1.5.1 Isoniazid 
Isoniazid resistance develops at a rate of 10-5-10-7 mutation/cell division in vitro (Riska et al., 
2000) which is more frequently than for most anti-tuberculosis drugs but has been suggested to 
be lower (~10-8 mutations/cell division) in vivo (Bergval et al., 2009) 
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A decrease in or total loss of catalase/peroxidise activity as the result of katG mutations are the 
most common genetic alterations associated with isoniazid resistance and so far more than a 
hundred mutations in katG  have been reported, with missense and nonsense mutations, 
insertions, deletions, truncations and more rarely full gene deletion leading to mutants with a 
variety of MICs (Almeida Da Silva and Palomino, 2011).   
The most common mutation in the M. tuberculosis katG gene correlating with resistance to 
isoniazid is a single nucleotide polymorphism (SNP) at codon 315, resulting in a coding change 
from the wild type serine (AGC) to threonine (ACC). This mutation greatly reduces the affinity of 
wild type KatG for isoniazid whilst the enzyme maintains reasonably good steady state catalytic 
rates. Poor binding of the drug to the enzyme limits drug activation and brings about isoniazid 
resistance (S. Yu et al., 2003). It has been postulated that this mutation does not incur a fitness 
cost, unlike some other isoniazid resistance mutations, it has been shown that strains with the 
katG S315T mutation were found to be in clusters almost as frequently as susceptible strains 
showing no transmissibility difference (van Soolingen et al., 2000). Downregulation of 
transcription of katG expression has also been shown to be associated with resistance to 
isoniazid (Ando et al., 2011). It has been estimated that globally, 64% of all observed phenotypic 
isoniazid resistance is associated with the katG315 mutation and 19 % in the inhA promoter 
region (Seifert et al., 2015). 
InhA is an enoyl-acyl carrier protein (ACP) reductase, mycobacteria utilise the products of InhA 
catalysis to create mycolic acids, important components of mycobacterial cell walls (Rozwarski 
et al., 1998) and can be seen in figure 1.3. 
An open reading frame (ORF) has been found immediately upstream of inhA in all mycobacteria 
tested thus far. This ORF, a strong homologue of many 3-ketoacyl reductases (KARs) was 
previously designated orf1 and later renamed mabA, due to its probable involvement in mycolic 
acid biosynthesis. Mutations that alter binding affinity of InhA to NAD(H) also ultimately result 
in isoniazid resistance. Overexpression of mabA does not confer the ability to titrate isoniazid, 
this rules out the possibility of MabA being a direct target in vivo for an active isoniazid like 
isonicotinic acyl NADH/NADPH. This conclusion is consistent with the fact that until now no 
mutations have been mapped to the mabA ribosome binding site (RBS) with high frequency and 
also in the inhA ORF with lower but significant frequency (Banerjee et al., 1998). Mutations in 
the putative promoter region of inhA have been demonstrated to result in hyper-expression and 
could lead to resistance due to titration of active isoniazid (isonicotinic acyl-NADH). An M. 
tuberculosis mutant carrying a mutation at -15 (C-15T) has been proposed as inducing 
overexpression of inhA, this mutation has been shown to produce a 20-fold increase in inhA 
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mRNA levels and subsequent InhA protein levels, showing the C-15T inhA promoter mutation 
mediates enhanced transcription of inhA mRNA levels, resulting in isoniazid resistance . 
katG and inhA are the only two genes that have been shown to confer greater than fivefold 
increased susceptibility or resistance to M. tuberculosis upon gene transfer (Vilcheze et al., 2005) 
The mutation described in katG is recessive in nature i.e. restoration of catalase peroxidise 
activity and isoniazid susceptibility is achieved when replaced or complemented with the wild-
type gene. This is consistent with the fact that KatG activates isoniazid. In contrast, 
overexpressed inhA alleles or alleles causing amino acid substitutions within the structural gene 
have been shown to confer isoniazid resistance in a dominant fashion i.e. conferring isoniazid 
resistance when the mutant alleles replace or complement the wild-type gene. This dominant 
nature is consistent with the hypothesis that inhA encodes the target of isoniazid (Vilcheze et 
al., 2005). 
Oxidative stress mechanisms have also been identified as an area of interest for isoniazid 
resistance. The OxyR regulon in members of the family Enterobacteriaceae and other organisms 
is a sophisticated oxidative stress regulatory pathway activated in response to environmental 
challenges (Sreevatsan, Pan, Zhang, Deretic, et al., 1997). M. tuberculosis has numerous 
frameshift mutations and deletions that render it naturally inactive (Deretic et al., 1995) 
therefore the sensitivity of M. tuberculosis to isoniazid is due at least partly to a mutated OxyR 
regulon. Expression of alkyl hydroperoxidase (AhpC) is under the control of this regulon along 
with KatG and it has been hypothesised that upregulation of ahpC could partially or entirely 
compensate for a defective OxyR regulon and in the case of katG mutants, a defective catalase 
hyperoxidase. Mutations in the ahpC promoter sequences in resistant M. tuberculosis may 
account for resistance to isoniazid in those isolates with no mutations in katG or the promoter 
region of inhA. Mutations in ahpC have been detected in isolates with katG mutations and it has 
been suggested that changes to the ahpC promoter are not casually involved in isoniazid 
resistance, rather they act as compensatory mutations occurring as a consequence of loss of 
catalase peroxidase activity (Sherman et al., 1996). Changes in this region are rare however and 
not obligatory in isoniazid resistant organisms, it has been hypothesised that mutations at codon 
315 of katG may still retain adequate residual enzyme activity and therefore do not require 
compensatory AhpC for increased survival. A recent study showed no single mutation in 
the ahpC-oxyR intergenic region had an individual frequency above 1.3%; rather multiple 
mutations (at positions -48, -39, -15, -12, -10, -9, and -6,) in the ahpC-oxyR intergenic region 
occurred at a total cumulative frequency of 5.4% among phenotypically resistant isolates and 
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demonstrated that inclusion of this region increased the detection capacity of isoniazid 
resistance in M. tuberculosis (Seifert et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.2 Rifampicin, Pyrazinamide, Ethambutol and fluoroquinolone resistance 
These antibiotics have been grouped together not because they are less important than 
isoniazid but because unlike isoniazid the resistance mutations to these antibiotics tend to be 
less complex. Resistance to these antibiotics tends to occur within a defined region of one gene 
unlike the complicated situation in isoniazid where mutations in multiple genes and regions have 
been shown to contribute to resistance. 
In greater than 95 % of rifampicin resistant M. tuberculosis isolates mutations are located within 
an 81 base pair section of the rpoB gene (Seifert et al., 2015) these mutations confer 
conformational changes leading to defective binding of the drug and consequently resistance. 
Mutations are dominated by single nucleotide changes, resulting in single amino acid 
Figure 1.5 The mechanism of action of isoniazid (INH), acquisition of resistance and 
combating oxidative stress. DPR; divergent promoter region. Taken from (Rattan et al., 
1998) 
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substitutions although in-frame deletions and insertions also occur at low frequencies. This 
region is known as the rifampicin resistance determining region (RRDR). Mutations at positions 
531, 526 and 516 being the most frequent and causing high level resistance (Zhang and Yew, 
2009) with Ser531 and His526 being documented in more than 70% of rifampicin resistant 
isolates (Rattan et al., 1998). The molecular mechanism of resistance in 4% of the rifampicin 
resistant M. tuberculosis isolates that lack RRDR changes is currently unknown. Resistance to 
rifampicin can be a surrogate marker for multi-drug resistant tuberculosis as can resistance to 
pyrazinamide with an estimated 16.2% of tuberculosis cases and more than half of all MDR-TB 
cases resistant to pyrazinamide globally (Whitfield et al., 2015). Pyrazinamide resistant isolates 
lose pyrazinamidase activity caused by mutations in pncA, the gene encoding pyrazinamidase. 
These changes include missense mutations, upstream presumed regulatory mutations, 
nucleotide insertions and deletions and termination mutations (Sreevatsan, Pan, Zhang, 
Kreiswirth, et al., 1997). The worldwide burden of resistance to pyrazinamide is poorly 
understood and the pyrazinamide drug susceptibility test is technically challenging and rarely 
performed routinely. This is an important antibiotic within the regime as it is thought to be active 
against bacteria with low metabolic rates, an understanding and detection of resistance to this 
antibiotic is important to adequately treat MDR-TB cases. 
As with pyrazinamide, resistance to ethambutol is not as clearly understood or reported as with 
isoniazid and rifampicin. Resistant isolates have been reported to have mutations on embB, a 
gene within the embCAB operon involved in arabinan biosynthesis, an important constituent of 
the mycobacterial cell wall. The ethambutol resistance determining region in embB is located in 
a cytoplasmic loop and mutations in this region are associated with around 70% of ethambutol 
resistant isolates of M. tuberculosis. Mutations in the embC-embA intergenic region have also 
been shown to contribute significantly to ethambutol resistance and inclusion of this region in 
susceptibility testing increased the rate of detection of ethambutol resistance. 
One group of antibiotics, the quinolones, have been successfully used against M. tuberculosis. 
There are still concerns with this class of antibiotic as resistance is already occurring. A multi-
drug efflux pump is thought to contribute to resistance mechanisms (Jacobs, 1999) along with a 
quinolone resistance determining region (QRDR). Resistance is mainly due to point mutations in 
the QRDR of the gyrA gene (codons 74 to 113), accounting for nearly 90 % of fluoroquinolone 
resistance in M. tuberculosis, these mutations lead to high level phenotypic cross resistance to 
fluoroquinolones in clinical isolates (Miotto et al., 2015). 
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1.6 In vitro models for studying Mycobacterium tuberculosis 
It is important to be able to model M. tuberculosis in vitro to enable studies of the interactions 
between the bacilli and compounds that may affect their growth. Being able to control 
environmental conditions gives the ability to study the effect on the growth, metabolism and 
susceptibility to antibiotics of bacteria. No single model will accurately capture all aspects of 
tuberculosis and in the same way there is no single model that can be used to demonstrate the 
efficacy of novel anti-tuberculous therapies. In vitro models tend to fall into two categories with 
respect to drug evaluation, static and dynamic. Static models evaluate M. tuberculosis responses 
to fixed concentrations of drugs and measures of response include colony-forming unit (CFU) 
counts or surrogates, such as optical density or time to positivity in liquid culture systems. The 
output from static models is most often the minimum inhibitory concentration (MIC) or less 
often the minimum bactericidal concentration (MBC), and even less often time-kill curves ( 
Gumbo et al., 2009). Dynamic models represent the changing concentration of antibiotic over 
time; the depletion of antibiotic in vivo is an important determinant in the microbial kill and 
emergence of resistance.  
The hollow fibre system (HFS) has been used under a variety of conditions to study the 
pharmacokinetic/pharmacodynamic (PK/PD) properties of antibiotics (Gumbo et al., 2009).  
The HFS was originally developed as an in vivo device allowing tumour cells to be grown in a 
mouse, allowing the effect of the host on cell replication to be studied as it allows soluble factors 
including proteins to distribute in the host; the tumour cells remain within the system, allowing 
them to be retrieved and studied (Hollingshead, Alley et al. 1995). The two compartment kinetic 
model was described and aimed to simulate human pharmacokinetics and to expose bacterial 
cultures to changing drug concentrations, avoiding some of the limitations of conventional 
antibiotic testing at constant drug levels  (Blaser et al., 1985). This system does not require large 
culture volumes, allows multiple cultures to be run simultaneously, mimics the timecourse of 
antibiotic concentration in extravascular infections sites and can study the antibacterial effects 
of two antibiotics with differing properties.  
Nutrients are supplied along with drugs to bacteria in controllable culture conditions and waste 
is taken away through a constant cycle of medium. Bacteria are said to be maintained in 
exponential growth due to this supply and recycling of media. As well as looking at time-kill 
kinetics under favourable growth conditions, this model has also been used to generate drug 
tolerant populations in M. tuberculosis due to the stress of low pH which is particularly 
important in studying pyrazinamide (Gumbo et al., 2009) 
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One area of particular interest in M. tuberculosis research has been hypoxic environments, this 
condition has been modelled in order to further understand the environment of the granuloma. 
This is the environment in which it is thought M. tuberculosis enters a non-replicating persistent 
state and understanding not only the mechanisms behind this phase but also the effect it has 
on the organism, the host response and tolerance to antibiotics is of great interest. In vitro 
models of hypoxia aim to reduce the oxygen concentration available and induce microaerophilic 
conditions over time. Some in vitro models are adapted glass tubes or flasks that can be sparged 
with gases to induce hypoxia like stress (Deb et al., 2009) (Wayne and Hayes, 1996) and these 
can be agitated or left to settle into an oxygen gradient (Wayne and Lin, 1982). The hollow fibre 
system has also been used by placing the system in an anaerobic chamber to induce hypoxia and 
the action of combinations of rifampicin and moxifloxacin were studied under these conditions 
(Drusano et al., 2010). Hu et al developed the hundred day static culture system which involves 
gradual nutrient depletion and self-generated hypoxia by incubating the cultures for long time 
periods with no agitation (Hu et al., 2006). After this prolonged period of incubation the cultures 
are resuscitated and exposed to antibiotic to study the phenotypic tolerance. 
In order to study the effects of nutrient starvation Betts et al developed a model in which 
exponentially growing cells were washed and then re-suspended in phosphate buffered saline 
(PBS) in micro-titre plates or standing flasks (Betts et al., 2002). Methylene blue was added to 
measure oxygen depletion and yielded interesting results but this is not a particularly quantitive 
process. This model was based on the Loebel model which was developed to investigate 
environmental conditions encountered by M. tuberculosis particularly the available of nutrients 
to convert to energy as early as 1933 (Loebel et al., 1933). 
1.6.1 Batch culture using fermenters 
A batch culture in a fermenter is an advantageous tool when compared to a flask or tube culture. 
Using probes and a controller with defined set points parameters can be monitored and tightly 
controlled if necessary. Aeration can be controlled via the addition of relevant gases, either 
directly into the culture or into the headspace, an alternative or additive way of control is to 
increase or decrease the stirrer or impellor speeds to alter agitation of the culture. Dissolved 
oxygen is usually the measure of the amount of aeration in a culture and this is done via a pO2 
probe which measures the proportion of oxygen dissolved within the liquid. Once levels reach 
0% dissolved oxygen, a redox (reduction oxidation) or oxidation reduction potential (ORP) probe 
can be used to measure the reducing potential of the medium, this is particularly useful in 
cultures running under micro-aerophilic or anaerobic conditions. 
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Temperature is able to be monitored or controlled via a temperature probe, the control can be 
via a water bath surrounding the vessel, a heat mat either underneath or wrapped around the 
culture or a water jacket around the vessel. Acid and base can be added as required to control 
pH, the set point can be altered throughout the culture to investigate the effect of pH meaning 
multiple pH values can be investigated within one culture experiment.  
Aside from the multiple parameters that can be both monitored and controlled another 
advantage to using fermenter cultures is that they can be sampled over a long time course due 
to the larger volume. In a flask or tube experiment, multiple samples can reduce the volume in 
the culture that may result in all of the volume being used in a short amount of time. By removing 
volume, the aeration parameters can change also as these are not controlled, the headspace 
and therefore surface area increases allowing more oxygen transfer; as more samples are taken 
the aeration increases which may not be ideal when for example, studying the effects of hypoxia. 
Fermenters are sterile and closed systems, samples are drawn through a sampling port which 
introduces a far lower risk of contamination than sampling flasks or tubes. Due to the larger 
volume of a fermenter culture multiple samples can be taken over a long timecourse without 
affecting the experiment. As the volume decreases, the dissolved oxygen can be controlled via 
the methods mentioned previously, maintaining the desired aeration parameter despite 
decreasing volume.  
Batch culture fermentation of M. tuberculosis has been used to study the effect of nutrient 
limitation (Bacon et al., 2014; Hampshire et al., 2004). By controlling air saturation it was 
possible to determine the effects of nutrient depletion rather than have the added variable of 
hypoxia induced stress. The aim was to look at NRP phase induced by nutrient depletion and 
these cultures were run for at least 100 days, the batch fermenter allowed multiple samples to 
be taken without compromising the aeration and also without contamination. This in vitro model 
has also been used to study stationary phase M. tuberculosis gene expression (Hampshire et al., 
2004) and extended to include non-replicating persistence (Bacon et al., 2014). 
1.6.2 Continuous culture  
Batch cultures are useful tools allowing control and monitoring of physiological conditions as 
described in section 1.6.1. A controlled batch culture is an important in vitro model for studying 
the natural growth phases and life cycle of Mycobacterium tuberculosis and determining the 
effects of long term growth in simulated in vivo environments. 
A limitation of batch cultures arises when specific variables such as growth rate want to be 
studied or controlled. Also the environment is constantly changing with time as a result of 
bacterial metabolism. The excretion of by-products and depletion of nutrients from the medium 
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result in an undefined environment, which has an unpredictable impact on the physiology and 
growth rate of the organism (Beste et al., 2005) 
Continuous culture is a method that enables control over the growth rate of an organism, once 
established, the influx of sterile medium from a reservoir is balanced by the efflux of spent 
medium, living cells and cell debris, allowing growth to occur at an equilibrium, with growth of 
new cells being balanced by those washed out (Hoskisson and Hobbs, 2005). The rate of growth, 
or doubling time, of the bacteria is equal to the rate at which the culture is being diluted, which 
is defined by the dilution rate, D=F/V (where D is the dilution rate, F= flow rate and V= volume 
of culture). The dilution rate is the flow of medium over the volume of the culture in the 
bioreactor. When there is a low number of cells within the vessel the growth rate of the 
organism can exceed the dilution rate as the nutrient is not limiting. Once the cell concentration 
becomes too high, the amount of cells that are removed from the vessel cannot be replenished 
by growth as the addition of the limiting nutrient is not sufficient to maintain this maximum 
growth rate, rates at or higher than the maximum growth rate result in wash out of the culture, 
that is dilution of the cells. 
The vessel in which this takes place is named the chemostat (Figure 1.6), the system and term 
were described by Novick and Szilard (Novick and Szilard, 1950) and Monod (Monod, 1950) in 
the 1950s. Most chemostat systems in the literature used to study M. tuberculosis are carbon 
limited, in that it is the flow rate which determines the amount of carbon available to the 
organism with everything else available in excess, controlling growth rate. Nitrogen limited 
cultures have also been used to study the nitrogen regulated transcriptome of M. smegmatis 
using RNA sequencing analysis (Petridis et al., 2015) 
Using continuous culture allows control of the growth rate and therefore the mean generation 
time of the bacilli is also controlled, allowing study of the effect of changes in the environment 
on the physiology and genetics of the bacteria. A culture can be maintained in steady state (the 
growth of the bacteria at a constant rate and under constant environmental conditions) allowing 
individual parameters to be varied independently so that the direct effect of a single stimulus 
on the physiology and molecular genetics of an organism can be established (Bacon and Hatch, 
2009).  
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Figure 1.6 The chemostat system used for continuous culture experiments as described in 
sections 2.2.3.1 and 2.2.3.6. The labels are as follows: 1. Air inlet 2. Medium supply 3. Air 
outlet/off-gas 4.  pH probe 5. Anti-grow back device as part of medium inlet 6. Spare ports 
for addition of acid and alkali 7. Air inlet tube 8.Temperature probe 9. Oxygen probe 10. 
Sample port 11. Peristaltic pumps 12. Effluent port 13. Effluent line 14. Off-gas condensate 
15. Heat pad 16. Glass pipette for flow rate measurement 17. Medium supply 18. Effluent 
waste pots or cell collection pots 19. Stirrer 20. Magnetic flea. Taken from (Bacon and Hatch, 
2009) 
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The influence of reduced oxygen availability on pathogenicity and gene expression was studied 
using continuous culture (Bacon et al., 2004) allowing investigation of oxygen parameters 
independent of other variables such as nutrient depletion which the batch models of hypoxia 
are lacking. The effect of environmental stress on the mutation rate of M. tuberculosis was 
measured by following the mutant frequency and distribution of mutations in the RRDR of the 
rpoB gene using continuous culture, where the pH of the culture was reduced (Bacon et al., 
2010; Jenkins et al., 2009). Methods for determining mutation rate (the rate at which a mutation 
occurs over time) have often been complicated and require large numbers of parallel cultures. 
Most commonly quoted is the mutant frequency, which is the number of mutants in a 
population. Continuous culture allows multiple samples to be taken over a long timecourse from 
a high titre population which is required to accurately measure the mutation rate and the effect 
on growth rate itself in the absence of antibiotic can be studied. Mutation rates of novel 
compounds can be assessed and compared to current therapeutics and evaluated as to their 
suitability for inclusion into a new regime. 
Continuous culture has been used as a powerful technique to study metabolic flux in M. 
tuberculosis, confirming the ability to fix carbon from carbon dioxide (CO2) and identifying that 
deletion of one of two isocitrate lyase genes impairs replication of M. bovis BCG at a slow growth 
rate, making both these processes possible drug targets (Beste et al., 2011). Metabolic flux 
analysis using labelled carbon is ideal for continuous culture as the amount of carbon available 
to the bacteria is known and controlled via the dilution rate in carbon limited cultures. The 
macromolecular composition of mycobacteria at slow and fast growth rates was also elucidated 
using continuous culture and found evidence for growth rate-mediated regulation of ribosome 
biosynthesis and lipid metabolism (Beste et al., 2005). These two growth rates were also used 
to study the transcriptomic response associated with slow growth, showing association of slow 
growth with induction of expression of several genes of the dormancy survival regulon (Beste et 
al., 2007a). This work also found high levels of similarity between the slow growing 
Mycobacteria in the chemostat and the transcriptional response of M. tuberculosis to growth in 
the macrophage, validating the use of continuous culture and these growth rates for the study 
of M. tuberculosis. Transposon site hybridisation selection was then used to define the genetic 
requirements of switching from a fast growth rate (23 hour doubling time) to a slow growth rate 
(69 hour doubling time) (Beste et al., 2009). 
To study antibiotic efficacy and the PK/PD of novel and current therapeutics, compounds can be 
added to the chemostat in a constant delivery at a known concentration or in pulses, this can be 
done in with one drug or in combination with another. This allows the study of drug interaction 
44 
 
with the bacilli but also how antibiotics work in combination in the current regime to combat 
tuberculosis infection. With continuous systems the volume of the culture is maintained so 
samples can be taken over a time course without disturbing the equilibria of the system. This 
also allows for samples for total viable count, optical density, and genomic study to be removed 
whilst knowing the precise readings of the culture and controlling certain aspects. Controlling 
the growth rate of M. tuberculosis using continuous culture allows the efficacy of antibiotics to 
be studied with respect to doubling time, to try to determine the mechanisms used by different 
sub-populations during infection.  
 
The work presented in this thesis has used a variety of batch and continuous culture models to 
elucidate differing mechanisms of antibiotic resistance and persistence with respect to growth 
rate and phase. Using slow and fast growth rates of 69 hours and 23 hours respectively the 
response of these two populations to isoniazid has been studied using continuous culture 
(Jeeves et al., 2015).  
1.7 Objectives and Aims of Thesis 
The main aim of this thesis was to establish whether persisting populations of M. tuberculosis in 
the presence of antibiotic have adapted through a genotypic mechanism i.e. mutation leading 
to resistance and persistence through treatment or  phenotypic mechanisms i.e. physiological 
changes allowing survival through treatment but maintaining wild type genetics. Other factors 
that may affect antibiotic efficacy with in vitro systems were also investigated. 
 
 Determine whether a high titre of cells in a system such as a chemostat reduces the 
efficacy of isoniazid and rifampicin.  
o The aim was to show titres that are routinely tested in laboratories in 
susceptibility tests do not represent in vivo titres and the minimum inhibitory 
concentration of an antibiotic can be affected by this. 
 
 Determine the susceptibility profile of M. tuberculosis growing at different growth rates 
and in different growth phases 
o The aim was to show slow growing cells and cells that are not dividing are more 
recalcitrant to cells dividing at a faster growth rate or within exponential phase. 
This work aimed to address the different populations found within a M. 
tuberculosis infection and show the differing actions of antibiotics 
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 Determine whether slow growing M. tuberculosis is adapted to isoniazid using 
phenotypic or genotypic mechanisms. 
o The aim was to compare two growth rates, controlled in continuous culture, 
with the hypothesis being that the slow growing M. tuberculosis was adapted 
intrinsically to isoniazid exposure. This was investigated using sequencing of 
colonies to investigate genotypic changes in known isoniazid resistance loci and 
transcriptomic data to investigate phenotypic adaptations. 
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Chapter 2. Materials and Methods 
2.1 Preparation of media for the culture of Mycobacterium tuberculosis 
2.1.1 Preparation of CAMR Mycobacterium Media MOD2 
The first two ingredients from table 2.1 were added to 500 ml of water, the remaining 
ingredients and CAMR Mycobacterium (CMYCO) solutions were added in the order listed and 
stirred to dissolve. The pH was adjusted to 6.5 with 20% KOH and the conductivity checked. The 
medium was filter sterilised and stored at 2˚C to 8˚C. 
CMYCO solutions 1, 2 and 3 were prepared by adding the ingredients listed in tables 2.1 a, b and 
c to water and stirring to dissolve. CMYCO Solutions 1 and 2 were kept between 2 °C and 8 °C 
for up to six months and solution 3 was used within 1 week of production. CMYCO solutions 4 
and 5 were made fresh each time they were required by adding the ingredients in the quantities 
specified in tables 2.1 d and e, these solutions were stirred to dissolve the ingredients. The CAMR 
Mycobacterium MOD2 medium (James et al., 2000) was prepared by the Health Protection 
Agency, Microbiological Services Porton, Media department. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 2.1 Ingredients of CAMR Mycobacterium Medium MOD2 
*Biotin 10 µg/ml solution = 0.01 g in 1000 ml Milli Q water 
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Table 2.1 a-e  
Table 2.1a Ingredients of CMYCO solution 1 
Table 2.1b Ingredients of CMYCO solution 2 
Table 2.1c Ingredients of CMYCO solution 3 
Table 2.1d Ingredients of CMYCO solution 4 
Ingredients of CMYCO solutions 1- 5 
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2.1.2 Preparation of CAMR Mycobacterium medium MOD6 
 
The ingredients listed in table 2.2 were added to water and the pH adjusted to 6.5 with 20% 
KOH. This medium was prepared by the Health Protection Agency, Microbiological Services 
Porton, Media department. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Culture of Mycobacterium tuberculosis 
All work with Mycobacterium tuberculosis was carried out within a containment level 3 facility 
using class III microbiological safety cabinets (MSCIII).  
2.2.1 Inoculation of a Seed Flask of Mycobacterium tuberculosis 
A seed vial of M. tuberculosis H37Rv (ATCC  25618™) strain was removed from -70C storage, 
plated evenly onto Middlebrook 7H10 Agar (Becton Dickinson 262710) plus OADC supplement ( 
Becton Dickinson 212351) and incubated for three weeks at 37 C until single colonies were 
evident. 200 ml of CAMR Mycobacterium Media MOD2 (section 2.1.1) was placed into a 1 litre 
Table 2.2 Ingredients and amounts for CAMR Mycobacterium MOD6 
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flask and inoculated with half a plate of this seed stock then left shaking at 37C at 200 rpm for 
72 hours.  
2.2.2 Turbidity measurement and total viable counts of Mycobacterium tuberculosis 
For a real time measurement of M. tuberculosis growth a 1 ml sample was removed from the 
culture pipetted into a cuvette and placed into a spectrophotometer, and an optical density (OD) 
measurement was made at 540 nm. The viability of cultures was measured by a total viable count 
(TVC) method, a sample was removed from the culture and 1 ml was transferred to a micro-
centrifuge tube. The cells were spun at 2415 x g for 5 minutes, the supernatant was removed, 
and the pellet was resuspended in phosphate buffered saline (PBS). This process was repeated, 
to wash any remaining antibiotic from the sample. A dilution series of the cells was prepared by 
adding 100 µl of the neat sample to 900 µl of PBS.  100 µl of the required dilutions (dictated by 
the turbidity of the culture) was plated onto Middlebrook 7H10 agar and spread. These plates 
were then incubated at 37C for three weeks.  To calculate the colony forming units per ml 
(cfu/ml) of culture, the number of colonies evident after 3-4 weeks incubation was recorded as 
was the dilution factor. Equation 2.1 was then used to calculate the cfu/mL. 
 
𝐶𝑓𝑢 
𝑚𝑙
=  𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 × 10 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 
 
 
Total viable counts performed using the Miles and Misra method (Miles et al, 1938) follow the 
method described above with the following modification: the plate was divided into quadrants 
for the dilutions. In each section, three 20 µl aliquots of the appropriate dilution were spotted, 
then left to dry at room temperature inside a MSCIII until no visible liquid could be seen. Plates 
were then incubated at 37C for three weeks. Colonies could be counted after three weeks 
(figure 2.1). To calculate the cfu/ml of culture, the number of colonies evident after 2.5 - 3 weeks 
incubation was recorded as was the dilution factor. Equation 2.2 was used to calculate cfu/mL. 
Equation 2.1 Calculation of cfu/ml  
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𝐶𝑓𝑢
𝑚𝑙
 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 × 50 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
 
 
 
2.2.3 Chemostat culture of Mycobacterium tuberculosis 
 
2.2.3.1 Assembly of a chemostat for continuous culture  
A 1 litre glass chemostat vessel (DASGIP 78903189) was rinsed with distilled water and oxygen 
and pH probes were inserted into ports in the chemostat head plate. The effluent and medium 
lines were assembled using silicon tubing and connected to the vessel along with the air inlet, 
off-gas condensate bottle, and sample port. Vent filters (0.2 µm) were added to the air inlets 
and outlets, sample port side arms, waste bottles, collection bottles and medium bottles to 
maintain sterility and prevent the buildup of pressure in the vessel as can be seen in figure 1.6. 
An electronic stirrer, two peristaltic pumps (medium and effluent), two autoclaved effluent 
reservoirs and the medium source (CAMR Mycobacterium MOD2, section 2.1.1) were placed 
inside an MSCIII. A magnetic flea and 600 ml of water were added to the chemostat vessel and 
the vessel was placed on top of the stirrer on a heat pad. The probes were then connected to 
the controller, which was used to maintain culture conditions. The signal of the oxygen probe 
was calibrated using a rough span of between 0% dissolved air saturation (via the addition of 
nitrogen) and 100% dissolved air saturation (via the addition of air) could be achieved. The pH 
Equation 2.2 Calculation of cfu/ml using the Miles and Misra method  
Figure 2.1 Mycobacterium tuberculosis colonies grown on Middlebrook 7H10 agar using the Miles and 
Misra method. 
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probe was calibrated with pH 4.0 and pH 7.0 buffers (Sigma 33665 and 33666) The acidity of the 
cultures was not controlled but was monitored. The water in the vessel was heated to 37C using 
the heat pad and the temperature probe was calibrated using a hand held thermometer.  The 
temperature in the vessel was measured until it reached 37C, this reading was then set on the 
controller. The vessel was pressure tested by submerging it in water, ensuring the probe fittings 
were under the level of the water but that the vent filters remained dry. The air inlet and outlet 
clamps were removed and the air outlet tubing was extended past the vent filter using additional 
tubing. The end of this tubing was placed below the surface of the water. A syringe was 
connected to the air inlet line and air was pumped in and bubbles were seen coming out of the 
air outlet. The air outlet was clamped and this process was repeated, to check that no air bubbles 
exited the chemostat. The vessel was autoclaved at 121C for 30 minutes with the air inlets re-
clamped and air outlet un-clamped. 
The chemostat was placed inside a MSCIII and the medium source and effluent reservoirs were 
connected and the tubing was connected to the peristaltic pumps. All probes and the stirrer 
were connected to the controller. The oxygen probe was calibrated by warming the vessel to 
37C whilst stirring and oxygen and nitrogen were pumped in alternately until it was calibrated 
between 0% and 100% dissolved air saturation (DAT) which is equivalent to 0 and 20% dissolved 
oxygen tension (DOT). The water was drained from the chemostat and then it was filled with 
400 ml of CAMR Mycobacterium media MOD2 (section 2.1.1) via the medium line and then 
warmed to 37C, the maximum and minimum stirrer speeds were set (Bacon and Hatch, 2009). 
Flow rates were set by calibrating the medium pump by measuring the amount medium pulled 
from the medium source in a set amount of time. The pump setting could then be set to the 
specific flow rate required. 
 
2.2.3.2 Calculation of the dilution rate and doubling time of bacteria within continuous 
culture 
The dilution rate is the flow of medium divided by the volume of the culture in the bioreactor. 
It was calculated using equation 2.3 
 
      𝐷 =
𝑓
𝑣⁄    
Equation 2.3 Dilution rate of a chemostat 
 
 
D = dilution rate (hr-1) 
f  = flow of medium into the vessel 
(ml/hr) 
v = volume of culture in vessel (ml) 
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Using the dilution rate value the doubling time of the bacteria was be calculated using equation 
2.4 
 
        𝑇𝑑 =  
log𝑒 2
𝐷⁄  
 
     ∴ 𝐷 =  
log𝑒 2
𝑇𝑑
⁄  
Equation 2.4 Calculation of doubling time of a bacterium in continuous culture. 
2.2.3.3 Calculation of specific growth rate and doubling time in uncontrolled bacterial 
cultures 
To calculate the doubling time of a population of cells in an experiment where the growth rate 
and doubling time are not controlled equations 2.5 and 2.5 b were used.  
 
    ln 𝑁𝑡 −  ln 𝑁0  = µ (𝑡−𝑡0)    
 
 
The following conversion allows the for use of log10 values rather than natural logs 
 
𝜇 = ((log10 𝑁 − log10 𝑁0)2.303)/(𝑡 − 𝑡0) 
 
Equation 2.5 Calculation of growth rate. 
 
  𝑇𝑑 =  (log10 𝑁𝑡 − log10 𝑁0)/ log10 2 
Equation 2.5b Calculation of doubling time 
 
 
 
 
D = dilution rate (hr-1) 
Td = Doubling time (hours) 
 
µ = Specific growth rate 
N = Number of cells at time t 
N0 = Number of cells at time zero 
t0 = Time zero 
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2.2.3.4 Calculation of theoretical washout of continuous culture 
The theoretical washout was calculated based on the flow rate of the chemostat and the 
doubling time of the bacterium as controlled by the dilution rate as shown in equation 2.6. 
 
𝐹𝑙𝑜𝑤 𝑜𝑓 𝑚𝑒𝑑𝑖𝑢𝑚 𝑝𝑒𝑟 𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 (𝑚𝑙𝑠)
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐ℎ𝑒𝑚𝑜𝑠𝑡𝑎𝑡 (𝑚𝑙𝑠)⁄  
 
Equation 2.6 Calculation of dilution factor for theoretical washout of bacteria from a continuous 
culture 
 
This gives a dilution factor, the viable count data from each generation could then be multiplied 
by this dilution factor to show the rate at which non-growing bacteria would be diluted from the 
system. 
2.2.3.5 Calculation of mutant frequency and mutation rate 
The mutant frequency was calculated as shown below. 
 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑖𝑠𝑜𝑙𝑎𝑡𝑒𝑑 𝑜𝑛 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑝𝑙𝑎𝑡𝑒
𝑇𝑜𝑡𝑎𝑙 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑜𝑢𝑛𝑡⁄  
The mutation rate was calculated as shown in equation 2.7. 
𝜇 = [(
𝑟2
𝑁2
)] − [(
𝑟1
𝑁1
)] × ln (
𝑁2
𝑁1
) = (𝑓2 − 𝑓1) × ln (
𝑁2
𝑁1
) 
 
μ = mutation rate 
r1 = observed number of mutants at first time-point 
r2 = observed number of mutants at last time-point  
N1 and N2 = total numbers of viable cells at first and last time-points respectively 
f1 and f2 = mutant frequencies at first and last time-points respectively 
 
Equation 2.7 Calculation of the mutation rate of bacteria within continuous culture 
 
2.2.3.5 Addition of isoniazid to continuous culture 
A 1 mg/ml stock of isoniazid (Sigma - I3377) was made by dissolving 10 mg of isoniazid in 10 ml 
of molecular grade water (Sigma W4502). This stock was then filtered through a Minisart 0.2 µm 
syringe filter (Sigma 16534K) and stored at 4˚C. The isoniazid stock was diluted to 0.1 mg/ml and 
10 ml of this stock was added aseptically to a 2 litre bottle of MOD2 medium (section 2.1.1) and 
mixed well. For addition of isoniazid directly to the chemostat vessel, a solution of isoniazid 
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containing 2.5 ml of a 0.1 mg/ml stock in approx 10 ml of MOD2 medium was prepared in a 
sterile glass universal. This allowed the antibiotic to be added via the sample port in a volume 
that would ensure complete addition of the antibiotic.  
The media line of a steady state continuous culture (section 2.2.3.1) was drained back to the 
medium source by switching off the medium pump and removing the tubing from the medium 
pump. The media line of the chemostat was then connected to the medium bottle containing 
MOD2 and 0.5 µg/ml isoniazid. The medium line was primed up to the chemostat vessel using a 
hand held pump attached to the vent filter of the medium bottle; the medium line was clamped 
at the point just before the medium was to enter the chemostat vessel. The medium tubing was 
then replaced in the medium pump (which was still switched off), the clamp removed and the 
effluent pump switched off. The antibiotic was added via the sample port to a final concentration 
of 0.5 µg/ml, and the sample port washed through several times to ensure the addition of the 
entire volume of antibiotic. The medium and effluent pumps were switched back on to maintain 
continuous culture with a constant concentration of isoniazid throughout the experiment. The 
continuous culture system described can be seen in Figure 2.2. The flow rate of the vessel was 
checked as described in section 2.2.3.1. 
 
2.2.3.6 Controlled batch culture to investigate nutrient starvation 
A 2-litre glass vessel was assembled following the instructions for continuous culture (section 
2.2.3.1) but no effluent or medium lines were required. The vessel was filled with MOD6 medium 
(section 2.1.2), pre-warmed and a fixed stirrer speed set. The dissolved oxygen tension (DOT) 
was maintained at 10% via addition of air and nitrogen as required. The vessel was left stirring 
once inoculated and no fresh nutrients were added or effluent removed. These cultures were 
set up by J. Allnutt, TB Research, Microbiology Services Porton, Health Protection Agency. 
 
2.3 Recovery of isoniazid resistant colonies from the chemostat 
Middlebrook 7H10 Agar plus OADC supplement was prepared and contained 1 µg/ml isoniazid 
(Sigma Aldrich I3377-5G), which was equivalent to 2 x MIC. 100 µl of the undiluted, 10-1 and  
10-2 diluted cells that had previously been prepared for the TVC (section 2.2.2) were spread onto 
the agar in triplicate and the plates were incubated at 37C for 3 – 4 weeks. The colonies were 
counted. Cells were also plated onto agar without antibiotic as a positive control to determine 
the viable count.  Colonies growing on antibiotic were kept for further genotypic and phenotypic 
analysis by storing on agar at 4˚C.  
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2.4 Antibiotic Susceptibility testing of M. tuberculosis under different growth conditions 
2.4.1 Susceptibility to antibiotics in liquid medium  
The medium that the sample of M. tuberculosis being analysed was cultured in was aliquoted 
into 10 ml universal tubes (Sterilin 128A/P) and antibiotic was added in the volumes outlined in 
table 2.3 
A 10 ml sample was removed from the nutrient starvation batch culture (section 2.2.3.6) at time 
points corresponding to the different mycobacterial growth phases (i.e. exponential, stationary, 
death and persistence) this was determined by OD540 nm readings and viable counts when 
available. A 10 ml sample was removed from the continuous culture vessels (section 2.2.3.1) 
when steady state growth at the desired dilution rate had been established for 3-5 mean 
generations. Steady state this was determined by OD540 nm readings and stable DOT, rpm and pH 
readings. The OD540 nm of the sample removed from the source culture was measured. The 
universals were inoculated with M. tuberculosis to give a starting OD540 nm of 0.05; this was 
calculated using equation 2.7. The cultures were mixed well and a 1 ml sample was removed for 
OD540 nm measurement and a 1 ml sample was removed for TVC using the Miles and Misra 
method (described in section 2.2.2). The cultures were then left shaking at 37˚C at 200 rpm. 
Additional samples for OD540 nm and TVC were removed immediately after inoculation and 24 
hours post inoculation for both the nutrient starvation culture and the continuous culture. 
Samples were taken at 144 hours post inoculation from the nutrient starvation batch culture 
and 96 hours post inoculation for samples from the continuous culture. 
 
 Table 2.3 The volume and concentration of antibiotic added to 10 ml medium to give required 
final concentration.  
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𝐴𝑐𝑡𝑢𝑎𝑙 𝑂𝐷 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔 𝑂𝐷 (0.05)
= 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑚𝑒𝑑𝑖𝑢𝑚 (𝑚𝑙)
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
= 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑡𝑜 𝑎𝑑𝑑 𝑡𝑜 𝑚𝑒𝑑𝑖𝑢𝑚 (𝑚𝑙𝑠) 
 
 
 
 
2.5. Heat killing of Mycobacterium tuberculosis for DNA extraction and inactivation 
100 µl of Tris-EDTA Buffer (TE Buffer) pH 8.0 (Applied Biosystems AM9849) was aliquoted into a 
suitable RNase and DNase-free screw cap tube with an o-ring.  Wooden toothpicks were 
autoclaved to sterilise them and the colony of interest was picked using the sterile toothpick 
from the agar and emulsified in the TE Buffer. 10 µl of this solution was spread onto a 
Middlebrook 7H10 agar plate to provide growth for glycerol stocks. Four colonies were spread 
onto each plate by dividing the plate into quarters. The tubes containing the remaining 
emulsified colony were then put in a heat block pre-warmed to 80˚C and heated for 20 minutes. 
The tubes were then stored at -80˚C. The plates were incubated at 37˚C until confluent growth 
was observed.  
 
2.5.1. Preparation of glycerol stocks of Mycobacterim tuberculosis colonies 
A solution of glycerol at a concentration of 20% (v/v) was prepared and autoclaved for 11 
minutes at 126 °C to sterilise it. 1 ml of this solution was aliquoted into screw cap tubes with an 
o-ring. Growth from the 10 µl plated out prior to heat killing (section 2.5) was scraped into the 
glycerol and mixed with a 10 µl inoculating loop. These tubes were then stored at -80˚C. 
 
2.6 RNA Extraction from Mycobacterium tuberculosis 
2.6.1. Isolation of RNA 
A 5M guanidine thiocyante (GTC) lysis solution was made by weighing out 591 g of GTC (Sigma 
Aldrich G9277), 5 g of N lauryl sarcosine (Sigma L9150), 7.3 g Trisodium citrate (Sigma S4641) 
and 5 ml of Tween 80 (Sigma P5188) and making up to 1 litre with nuclease free water. 1 volume 
of culture sampled was added to 4 volumes of GTC lysis solution. The GTC – sample mixture was 
incubated at room temperature for 1 hour. The sample mixture was spun down in a bench top 
centrifuge for 15 minutes at 1935 x g. The supernatant was then poured off leaving a small 
amount (<100 µl) of GTC in the bottom of the tube. The pellet(s) were re-suspended by pipetting 
Equation 2.8 Calculation to determine the amount of inoculum to add to give a starting 
OD540 nm of 0.05 
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gently up and down, 1.2 ml of Trizol (Invitrogen 15596018) was added and the pellet(s) re-
suspended thoroughly. The sample was then transferred to a 2 ml tube containing 0.5 ml 0.1 
mm silica beads (Fisher Scientific MBR-247-105B) and these were lysed using a reciprocal shaker 
(FastPrep FP120) for 45 seconds at a speed of 6.5. The pink solution above the beads was then 
transferred into 240 µl of chloroform and shaken vigorously for 20 seconds. This solution was 
spun at 2415 x g for 10 minutes. The aqueous phase was then removed and added to 600 µl 
chloroform, shaken vigorously for 20 seconds and spun for 10 minutes at 2415 x g - this step was 
then repeated.  The aqueous phase was then added to 600 µl isopropanol plus 60 µl sodium 
acetate (Sigma Aldrich S7899) and frozen at -70˚C at least overnight to aid precipitation. 
 
2.6.2 Purification of Total RNA  
Total RNA was isolated from the extractions detailed in section 2.6.1 using the mirVana™ miRNA 
Isolation kit (Agilent AM1561). The sample was prepared by thawing it on ice and then adding 
1.25 volumes of room temperature 100% ethanol to the extraction. A filter cartridge was placed 
into a collection tube (both provided in the kit) and the sample/ethanol mixture was applied to 
the filter. A volume of 700 µl was applied at a time, for sample volumes larger than this the 
mixture was applied in successive applications to the same filter. The cartridge assembly was 
then centrifuged for 15 seconds at 10,000 x g to allow RNA to bind to the filter cartridge. The 
flow through was discarded and this process repeated until all of the sample/ethanol mixture 
was through the filter. The collection tube was re-used for the following wash steps, 700 µl of 
miRNA Wash Solution 1 (provided with the kit) was applied to the filter cartridge and this was 
spun at 10,000 x g for 5-10 seconds. The flow through was discarded from the collection tube 
and the filter replaced into the same collection tube. 500 µl of Wash Solution 2/3 (provided with 
the kit) was applied to the filter cartridge and drawn through as in the previous step. This process 
was then repeated with a second 500 µl amount of Wash Solution 2/3. After discarding the flow 
through from the last wash the filter cartridge was replaced into the same collection tube and 
the assembly spun for 1 minute to remove residual fluid from the filter. The filter cartridge was 
then transferred into a fresh collection tube and 100 µl of pre-heated (95˚C) RNase-free water 
(Sigma W4502) was applied to the centre of the filter and the cap closed. The assembly was spun 
for 20-30 seconds at maximum speed (13,000 x g) to recover the RNA. The eluate was collected 
which contained the RNA and stored at -70˚C this was performed according to instructions from 
Invitrogen (http://tools.invitrogen.com/content/sfs/manuals/cms_055423.pdf). 
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2.6.3 Quantification of RNA 
The concentrations of RNA prepared in sections 2.6.1 and 2.6.2 were determined by using the 
NanoDrop 2000 and NanoDrop 3000 (Thermo Scientific). The blank measurement was taken 
using RNase-free water; this was the same solution the RNA was eluted into at the end of the 
total RNA isolation procedure (section 2.6.2). Along with the RNA concentration, the 260/280 
and 260/230 ratios of each sample were recorded to allow assessment of phenol or GTC 
contamination. 
2.6.4 Analysis of RNA integrity 
The Agilent 2100 bioanalyzer (Agilent Technologies, CA, USA) was used to assess the integrity of 
the RNA isolated in section 2.6.2. The Agilent RNA 6000 Nano Kit (Agilent, 5067-1511) was used 
and the RNA 6000 Nano Quick Start Guide followed. Samples to be analysed were heat 
denatured at 70˚C for 2 minutes before loading them onto the bioanalyser chip. 
To prepare the Agilent RNA 6000 ladder (with a range from 25 – 6000 nucleotides) it was heat 
denatured in an RNase free tube at 70˚C for 2 minutes and was then immediately cooled down 
on ice. Aliquots were prepared corresponding to daily usage and stored at -70˚C. To prepare the 
gel, 550 µl of RNA 6000 Nano gel matrix was pipetted into a spin filter (provided with the kit) 
which was centrifuged at 1500 x g for 10 minutes at room temperature. 65 µl of this filtered gel 
was aliquoted into RNase-free tubes and used within 4 weeks. Before preparation and loading 
of the gel-dye mix, the RNA 6000 Nano dye concentrate was allowed to equilibrate to room 
temperature for 30 minutes and was then vortexed for 10 seconds, spun down and 1 µl added 
to a 65 µl aliquot of filtered gel. This solution was then briefly vortexed to ensure mixing and 
centrifuged at 13000 x g for 10 minutes at room temperature. 
To load the gel-dye mix, a new RNA 6000 Nano chip (provided with the Agilent 6000 Nano Kit) 
was placed on the chip priming station and 9 µl of gel-dye mix was pipetted into the well 
indicated by the protocol and symbols on the chip. The chip priming station was then closed and 
the plunger on the attached syringe pressed until it is held by the clip on the chip priming station, 
the clip was released after exactly 30 seconds.  A further 9 µl of the filtered gel was then pipetted 
into the second and third gel wells on the chip. To load the RNA 6000 Nano Marker, 5 µl of 
marker was loaded into all 12 sample wells and in the well marked with a ladder symbol. 1 µl of 
prepared ladder (after thawing) was loaded into the well marked with the ladder symbol and 1 
µl of each sample to be analysed was loaded into each of the sample wells required, any unused 
sample wells had 1 µl of RNA 6000 Nano Marker loaded. The chip was vortexed for 1 minute at 
2400 rpm and the chip was run in the Agilent 2100 bioanalyser within 5 minutes by selecting the 
corresponding assay parameters. 
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The RNA quality was assessed by review of the integrity of the 16S and 23S rRNA peaks (Fig 2.3), 
ensuring that the trace showed a flat baseline punctuated with narrow peaks and a complete 
absence of broad, rounded peaks. The entire electrophoretic trace was used by the Agilent 2100 
bioanalyzer software to calculate a RNA Integrity Number (RIN) allowing comparison between 
samples independent of sample concentration. The scale of the RIN is 1-10 with 1 being the 
lowest and 10 being the highest. A RIN of greater than 7 would indicate a sample of high enough 
quality for downstream transcriptomic analysis such as microarray.  
The presence of small RNAs was also detected by a peak on the electropherogram, this peak 
appeared at around 25 seconds corresponding to RNA of 20-200 nucleotides, this represents the 
5s region. 
 
 
 
 
 
 
 
2.7 Transcriptomic analysis 
The work in the following sections was performed by Dr Rose Jeeves, PHE, Porton Down, UK. 
The methods are taken from (Jeeves et al., 2015) 
 
2.7.1 RNA Labelling 
RNA was labelled using the Kreatech ULS™ Fluorescent Labeling Kit for Agilent arrays (Kreatech 
EA-023). The labelled RNA was fragmented by adding 2 µl 10x fragmentation buffer, incubating 
Figure 2.2 Example of a bioanalyser trace with a RIN of 10 including the presence of small 
RNAs. The x-axis represents time in seconds [s] in the assay and the y-axis represents 
fluorescence units absorbed [FU]. The 16S and 23S peaks are assigned by the Bioanalyzer 
software using the ladder as reference.  
Marker  
16S peak 
23S peak 
Small RNAs 
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for 15 minutes at 70°C, then adding 2 µl stop solution (Ambion® AM8740). Labelled RNA (20 µl) 
was added to 27.5 µl Kreatech blocking reagent (Kreatech EA-023), 55 µl of 2x Hybridisation 
buffer and 7.5 µl of molecular grade water. Arrays were hybridised overnight at 65°C, then 
washed in Gene Expression wash buffer 1 (Agilent 5188-5327) for 1 minute at room temperature 
with agitation, then in Gene Expression wash buffer 2 for 1 minute at 37°C with agitation. Slides 
were scanned immediately using an Agilent Scanner.  
 
2.7.2 Transcriptomic analyses 
Whole genome gene expression analyses were performed. Microarray experiments were per- 
formed using a custom Agilent tiling array (ArrayExpress accession A-BUGS-47) with 180,000 60-
mer oligos evenly tiled across the M. tuberculosis H37Rv genome. Features were extracted from 
the array images using Agilent Feature Extraction Software (v10.7) with local background 
correction. Probes were first filtered to only include those covering annotated genes. Intensity 
values were normalised and analysed using GeneSpring software (version 12.6 GX). Firstly, 
quantile normalisation was applied across the combined slow and fast growth rate datasets, fol- 
lowed by an averaging of the expression level of all probes across each open reading frame, on 
either the sense (S) or antisense (AS) strand. A 2-way ANOVA (using a Benjamini-Hochberg 
correction p-value of P = 0.05 and growth rate and MGT as conditions) was used to identify 
significantly differentially expressed genes between fast growth rates and slow growth rates 
either in the presence or absence of isoniazid. A further filter was applied to select genes with 
at least a two-fold change in gene expression. Gene lists derived from all pairwise comparisons 
can be found in the supporting information in (Jeeves et al., 2015). Genes were assigned groups 
based on their entries in Tuberculist (http://tuberculist.epfl.ch/). For the analysis of the 
expression of small and non-coding RNAs, Limma (Ritchie et al., 2015) analyses were performed 
following quantile normalisation between arrays to find differentially expressed regions (oligos) 
within the genome. Ratios of fluorescence intensity values across the genome were visualised 
using a custom version of the genome browser JBrowse (http://www. 
ncbi.nlm.nih.gov/pubmed/19570905) which included the novel tracks MultiBigWig and 
MultiXYPlot (Source code and data available at https://github.com/rtylerr/jbrowse1.11-
MultiBigWig). The differentially expressed regions identified by Limma could then be visualised 
alongside the calculated ratio plots for manual curation. 
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2.7.3 Real –time quantitative PCR (RTq PCR) 
PCR reactions utilised the 16S rRNA gene as an endogenous control. The ahpC primer and probe 
sequences were designed using Primer3 software (http://primer3.ut.ee/). Primers and probes 
were optimised to have a reaction efficiency of 90–110% to validate them for use with the ΔΔCt 
method of quantification; these data can be found in the supporting information (Jeeves et al., 
2015) along with primer and probe sequences. Reverse transcription took place in a total volume 
of 20 μl containing 100 ng total RNA, 300 ng random primers (Invitrogen™ Life Technologies), 
10 mM DTT, 0.5 mM each of dCTP, dATP, dGTP and dTTP, and 200 units Superscript III 
(InvitrogenTM Life Technologies). The 20 μl reactions were assembled in a standard ABI 96-well 
plate in triplicate as follows; 1.8 μl of 10 μMahpC primers or 1 μlof10 μM16S primers, 0.5 μlof10 
μMof probe, 10 μl of Taqman Universal Mastermix II with UNG (Applied Biosystems part No 
4428175) and 1 μl of cDNA. 16S rRNA was used as an endogenous control. Reactions were 
performed in an ABI-7900 light- cycler with the program as follows; 50°C for 2 minutes, 95°C for 
10 minutes, 40 cycles of 95°C for 15 seconds and 55°C for 45 seconds. Data were analysed using 
the SDS 2.4 and RQ Manager 1.2.1 Software (ABI) to calculate ΔΔCt and relative quantification 
values. 
 
2.8 Polymerase Chain Reaction (PCR) 
PCR was performed with Readymix™ Taq PCR Reaction Mix (Sigma P4600) according to the 
manufacturer’s instructions. Unless otherwise stated PCRs were performed with the following 
reaction conditions; 12 minutes at 94˚C; 40 cycles of 30 seconds at 94˚C, 30 seconds at 60˚C, 1 
minute at 72˚C; 10 minutes at 72˚C. Colony PCR was performed by using 1 µl of the heat killed 
suspension described in section 2.5 as the template for PCR. PCR products were visualised by 
gel  electrophoresis on 2% (w/v) TAE (4.84 g Tris, 1.14 ml acetic acid, 2 ml EDTA pH 8.0, per litre) 
agarose gels containing 1x (v/v) SYBR® safe DNA gel stain (Invitrogen) in 1x TAE buffer. TrackIt™ 
1 kb Plus DNA ladder (Invitrogen) was used according to manufacturer’s instructions and the 
gels were run at 80 v for 45 minutes before the DNA was visualised in a UVIdoc (UVITECH 
Cambridge) gel documentation imaging system. 
The primers used to amplify the regions of interest of each gene are listed below in table 2.4 
and shown in figures 2.4 and 2.5 along with the sequencing primer used in the pyrosequencing 
assay.  
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Table 2.4 Primers used for PCR amplification and pyrosequencing 
 
 
 
 
 
 
 
 
 
Figure 2.3 The amplicon of katG that was produced by using primers specified in Table 2.4. The 
region sequenced is directly after the sequencing primer. Codon 315 is highlighted with the 
single nucleotide polymorphism (SNP) being reported at the G position. The PCR primers and 
sequencing primers were taken from (Arnold et al., 2005) 
 
 
 
 
 
Figure 2.4 The amplicon of inhA that was produced by using primers specified in Table 2.4. The 
region sequenced is directly after the sequencing primer.  Positions that SNPs have been 
reported at in clinical isolates are highlighted in bold. The PCR and sequencing primers were 
taken from (Garza-Gonzalez et al., 2009) 
 
Gene Forward primer  Reverse Primer  Sequencing 
Primer 
katG CGGTCACACTTTCGGTAAGA B-CCGTACAGGATCTCGAGGA GGACGCGAT
CACCA 
inhA B-GAGCGTAACCCCAGTGCGAAAG CCAGGACTGAACGGGATACG
AATG 
TGGCAGTCA
CCCC 
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2.9  Pyrosequencing of PCR amplicons 
2.9.1 Preparation of sample 
Once thawed, 20 µl of PCR product was mixed with 3 µl streptavidin-coated Sepharose beads, 
40 µl binding buffer (Qiagen 979006) and 17 µl nuclease free water in a 96-well PCR plate. The 
plate was covered with sealing foil. This mixture was then incubated for 5-10 minutes at room 
temperature while shaking at 1400 rpm in a micro-titre plate shaker. A PSQ® plate (Qiagen 
979002) was prepared by adding 45 µl of 0.3 µM sequencing primer (as detailed in Table 2.4) in 
Annealing buffer (Qiagen 979009) per well. The ‘well layout’ for the PSQ® plate corresponded 
to the layout of the PCR plate. To remove non-annealed primers and non-biotinylated product, 
the solution, with the beads in suspension, was aspirated using the Vacuum Prep Tool (Qiagen 
9001740). The beads stuck to the filters of the tool’s pins and the tool and PCR plate were kept 
together whilst tilting them to check that all the solution had been aspirated. The tool was then 
transferred to the first trough and 70% ethanol was aspirated for roughly 5 seconds. The tool 
was then transferred to the second trough and 0.2 M NaOH was aspirated for roughly 5 seconds 
to denature the DNA, then the tool was transferred to the third trough where it was aspirated 
with washing buffer (Qiagen 979008) for roughly 5 seconds. The vacuum was then released and 
the tool was placed in the PSQ plate containing 45 µl 0.3 µM sequencing primer in Annealing 
buffer and gently shaken to release the beads with the single-stranded PCR product attached. 
The sequencing primer was annealed to the PCR product by heating the plate at 80˚C for 2 
minutes and then allowing it to cool down to room temperature by removing the plate and 
placing it on the bench. The Vacuum Prep Tool was shaken in the fourth trough containing MilliQ 
water, to release any leftover beads and then washed by aspirating water for 20-30 seconds. 
 
2.9.1.2 Sequencing 
The powdered enzyme and substrate mixes from the PyroMark Gold Q96 Reagents Kit (Qiagen 
972804) were reconstituted in 620 µl nuclease free water each. A new SNP run was created and 
the details of the dispensation orders used are shown in table 2.5. The dispensation order was 
designed to cover the region of the single nucleotide polymorphism (SNP) directly after the 
sequencing primer and the region after this to confirm the presence of wild type sequence. To 
sequence the SNP, nucleotides A, C, T and G were added at this position. 
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The enzyme mix, substrate mix and the four deoxynucleotides were added to the PSQ® 96 
cartridge (Qiagen 979004), the quantities to be added to the cartridge were calculated once the 
plate layout and dispensation order had been defined. The PSQ® plate and cartridge were loaded 
into the PSQ96 MA instrument and the sequencing run was started. Once finished, the plate and 
cartridge were removed from the instrument, the plate was disposed of and the cartridge 
washed with MilliQ water to be re-used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene and 
Position of SNP 
Name of 
Dispensation order 
Dispensation Order 
katG Codon 315 katG ACTGCGCATCGA 
katG Codon 315 katG plus ACTGCGCATCGAGTCGTATG 
katG Codon 315 katG extended ACTGCGCATCGAGTCGTATG[actg]30 
inhA promoter 
region 
inhA GACACTATCGTCTCGCGCGCATCGTATGTCAGCTA
GCT 
Table 2.5 Dispensation orders designed for detection of SNPs in Mycobacterium tuberculosis 
by pyrosequencing  
65 
 
Chapter 3. Factors affecting the efficacy of isoniazid and rifampicin against 
Mycobacterium tuberculosis in vitro 
3.1 Introduction 
In work performed by Kim Hatch within the Tuberculosis Research Group at Public Health 
England, Porton Down, found that the MICs of isoniazid and rifampicin used in a chemostat 
system did not perform as expected and this was particularly evident with rifampicin. The MICs 
had been established using a standard inoculum cultured in a low volume batch culture. It was 
noted that perhaps the high titre of bacteria in this system, akin to in vivo titres, was affecting 
the result. The factors that may have been affecting the efficacy of a drug were investigated to 
enable fuller interpretation of any results and to improve the modelling of M. tuberculosis 
interacting with antibiotics in vivo. 
Most of the current drug susceptibility/efficacy methods for M. tuberculosis suffer from low 
predictability along with a clinical irrelevance and from unacceptably low reliability resulting 
from poor reproducibility (Kim, 2005). This is due to drug susceptibility testing methods and 
interpretation varying greatly. There are a variety of different conventional culture methods 
using agar based media are still the most widely utilised in many countries. The standard 
methods using Lowenstein–Jensen medium include the proportion method, the absolute 
concentration method and the resistant ratio method (Canetti et al., 1963), which are fairly well 
standardised with clinical samples, at least for the major anti-tuberculosis drugs. Microscopic 
observation of growth with and without the addition of antibiotic is a low cost, low technology 
tool (Brady et al., 2008) for assessing drug susceptibility in liquid culture. The resazurin microtitre 
assay (REMA) is a colourimetric, culture based drug susceptibility assay which has been endorsed 
by the World Health Organisation (Katawera et al., 2014). These assays along with the widely 
used mycobacterial growth indicator tube (MGIT) (BD Diagnostics) are liquid culture methods 
used for rapid detection and drug susceptibility testing of M. tuberculosis.  Molecular methods 
for detection of resistant isolates are also being developed and are attractive as they are rapid, 
are able to be standardised and can require less training. Non-molecular methods are still widely 
used however due to the cost of setting up molecular laboratories, particularly in areas with high 
tuberculosis incidence. Molecular methods do not completely eliminate the need for culture 
and require known loci and mutations in order to accurately detect resistance (Wilson, 2013). 
Many in vitro models and experimental readouts, such as MIC (minimum inhibitory 
concentration), used to determine the efficacy of an antibiotic do not take into account a 
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number of realities in an infected host. The complex interactions between a host and a 
bacterium are not fully understood, it is necessary to develop models and experiments that take 
into account factors that contribute to an antibiotic’s efficacy against a bacterium. Changes to 
the environmental conditions of the bacterium, such as pH, caused by natural bacterial growth 
processes may result in an environment that is not optimal for the action of the antibiotic 
(Udekwu et al., 2009). The physiological state of the bacteria, such as the growth rate or the 
phase of growth is important as all antibiotics have a mode of action that targets cellular 
processes. In granulomas, formed during latent tuberculosis disease, the antibiotic may not be 
able to penetrate to reach the bacteria. 
Bacteria that are not actively growing or grow slowly can be more recalcitrant to the effect of 
drugs, similarly persister sub-populations of bacteria can emerge within a population of 
exponentially growing cells. It has been found that the fraction of persister cells increases with 
decreased growth rate in continuous culture (Sufya et al., 2003), indicating growth rate could 
have a significant impact on the efficacy of TB treatments. In the case of tuberculosis, depending 
on the stage of infection, some of the M. tuberculosis organisms are actively multiplying, very 
probably at a rate similar to that in a log phase culture, while at the other extreme, their 
metabolism and growth is completely inhibited. It is important to study and define the action of 
anti-tuberculosis therapies against slow growing and dormant bacteria as these are the thought 
to be the population of M. tuberculosis cells that are responsible for the re-activation of TB 
disease. Since virtually all antibiotics preferentially kill rapidly replicating bacteria, it has been 
hypothesized that the reduced growth and metabolic activity of these quiescent populations is 
responsible for the ‘antibiotic tolerance’ observed during infection (Baek et al., 2011) Growth 
limitation by lack of available nutrients  gives rise to cells with reduced growth rates and 
coincidentally radically altered cell envelopes. When the envelope itself contains the primary 
target for drug action a reflection in the relative abundance of the target material may reduce 
the overall susceptibility of the cells (Brown et al., 1990) for example, reduced susceptibility to 
isoniazid has been characterised as one of the defining features of dormancy (Petros C. 
Karakousis, Ernest P Williams and William R. Bishai, 2007). 
The cell density of a bacterial population is another major factor that may affect the efficacy of 
an antibiotic. In vitro studies would ideally be carried out using inocula that are comparable to 
the titre of bacteria that would be seen in an infection in vivo because they might better predict 
the efficacy of an antibiotic (Davey and Barza, 1987). MICs are usually estimated over a short 
period, using optical density (OD540nm) measurements in cultures inoculated with around 5x105 
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cells ml-1 of exponentially growing bacteria. These experiments are carried out at temperatures 
and in media optimal for their growth and the action of the antibiotic (Udekwu et al., 2009)  A 
reduction in the effective concentration of the antibiotic (free active drug) in the medium due 
to antibiotic-denaturing enzymes or by binding of the antibiotic to bacterial cell components 
would reduce the efficacy of an antibiotic.  The rate and extent at which this occurs would be 
proportional to the density of the bacteria exposed and therefore the concentration of enzymes 
and availability of cell components. It has been shown that in cultures with a low inoculum the 
level of antibiotic was higher than the MIC for 100% of the timecourse, whereas in cultures with 
a  high inoculum, this level was only maintained for 38% of the same period of time (LaPlante 
and Rybak, 2004). The rate of killing or inhibition of growth may be proportional to the amount 
of antibiotic available to each bacterium at the time of exposure. This may be due to 
pharmacodynamic, pharmacokinetic and physiological reasons that are likely to vary among 
species of bacteria and antibiotics in vivo. This is something that needs to be considered in vitro, 
for example, for the same concentration of an antibiotic in the medium (1mg/L), for a culture 
containing 108 bacteria/ml, the amount of drug available per bacterium is 1/1000 as great as 
that in culture of 105 bacteria/ml. At both densities the number of antibiotic molecules per 
bacterium would be enormous but the ability of antibiotics to kill or inhibit the growth of 
bacteria may require a large number of molecules of the drug per cell or per target due to 
physiological factors meaning uptake or conversion of drug is not optimal (Udekwu et al., 2009), 
this will vary depending on the target of the antibiotic. 
In many infectious diseases including tuberculosis, the quantity of bacteria can far exceed the 
standard MIC inoculum, with levels of 108 cfu/ml of lung and above being isolated from the lungs 
of mice (De Groote et al., 2011) and guinea pigs (Ordway et al., 2010) infected with M. 
tuberculosis. MRI imaging of the lungs of infected non-human primates has also shown the 
formation of lesions with large numbers of bacteria at a high cell density in granulomas similar 
to the pathology presented in humans (Sharpe et al., 2009, 2010a). The chemostat system allows 
for high titres of bacteria to be grown under controlled conditions in a continuous culture, there 
is a constant flow of nutrients. This is in contrast to a closed batch culture which does not allow 
for control of factors such as pH and oxygen level and allows an accumulation of bacterial waste 
and toxins and a depletion of available nutrient. In previous work (carried out at PHE, Porton 
Down – data not shown) using these chemostat systems we have found that an MIC calculated 
using a low titre (105 cfu/ml) batch culture is not entirely applicable, there are a number of 
factors that can affect the susceptibility of an organism or the effectiveness of a drug to be 
delivered and/or activated. 
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The work in this chapter aims to identify whether factors such as cell density, the doubling time 
of the bacteria and the phase of growth of a bacteria influence the susceptibility to isoniazid and 
rifampicin. This will then help to interpret results in future experiments and indicate whether 
the current MIC testing practices are a true reflection of the environment in the host that the 
treatment is going to be active in. 
The specific objectives for this work were as follows: 
1. To determine whether cell titre has an effect on the MIC of isoniazid and rifampicin 
against M. tuberculosis  
 
2. To determine whether the growth phase of M. tuberculosis culture has an effect on the 
efficacy of Isoniazid and Rifampicin at a range of concentrations to include the MIC 
 
3. To determine whether the growth rate i.e. doubling time of M. tuberculosis has an effect 
on the efficacy of Isoniazid and Rifampicin at a range of concentrations to include the 
MIC 
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3.2 Establishment of exponential growth in flask cultures for use as an inoculum 
For experiments that were investigating the effect of cell density on the efficacy of isoniazid and 
rifampicin against M. tuberculosis a population of exponentially growing cells was required in 
order to provide the starting inoculums. By using cells that were still actively dividing, any effects 
on the results caused by cells being in stationary phase or being nutrient depleted could be 
minimised. Four seed flasks were set up as described in section 2.2.1, each inoculated with a 
quarter of a plate of confluent growth of M. tuberculosis seed stock that was 2-3 weeks old.  
 
 
 
 
 
 
 
 
 
 
The viable count data in figure 3.1 shows that the average titre of the flasks after 24 hours of 
growth was 9.0 x 106 cfu/ml. It was not possible to take a value at 0 hours as the inoculum from 
the plate is clumpy and does not disperse well immediately, making any sampling at this time 
point inaccurate. After 48 hours there was no significant difference in the titre compared to the 
previous timepoint, this could be due to the M. tuberculosis adapting to a new growth medium, 
having being cultured on agar before being inoculated into the flask leading to a lag phase. The 
24 hour result could also be artificially high as it was noted that there were still clumps of 
bacteria in the flask, if one of these aggregates was sampled it could have led to a titre appearing 
artificially high.  After 48 hours, the flasks all increased in cell titre and by 168 hours after 
inoculation had risen to an average titre of 5.5x107 cfu/ml.  
Flasks were sampled at 72 hours of growth for use as an inoculum in cell density experiments,  
figure 3.1 showed that this would provide a  cell sample that was exponentially growing and not 
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Figure 3.1 Growth of M. tuberculosis in flasks in MOD 2 medium (section 2.1.1) 
shaking at 200 rpm at 37°C to determine the optimum time to sample 
exponentially growing cells. These data comprise of four separate flask 
experiments, each with three viable count readings at each timepoint. The error 
bars represent the standard error of the mean (SEM). 
70 
 
in a stationary or lag phase. It appeared that sampling at around 48 hours would not be ideal 
due to the lag phase.  
3.3 The effect of cell density on the efficacy of Isoniazid 
A flask was filled with approximately 300 ml of CMM MOD 2 medium (section 2.1.1) and 
inoculated with confluent growth of  M. tuberculosis from agar plates that had been incubated 
for 2-3 weeks to provide exponentially growing cells at a high titre. The flask was left to grow for 
72 hours, these cells were then used to inoculate two sets of flasks containing 50 ml of CMM 
MOD 2 medium each to a level of 1x107 cfu/ml, 1x106 cfu/ml and 1x105 cfu/ml. A set without 
isoniazid to provide positive control data and a set containing 0.5 µg/ml isoniazid (1 x MIC) were 
produced. These were then sampled over a timecourse of 10 days to provide viable count and 
optical density data and to test the hypothesis that cells at a higher density will be killed more 
slowly than those at a lower cell density.  
The results have been categorised as shown in table 3.1. These parameters were taken from 
(LaPlante and Rybak, 2004) 
Result Definition of effect of antibiotic 
>  3-log10 cfu/ml reduction Bactericidal 
< 3-log10 cfu/ml reduction Bacteriostatic 
No observed reduction  Inactivity 
 
 
 
Table 3.1 Parameters by which the effect of an antibiotic on M. tuberculosis is defined. 
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3.3.1 The effect of a high cell density (1 x 107cfu/ml) of Mycobacterium tuberculosis on the 
efficacy of isoniazid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 A graph showing cells growing at a cell density of 1 x 107 cfu/ml in the presence 
of 0.5 µg/ml isoniazid (MIC) and without the presence of isoniazid. The data is the result 
of 3 independent flasks with 3 viable counts for each timepoint. The error bars represent 
the SEM. 
Figure 3.3 A graph showing cells growing at a cell density of 1 x 107 cfu/ml in the presence 
of 0.5 µg/ml isoniazid (MIC) and without the presence of isoniazid. This is a replicate 
experiment of Figure 3.2, each symbol is the mean of three viable count measurements.  
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Figures 3.2 and 3.3 show that the flasks were inoculated with an average starting titre of 
1.67x107 cfu/ml in the control flasks (without isoniazid) and 1.03x107 cfu/ml in the flasks 
containing isoniazid.  
The control cultures in both experiments grew, doubling after less than 24 hours to a cell titre 
of 2.1x107 cfu/ml at the 24 hour timepoint, showing conditions were favourable for growth of 
M. tuberculosis. After 48 hours one of the control flasks became contaminated and no further 
data was available but this flask was showing continuing exponential growth, reaching a peak of 
1.43x108 cfu/ml. 
Exponential growth continued to 72 hours post-inoculation (in the remaining control flask), 
reaching a peak cell titre of 1.4x108 cfu/ml. After this point the viable count declined. This is 
possibly due to a  typical bacterial growth curve occurring within the flask with the cells entering 
a stationary and then death phase 100 hours post inoculation and beyond. The starting titre was 
intentionally high and could have limited the amount of growth possible due to nutrient 
depletion and bacterial toxins building up within a batch system such as a flask. A lag phase was 
seen in Fig 3.2 which lasted for around 48 hours. This lag phase needs to be considered when 
analysing the data from the flask with isoniazid exposure, any apparently bacteriostatic action 
of the drug within this first 48 hours could just be a mirroring of this lag phase.  
The two independent replicate flasks of M. tuberculosis exposed to 0.5 µg/ml isoniazid (1 x MIC) 
added showed different profiles to each other. The results from these experiments were not 
combined and averaged as the profiles showed differing trends. 
After 48 hours exposure to isoniazid there is a significant decrease in viable cells (p=0.005), 
dropping to 7.6x104 cfu/ml (figure 3.2). This level of viability then remains constant at 72 hours 
with no further killing occurring until 96 hours when a drop in viability to the limit of detection 
is seen (5x103 cfu/ml), this value is then maintained until 216 hours after exposure with isoniazid 
when a viable count of 1x104 cfu/ml was detected. This indicates that there were still viable cells 
present in the culture throughout the exposure to isoniazid. The effect of the isoniazid appears 
to bactericidal throughout the experiment. 
There was no significant change in the viable cell number after 24 hours (p=0.100 using Mann 
Whitney) (figure 3.3). This is in contrast to the flask containing no isoniazid acting as a control 
culture and shows the effect of isoniazid after 24 hours exposure appears to be bacteriostatic. 
This flask shows no further change after 96 hours (p=0.2683), with the viable count remaining 
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stable at around 1x107 cfu/ml. At the end timepoint of the experiment the cell titre is still high 
at 1.6x107 cfu/ml, showing no significant difference (p=0.2683) to the starting cell titre at 0 
hours. The action of isoniazid appears to remain bacteriostatic throughout this culture as would 
be expected from an MIC dose, neither causing cell death nor allowing growth of M. tuberculosis, 
using the definitions in table 3.1, isoniazid in this Fig 3.3 would be defined as inactive, if this were 
an infection there would be a very high titre of bacteria still remaining. This effect appeared to 
be immediate as there was no increase in cell numbers after 24 hours which would be slightly 
more than the doubling time for M. tuberculosis in vitro. This did not reflect the result seen in 
figure 3.2 in terms of cfu/ml but both flasks showed a population of cells that persist through 
treatment of isoniazid. Previous work using these techniques has found the MIC of isoniazid to 
be 0.5 µg/ml which was reflected in the results shown in figure 3.3, this could indicate that these 
results are the true result and that the results obtained in figure 3.2 are anomalous. The limit of 
detection was also high in the results shown in figure 3.2 and so for the repeat of this work (the 
results seen in figure 3.3) the design of the method was altered by plating out more dilutions to 
achieve a lower limit of detection. The results at the lower cell densities may also give an 
indication as to which set of results reflects the true nature of the effect of cells growing at 107 
cfu/ml on the efficacy of isoniazid. 
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3.3.2 The effect of intermediate and low cell densities (1 x 106 cfu/ml and 1x 105 cfu/ml) of 
Mycobacterium tuberculosis on the efficacy of isoniazid 
 
 
 
 
 
 
 
 
 
The growth of M. tuberculosis at a titre of 106 cfu/ml (figure 3.4) showed reproducibility and the 
data was averaged to increase the statistical power and reliability of the results. The flasks were 
inoculated with the desired starting cell titre of 1x106 cfu/ml, with an average of 1x106 cfu/ml in 
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Figure 3.4 The effect of cell density on cells at 106 cfu/ml with and without 0.5 µg/ml (1 x MIC) 
Isoniazid. The lines represent the average of at least two independent flasks with 6 viable 
counts from each flask at each timepoint, error bars are present denoting the SEM. The limit 
of detection is represented by the solid reference line. 
 
Figure 3.5 The effect of cell density on cells at 105 cfu/ml with 0.5 µg/ml (1 X MIC) isoniazid 
and without isoniazid. The lines represent the average of two independent flasks, with 6 
viable counts performed on each flask at each timepoint. Error bars were applied denoting 
the SEM, in cases of very small error these may not be visible due to the scale of the y-axis. 
The limit of detection is represented by the solid horizontal reference line 
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the control cultures and 1.3x106cfu/ml in the cultures containing isoniazid. The control cultures 
grew exponentially between 0 and 96 hours reaching a peak viable count of 3.1x107 cfu/ml, 
indicating conditions were favourable for growth of M. tuberculosis. There was no decline in this 
viability up to 192 hours post inoculation indicating any decline in viability seen in the flask 
containing isoniazid would be due to the presence of antibiotic rather than unfavourable growth 
conditions.  
The flasks inoculated at a titre of 1x105 cfu/ml (figure 3.5) were to represent the standard titre 
that is usually used in assessing drug efficacy, such as MIC experiments and determining 
susceptibility of organisms to antibiotics (Udekwu et al., 2009). The data in figure 3.5 shows that 
the control flasks were inoculated with an average cell titre of 1x105cfu/ml and the flasks 
containing isoniazid were inoculated with an average cell titre of 9.5x104 cfu/ml. The control 
cultures grew exponentially, reaching a peak 2x106 after 192 hours post inoculation, showing 
that at this starting titre the M. tuberculosis is able to proliferate and that the growth conditions 
were favourable.  
At 24 hours of growth and drug exposure the cultures containing isoniazid at the intermediate 
cell density (figure 3.4) showed a decrease in viability which was statistically significant 
(p=0.0028) when compared to the 0 hour value. This is in contrast to the low cell density 
experiment results seen in figure 3.5 which shows a delay in the reduction of the viable count 
until after the 24 hour timepoint as there is no significant difference between this cell titre and 
the 0 hour value (p=0.5242) 
After 24 hours the viable cell number began to decline steadily at both intermediate and low 
cell densities. In the intermediate cell density experiment the cells with a starting titre of 1x106 
cfu/ml showed a decrease in viability of 60% between 48 and 72 hours post inoculation and 
exposure, which increases to 83% between 72 hours and 96 hours. The difference in the viable 
cell numbers between 96 and 168 hours showed a decrease in viable cell count of 94%, this is a 
reduction in the rate of killing when compared to between 72 and 96 hours as this drop in 
viability is over a shorter time period. The low cell density cultures resulted in a drop in titre 
after 48 hours to 1.7x104 cfu/ml and continued to fall to 3.3x102 cfu/ml by 168 hours 
In the intermediate cell density experiment (figure 3.4) after 168 hours exposure to isoniazid the 
rate of death slowed considerably with 90% of the population that were viable at 168 hours 
remaining viable 24 hours later, this period is then followed by a further increase in killing at 216 
hours resulting in a final viable cell titre of 2.3x102 cfu/ml. In the low cell density experiment a 
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slight increase in viable count was seen at 192 hours which also occurred in the high and 
intermediate cell density experiments (figure 3.2 and 3.4), followed by a period of more rapid 
killing than seen throughout the timecourse, resulting in a viable count of 5x101 cfu/ml. 
There is a clear difference in the response of the control and drug exposed cultures at both 
intermediate and low cell density experiments indicating that the cell death seen in the drug 
exposed cultures was due to the presence of isoniazid. The overall trend of these results shows 
that 0.5µg/ml isoniazid results in a bactericidal killing trend when the culture is inoculated with 
either 1x106 cfu/ml or 1x105 cfu/ml. The bactericidal action of isoniazid seems to be delayed 
however as death rates at the beginning of the time course are much lower than after 48 hours 
exposure in both the intermediate and low cell density experiments.  
It is worth noting that the half life of isoniazid has been calculated to be between 1 and 5 hours  
in vivo, with variation due to the speed of acetylation in the liver of a patient, the half life of 
rifampicin is around 3.5 hours and it is also metabolised in the liver (Arbex et al., 2010). In 
experiments such as the ones performed in this chapter, antibiotic is not re-added to the 
cultures so the half life becomes important. Within the liquid culture however, the enzymes 
responsible for the metabolism of isoniazid in vivo are not present. Nevertheless, the MIC of 
isoniazid and rifampicin was tested after culture in medium for a prolonged period at PHE, 
Porton Down (data not shown) and the MIC was found to be unaffected. This means that the 
antibiotics used in prolonged experiments was still active within the medium. 
3.4. The effect of different cell densities on the efficacy of rifampicin against Mycobacterium 
tuberculosis  
These experiments were set up as described in section 3.3 but the antibiotic added was 
rifampicin at a concentration of 8 ng/ml. This was the MIC calculated previously within the 
tuberculosis research group at PHE, Porton Down. The hypothesis was that cells at a higher 
density would be more recalcitrant to the effects of rifampicin within the medium. 
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3.4.1 High cell density 
 
 
 
 
The culture with rifampicin added in figure 3.6 showed the inoculum was 1.4x107 cfu/ml. This 
culture showed an increase in viability between the 0 hour and 168 hour final time point. The 
resulting viable count was 4.3x108 cfu/ml. The viable cells then doubled in number between 24 
and 48 hours, 48 and 96 hours and 96 and 168 hours.  The doubling time of the M. tuberculosis 
cells exposed to rifampicin increased throughout the course of the experiment from 24 hours to 
48 hours to a final doubling time of 72 hours, indicating that the rifampicin was having an effect 
on the growth rate but not the viability of the cells. 
 
 
 
 
 
 
  
Figure 3.6 The effect of cell density on cells at 107 cfu/ml with 8 ng/ml (1 x MIC) rifampicin 
and without rifampicin. The lines represent the average of two independent cultures, with 
each having 3 viable counts at each timepoint (n=6) error bars are present denoting the 
standard deviation. 
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Figure 3.8 The effect of cell density on cells at 105 cfu/ml with 8 ng/ml (1 x MIC) rifampicin and 
without rifampicin. The lines represent the average of two independent cultures, with at least 
6 viable counts at each timepoint (n=≥ 12). Error bars are present denoting the standard 
deviation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 The effect of cell density on cells at 106 cfu/ml with 8 ng/ml (1 x MIC) rifampicin 
and without rifampicin. The lines represent the average of two independent cultures, with 9 
viable counts at each timepoint (n=18) error bars are present denoting the standard 
deviation. 
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3.4.2. Intermediate cell density 
The intermediate cell density data (figure 3.7), shows that the control cultures increased in 
viability to a final viable count of 1.28x108 cfu/ml, indicating conditions were favourable for 
growth from a starting inoculum of 1x106 cfu/ml. The average inoculum at 0 hours for the control 
cultures was 1.8x106 cfu/ml and for the cultures containing rifampicin it was 1.6x106 cfu/ml and 
there was no significant difference between these numbers (p=0.1605 Mann Whitney). At 24 
hours after inoculation, there was no significant difference seen between the control and drug 
containing cultures, both showing an increase in viable cell numbers. This indicates that the 
rifampicin is not acting on the M. tuberculosis cells within the first 24 hours of exposure, this is 
similar to the high cell density experiment seen in Fig 3.6. At 48 hours the rifampicin flasks are 
showing a significantly lower cell titre than the control (p=<0.0001) indicating the rifampicin was 
inhibiting the growth of the bacteria. Evidence of rifampicin having an effect was also seen in 
the high density experiment but in contrast there is a loss of viable cells in the intermediate cell 
density rather than a slowing of the growth rate as seen in the high density experiment.  
No additional effect of rifampicin was seen after 48 hours of exposure, the control culture and 
culture containing rifampicin both maintained a viable count, showing the rifampicin appears to 
have reduced the viable count by 1 log in the first 48 hours when compared to the control 
culture. Between 96 and 168 hours the viable count increases to 7.9x107 cfu/ml in the control 
flask and 7.8x106 cfu/ml in the rifampicin containing flasks continuing the log difference between 
the flasks and showing that the M. tuberculosis is adapting to the presence of rifampicin, with a 
doubling time of approximately 36 hours. This doubling time is slower than the observed in vivo 
and in vitro value of around 24 hours and as also seen in the high density experiment, it is 
showing that a reduction in growth rate could be reducing the effect of rifampicin.  
3.4.3 Low cell density 
The average starting titre of the control cultures was 1.3x105 cfu/ml and 1.8x105 cfu/ml for the 
cultures containing rifampicin, this difference was not statistically significant (p0.2896) (figure 
3.8) 
By 24 hours the control cultures had increased to 4.8x105 cfu/ml  and the rifampicin containing 
cultures maintained a population at 1.9x105 cfu/ml, signifying that rifampicin is having a 
bacteriostatic effect on the M. tuberculosis cells, that continues through to  48 hours of 
incubation with no significant difference between the 24 and 48 hour viable counts (p=0.3181). 
At 72 hours there is a drop in viability within the cultures containing rifampicin to 4x104 cfu/ml 
indicating the rifampicin is having an effect, this is confirmed by the control flasks, containing no 
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rifampicin, increasing in viability. This drop continues to the end timepoint when an average of 
7x103 cfu/ml were recovered from the rifampicin treated cultures. There is still a population of 
cells remaining in the flasks after 192 hours and the killing slowed between 168 and 192 hours 
but these viable counts were on or very close to the limit of detection so the reliability of these 
numbers is perhaps not as high as earlier in the timecourse. This is in contrast to the higher cell 
densities where growth was seen in the presence of rifampicin by the end of the time course. 
These results indicate that an MIC dose of rifampicin added to cells growing at 1 x 105 cfu/ml, as 
would be the case in a clinical setting (Udekwu et al., 2009) result in the expected growth curve, 
bacteriostasis and some death. At higher, perhaps more clinically relevant bacterial titres (De 
Groote et al., 2011; Ordway et al., 2010; Sharpe et al., 2009, 2010a) the effect of the rifampicin 
is diminished. Along with the findings in this chapter and work done in the chemostats at PHE, 
Porton Down by members of the TB research group, it appeared that 8 ng/ml was not a high 
enough concentration of rifampicin for an MIC within high titre cultures. Further MIC 
experiments were performed using cultures grown in flasks, allowing a high cell density to be 
achieved, to determine an appropriate concentration to be used. The results showed that 32 
ng/ml rifampicin was the concentration that yielded the response expected of an MIC 
(bacteriostasis) (figure 3.9). This result was true regardless of the length of exposure and this  
concentration (32 ng/ml) was used in subsequent experiments in this thesis as an MIC for 
rifampicin. 
 
 
 
 
 
 
 
Figure 3.9 The OD540 of M. tuberculosis cultures after 4, 7 and 8 days of exposure to 
varying levels of rifampicin (0-256 ng/ml). The MIC was taken as the first concentration 
with no increase in growth (32 ng/ml) 
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3.5 The impact of the growth rate of M. tuberculosis on the efficacy of isoniazid and rifampicin 
It has been shown that growth rate can have an effect on the number of persister cells in a 
population (Sufya et al., 2003). M. tuberculosis is thought to grow at different rates in vivo with 
slow growing cells thought to reduce the efficacy of treatment which as with many antibiotics 
preferentially kill rapidly dividing bacteria. The chemostat allows control of growth rate, using 
this model doubling times of 23.1 hours, 69.3 hours and 138.6 hours were chosen to represent 
actively dividing, slow growing and very slow growing populations of M. tuberculosis that might 
be encountered by isoniazid and rifampicin. These experiments were set up as described in 
section 2.4 and the cells used as an inoculum, were sampled from continuous cultures at the 
aforementioned doubling times. The readout for antibiotic efficacy was the growth ratio of the 
cultures. This was calculated by dividing the viable count at 96 hours post-inoculation by the 
initial viable count at 0 hours (inoculation), the method is described in section 2.4. When cells 
are referred to having an MGT of 23.1, 69.3 or 138.6 hours in the following sections, this refers 
to the MGT of the chemostat the samples of cells were taken from, the results presented in the 
following sections represent these chemostat samples used as inoculums for batch cultures 
exposed to isoniazid. 
3.5.1 M. tuberculosis at varying growth rates exposed to isoniazid 
To assess whether the differences in the susceptibility to isoniazid between growth rates was 
apparent after just 24 hours, analyses were performed on viable counts taken 24 and 96 hours 
after the initial antibiotic exposure and the growth ratio was calculated. This would then inform 
as to how quickly the antibiotic acted on the bacterial cells and also how early on in the 
timecourse the effects of growth rate could be seen to affect the susceptibility. The drug 
concentrations in these experiments are static, however, by using a wide range of 
concentrations and assessment of mycobacterial killing at different time points during drug 
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exposure, insight can be provided into the dynamic killing capacity of fluctuating drug 
concentrations (de Steenwinkel et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. M. tuberculosis exposed to varying concentrations of isoniazid (MIC 0.5 µg/ml) 
over 24 hours. Cells were removed from continuous culture in which the doubling time had 
been controlled at either 23.1 hours, 69.3 hours or 138.6 hours and used as inocula for smaller 
cultures with varying levels of isoniazid present. P-values (calculated using Mann-Whitney t-
test in Graph Pad Prism 5) are equal to *** <0.001 ** 0.001 to 0.01 or *0.01 to 0.05. Each 
symbol represents a growth ratio of a viable count taken at 0 and 24 hours. Two independent 
chemostat experiments were run for each growth rate, where the results are bimodal the 
results have been separated (colour and black) based on the chemostat the inoculum 
originated from. 
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When the results were analysed after 24 hours of antibiotic exposure (Figure 3.10) there was no 
difference between the fastest growth rates (23.1 hour MGT and 69.3 hour MGT) in the 
susceptibility of cells to sub-MIC levels (0.25 µg/ml) of isoniazid, with both showing positive 
growth ratios (an increase in the number of viable cells). The slowest growing cells also showed 
a positive growth ratio but this was significantly higher than the cells growing at the two faster 
growth rates indicating reduced susceptibility to isoniazid at a very slow growth rate. After 96 
hours of exposure (as seen in Fig 3.11) the slowest growing cells were the most susceptible. 
At MIC levels of isoniazid there was no growth rate effect at 96 hours, there was a similar pattern 
after 24 hours of exposure. The data is more spread at 96 hours however, this suggests there 
may be more heterogeneity in the populations of M. tuberculosis after exposure to isoniazid for 
96 hours. 
Figure 3.11. M. tuberculosis exposed to varying concentrations of isoniazid (MIC 0.5 µg/ml) 
over 96 hours. Cells were removed from continuous culture in which the doubling time had 
been controlled at either 23.1 hours, 69.3 hours or 138.6 hours and used as inocula for smaller 
cultures with varying levels of isoniazid present. P-values (calculated using Mann-Whitney t-
test in Graph Pad Prism 5) are equal to *** <0.001 ** 0.001 to 0.01 or *0.01 to 0.05. Each 
symbol represents a growth ratio of a viable count taken at 0 and 96 hours. Two independent 
chemostat experiments were run for each growth rate, where the results are bimodal the 
results have been separated (colour and black) based on the chemostat the inoculum 
originated from. These results are from the same experiment as the earlier timepoint of 24 
hours seen in Figure 3.10 
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At levels of isoniazid above the MIC at 96 hours (figure 3.11) the cells with an MGT of 69.3 hours 
were significantly less susceptible to isoniazid than those at the fastest growth rate, there was 
no discrimination between cells with an MGT of 69.3 and 138.6 hours.  The effect of the isoniazid 
is concentration dependent up to 2 x MIC, increasing the concentration above this does not have 
an effect until 16 x MIC. Conversely, at 24 hours the effect of isoniazid was concentration 
independent at the two fastest growth rates when all levels of isoniazid appeared to be 
inhibiting growth rather than killing. This lag in kill was also seen in the cell density results in 
sections 3.3.1 – 3.4. This difference in susceptibility between the two fastest growth rates was 
generally apparent after 24 hours of exposure, the slowest growing cells however were the most 
susceptible at levels of isoniazid at MIC and above at 24 hours which is in contrast to the result 
after 96 hours.  
These very slow growing cells appeared to be affected quickly by isoniazid at 24 hours and the 
effect was concentration dependent until 2 x MIC, following a similar pattern to the faster 
growth rates at 96 hours. The control data (0 µg/ml isoniazid) at 24 and 96 hours (figures 3.10 
and 3.11) showed the cells with an MGT of 138.6 hours had grown the most and appeared to 
have adapted to batch culture more successfully than the two faster growth rates. The M. 
tuberculosis with an MGT of 138.6 hours did not appear to have a lag phase and consequently 
the isoniazid acted within 24 hours resulting in a similar pattern of results seen at 96 hours with 
the two faster growth rates. During the timecourse of this experiment between 24 and 96 hours 
a population of very slow growing cells emerged that were adapted and therefore less 
susceptible than the faster growth rates to very high levels of isoniazid. 
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3.5.2 The effect of the growth rate of M. tuberculosis on the efficacy of rifampicin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 M. tuberculosis exposed to varying concentrations of rifampicin (MIC 32 ng/ml) 
over 24 hours. Cells were removed from continuous culture in which the doubling time had 
been controlled at either 23.1 hours, 69.3 hours or 138.6 hours and used as inocula for 
smaller cultures with varying levels of rifampicin present. P-values (calculated using Mann-
Whitney t-test in Graph Pad Prism 5) are equal to *** <0.001 ** 0.001 to 0.01 or *0.01 to 
0.05. Each symbol represents a growth ratio of a viable count taken at 0 and 24 hours. Two 
independent chemostat experiments were run for each growth rate, where the results are 
bimodal the results have been separated (colour and black) based on the chemostat the 
inoculum originated from.  
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Figure 3.13 M. tuberculosis exposed to varying concentrations of rifampicin (MIC 32 
ng/ml) over 96 hours. Cells were removed from continuous culture in which the doubling 
time had been controlled at either 23.1 hours, 69.3 hours or 138.6 hours and used as 
inocula for smaller cultures with varying levels of rifampicin present. P-values (calculated 
using Mann-Whitney t-test in Graph Pad Prism 5) are equal to *** <0.001 ** 0.001 to 0.01 
or *0.01 to 0.05. Each symbol represents a growth ratio of a viable count taken at 0 and 
96 hours. Two independent chemostat experiments were run for each growth rate, where 
the results are bimodal the results have been separated (colour and black) based on the 
chemostat the inoculum originated from.  
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The results from the cell density work indicated that an MIC of rifampicin of 8 ng/ml was 
unsuitable for high titre cultures and the MIC was adjusted to 32 ng/ml (section 3.4.2). At a sub-
MIC level (16 ng/ml) of rifampicin there was a decline in viability after 96 hours in the cells with 
an MGT of 23.1 and 69.3 hours with no difference between these growth rates. The growth of 
the slowest growing cells was inhibited showing a bacteriostatic effect of this level of drug. The 
discrimination between growth rates is obvious after 96 hours of exposure (figure 3.13) but at 
24 hours this effect is reduced. 
Levels of rifampicin at MIC and above showed a pattern, the longer the MGT of the cells, the 
less susceptible they were to rifampicin after 96 hours (figure 3.12). This pattern continued until 
16 x MIC (512 ng/ml) when the two fastest growth rates are indistinguishable from each other 
but the slowest growth rate was significantly less susceptible. The effect of rifampicin appeared 
to be concentration independent at all growth rates at 96 hours which is in contrast to the 
isoniazid results (figure 3.10) which showed a concentration dependent effect up to 2 x MIC. 
The clear distinction between growth rates observed after 96 hours of exposure could not be 
observed after 24 hours of exposure. There is a significant difference between the 23.1 and 69.3 
hour MGT populations, with the latter being slightly less susceptible, the range of killing was 
small and there was no difference between 69.3 and 138.6 hour MGT populations until 8 x MIC. 
This is in contrast to the isoniazid results in section 3.5.1 which showed the slowest growing cells 
to be the most susceptible after 24 hours, this was only true at the highest levels of rifampicin. 
Rifampicin affected the slowest growing cells after 24 hours but did not have any further effect 
as evidenced in figure 3.12, the cells with an MGT of 23.1 and 69.3 hours seemed to lose most 
of their viability after 24 hours of exposure. This delay in killing of the faster growth rates is a 
similar pattern to the isoniazid results. 
The results for isoniazid and rifampicin are not the same with differences at sub-MIC and MIC 
levels of antibiotic being particularly striking. Cells growing in sub-MIC levels of isoniazid showed 
growth which was in contrast to the decline in viability seen when the cells were grown in 
rifampicin. The highly significant difference seen between growth rates when cells were exposed 
to rifampicin (the slower the growth, the less susceptible to cells) was not seen when exposed 
to MIC levels of isoniazid. At levels of antibiotic above the MIC the susceptibility profiles of the 
bacteria to both isoniazid and rifampicin were very similar with a high level of killing with the 
slowest growth rate being the least susceptible. This population of very slow growing cells (MGT 
138.6 hours) appears the most susceptible to both antibiotics at 24 hours but there is no further 
killing of this population over the timecourse, it appears there may be two populations, one that 
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is highly susceptible to isoniazid and rifampicin that is killed within 24 hours and another that is 
recalcitrant and able to persist through the presence of drug. 
3.6 The effect of the growth phase of M. tuberculosis on the efficacy of isoniazid and rifampicin 
The aim of this work was to establish whether the phase of growth of M. tuberculosis has an 
effect in the susceptibility to isoniazid and rifampicin. Most antibiotics target actively dividing 
cells which are exponentially growing. M. tuberculosis can reside in the host in a variety of states 
including in granulomas where it is thought to be dormant or non-replicating. This population of 
bacteria is very difficult to treat and this work aims to use a culture modelling different phases 
of growth as a source of cells to determine the effect of growth phase on the effectiveness of 
isoniazid and rifampicin.  
The experiments were set up as described in section 2.4, using growth ratio of the cultures as a 
readout for antibiotic efficacy. This was calculated by dividing the viable count at 144 hours post-
inoculation by the initial viable count at 0 hours (inoculation), the method is described in section 
2.4.1. 
The cells used as an inoculum, were growing in an extended controlled batch culture as 
described in section 2.2.3.6 and (Bacon et al., 2014). The aim was to remove cells at different 
growth phases; exponential, stationary, death phase and non-replicating persistence caused by 
nutrient starvation. The total viable count data for the batch culture can be seen in figure 3.14 
with annotation to describe when in the culture the samples were removed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 M. tuberculosis grown in batch culture as described in section 2.2.3.6. 
Samples were taken for antibiotic susceptibility testing at days 2, 9, 30, 65 and 277.  
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Samples taken at days 2 and 9 were in the exponential phase of growth (figure 3.14). It appears 
that the exponential phase slowed after day 9 leading to stationary phase which was sampled 
at day 30, this phase lasted around 40 days. The sample taken at day 65 was in late stationary 
phase and also coincided with the beginning of a death phase, where there was a decline in 
viable count over the course of 60-70 days as the culture became nutrient depleted. The sample 
taken at the end of the culture (day 277) was when the culture was in a non-replicating 
persistent (NRP) phase, characterised by a slow growing or non-replicating dormant-like state, 
in this culture, this phase lasted for at least 60 days. 
 
3.6.1 The effect of growth phase of M. tuberculosis on the efficacy of isoniazid 
 
 
 
 
 
 
 
Figure 3.15 M. tuberculosis grown in batch culture and sampled at either 2 days, 9 days, 30 days, 
65 days, or 277 days. These samples were used as inocula for smaller cultures exposed to varying 
concentrations of isoniazid (MIC 0.5 µg/ml) over a 144 hour period. This graph shows levels of 
isoniazid from 0 µg/ml to 0.5 µg/ml). P-values (calculated using Mann-Whitney t-test in Graph 
Pad Prism 5) are equal to *** <0.001 ** 0.001 to 0.01 or *0.01 to 0.05 (n=≥3). 
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At a sub-MIC level of isoniazid (0.25 µg/ml) cells cultured for 65 days were the least susceptible 
to isoniazid (figure 3.15). There was no significant difference between cells that were cultured 
for 9 and 30 days, perhaps showing that day 9 was the start of stationary phase as evidenced in 
figure 3.13. The cells taken from the non-replicating persistence phase were more susceptible 
to isoniazid than the cells removed at 65 days of culture but the non-replicating persistence 
sample was still less susceptible than all other time points earlier than day 65. 
The exponentially growing cells (day 2 sample) were the most susceptible to an MIC level of 
isoniazid with the NRP cells being the least susceptible. An increase in susceptibility was seen 
between days 9 and 65 (from early to late stationary/death phase). At levels of isoniazid above 
the MIC (figure 3.16), the overall trend was a decrease in susceptibility the longer the bacteria 
were cultured for. As was seen with a sub-MIC level of isoniazid, at 2 x MIC and 4 x MIC there 
was no significant difference between cells removed from culture at day 9 and day 30, indicating 
that these cells could be in a similar growth phase.  
Figure 3.16 M. tuberculosis grown in batch culture and sampled at either 2 days, 9 days, 30 
days, 65 days, or 277 days. These samples were used as inocula for smaller cultures exposed 
to varying concentrations of isoniazid (MIC 0.5 µg/ml) over a 144 hour period. This graph 
shows levels of isoniazid from 1.0 µg/ml to 32 µg/ml). P-values (calculated using Mann-
Whitney t-test in Graph Pad Prism 5) are equal to *** <0.001 ** 0.001 to 0.01 or *0.01 to 
0.05 (n=≥3). 
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When samples were removed at 65 days (late stationary/early death phase) and from the NRP 
phase, the level of isoniazid was increased from 16 x MIC to 64 x MIC to try to determine what 
level of isoniazid would be highly effective against these cells, due to a large proportion of them 
remaining viable at the lower isoniazid concentrations. There was a high level of kill seen in the 
cells removed in the late stationary/early death phase (day 65), this was the highest level of kill 
seen throughout this experiment. Cells in the NRP phase showed a small level of kill similar to 
the lower concentrations of isoniazid, appearing much less susceptible to high levels of isoniazid 
than cells taken earlier in the culture. It must be noted that only two data points (i.e. comparable 
viable counts at the beginning and end of the experiment) are available at this concentration so 
the data is less reliable than earlier time points and lower antibiotic concentrations.  
The control data for the cells removed at the NRP phase also needs to be discussed. The overall 
growth ratio is negative, due to poor growth of the control samples. A sample was taken from 
the NRP phase prior to this experiment to determine how long it would take for these M. 
tuberculosis cells to re-grow (using OD540nm as a measurement), the result being  that it took 12-
14 days to see an increase in OD540nm.. Based on this finding, the antibiotic susceptibility assay 
was left for a further 192 hours (a total of 336 hours) but when the samples were plated out 
they were found to be contaminated.  The poor growth of the control could be due to a lag 
phase indicated by the amount of time it took to see an increase in OD540nm. 
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3.6.2 The effect of growth phase of M. tuberculosis on the efficacy of rifampicin 
 
 
 
 
 
 
  
Figure 3.17 M. tuberculosis grown in batch culture and sampled at either 2 days, 9 days, 30 
days, 65 days, or 277 days. These samples were used as inocula for smaller cultures exposed 
to varying concentrations of rifampicin (MIC 32 ng/ml) over a 144 hour period. This graph 
shows levels of rifampicin from 0 ng/ml to 32 ng/ml). P-values (calculated using Mann-
Whitney t-test in Graph Pad Prism 5) are equal to *** <0.001 ** 0.001 to 0.01 or *0.01 to 
0.05 (n=≥3). 
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At a sub-MIC level of rifampicin the M. tuberculosis cells became less susceptible to rifampicin 
the longer they were cultured for (figure 3.17). This is true for all the growth phases apart from 
the exponential phase cells (day 2) that were significantly less susceptible than the stationary 
phase samples. When the rifampicin concentration was increased to an MIC level, the 
exponential phase cells were once again less susceptible than the stationary and late 
stationary/early death phase samples. The samples removed at days 9 and 30 were similar in 
their susceptibility profiles, this was also seen in the isoniazid data (section 3.7.1). The 
susceptibility to rifampicin began to decrease in the cells removed in the late stationary/early 
death phase (day 65). 
At 2 x MIC and 4 x MIC (64 ng/ml and 128ng/ml) there was more cell death than at MIC levels of 
rifampicin in the exponential phase cells, there was a similar level of killing in the stationary and 
late stationary/early death phase cells (days 30 and 65) (figure 3.18). The difference between 
the samples taken at day 30 and 65 was more pronounced at lower levels of rifampicin. The NRP 
cells were significantly less susceptible than the cells growing in the exponential or stationary 
Figure 3.18 M. tuberculosis grown in batch culture and sampled at either 2 days, 9 days, 30 
days, 65 days, or 277 days. These samples were used as inocula for smaller cultures exposed 
to varying concentrations of rifampicin (MIC 32 ng/ml) over a 144 hour period. This graph 
shows levels of rifampicin from 64 ng/ml to 512 ng/ml). P-values (calculated using Mann-
Whitney t-test in Graph Pad Prism 5) are equal to *** <0.001 ** 0.001 to 0.01 or *0.01 to 
0.05 (n=≥3). 
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phases of growth. Increasing the concentration of rifampicin to 8 and then 16 x MIC did not 
result in the growth ratio of the exponential phase cells decreasing, this is also true of the 
stationary phase (day 30) data and is true of the late stationary/early death phase cells at 8 x 
MIC. At the highest level of antibiotic used (512 ng/ml 16 x MIC) the late stationary/early death 
phase cells showed a marked decline in viability compared with the lower rifampicin 
concentrations indicating this is the level required to observe further killing than was seen at 2 
x MIC (64 ng/ml) 
The data from the sample taken 9 days post inoculation from the batch culture is incomplete 
due to the plating out of the susceptibility assay at 2 x MIC and 4 x MIC resulting in no colonies 
growing on agar, this was true even when the sample was plated undiluted. It is unclear as to 
whether this result is an anomaly; if it is a genuine result then it appears that the cells from the 
day 9 sample are the most susceptible to rifampicin. The data from the day 9 cultures in sub-
MIC, 8 x MIC and 16 x MIC support this observation. In order to confirm this, repeat cultures 
would need to be sampled and assayed. There are also results missing from the NRP sample at 
256 ng/ml and 512 ng/ml rifampicin, this was also due to no colony growth at any dilution that 
was plated out. 
The differences between the effect of isoniazid and rifampicin was seen at an MIC level, the 
exponentially growing cells were the most susceptible to isoniazid but the least susceptible to 
rifampicin. Above MIC levels of drug the susceptibility to isoniazid decreased the longer the cells 
had been in batch culture for which was a clear pattern, the link between growth phase and 
susceptibility to rifampicin was not as clear although the NRP cells were the least susceptible. 
There was no difference in the susceptibility of cells that were in culture for 65 days and those 
from the NRP phase at levels of isoniazid above MIC, showing that cells in the NRP phase have 
no susceptibility advantage to isoniazid over those in the late stationary phase. Overall there 
was more kill with rifampicin, particularly with the day 65 cultures, reflecting that these cells 
were not dividing. It therefore appears that isoniazid was less effective but that the cells were 
still synthesising RNA enabling rifampicin to have more of an effect even if metabolism is slowed.  
3.7 Discussion 
Cell density was one of the factors investigated in this chapter because it is thought that there 
are differences in the number of bacteria throughout the host during infection. MICs of 
antibiotics have been shown to increase with the increasing number of bacteria exposed 
(Udekwu et al., 2009), this suggests that an antibiotic could clear the bacteria growing at a low 
concentration of cells but leave a populations of high concentrations of cells that could act as a 
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reservoir of infection. The results in sections 3.3 and 3.4 show that the action of both isoniazid 
and rifampicin are affected by cell density. It has been suggested that a reason for a cell density 
effect would be that in a high cell density population of bacteria there would ultimately be a lack 
of nutrients at the core of an infection (LaPlante and Rybak, 2004). In a batch culture, nutrients 
would certainly be depleted faster if more bacteria growing and it could be that the metabolism 
of high cell density bacteria is lower due to the decreasing availability of nutrients. Antibiotics 
such as isoniazid and rifampicin acting on cellular processes may become less effective as the 
metabolism slows. The results in these sections showed that the doubling time of the M. 
tuberculosis cells exposed to rifampicin was increased. Also, at a high cell density a reduction in 
the effective concentration of the antibiotic (free active drug) may well be bound to the cell 
structure of killed as well as viable bacteria and/or other structural or chemical components 
(Udekwu et al., 2009)  
Isoniazid appears to be effective killing low and intermediate density populations with a 
bactericidal effect but the high cell density results were inconclusive due to variation between 
replicates. The results from the susceptibility testing of antibiotics against other bacteria (Davey 
and Barza, 1987; LaPlante and Rybak, 2004; Udekwu et al., 2009) suggest the findings in this 
chapter that show ineffectiveness of isoniazid at a high cell density (figure 3.3) are supported by 
evidence in other systems. An increase in MIC was seen at a high cell density for six antibiotics 
tested against Staphylococcus aureus, these antibiotics included vancomycin, daptomycin and 
oxacillin (Udekwu et al., 2009). These antibiotics disrupt cell wall synthesis and the cytoplasmic 
membrane of bacteria in a similar mode of action to isoniazid against M. tuberculosis and the 
cell density effect was most apparent at cell titres of 107 cfu/ml and above. The result in figure 
3.3 showed inactivity of isoniazid at a high cell density of 107 cfu/ml, in the context of other work 
this is evidence of cell density affecting the efficacy of isoniazid. 
Rifampicin showed a more striking cell density effect with inactivity at high and intermediate 
cell densities and a bacteriostatic effect at a low cell density. Rifampicin has been shown to form 
a drug-enzyme complex with RpoB within 10 minutes of incubation (Gumbo et al., 2007) 
whereas isoniazid requires conversion to an active form mediated by the enzyme KatG. In a high 
density population the rifampicin available may run out faster than isoniazid due to rapid 
binding. A reduction in metabolism caused by the limiting of nutrients at a high density may 
affect isoniazid less quickly than rifampicin. Isoniazid pro-drug can accumulate intracellularly 
before conversion to an active form so a reduction in metabolism may slow the conversion. 
Uptake however may have already occurred and efflux pumps may be slowed.  These 
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adaptations may also allow time for a drug tolerant population to emerge as in a high titre 
population there is also more chance of a spontaneous mutation occurring.  
The different activities of isoniazid and rifampicin against high cell density populations of 
bacteria highlight the need for a multi-drug approach in the treatment of M. tuberculosis 
infection. These results have also served to inform that in experiments aiming to model infection 
that has a high bacterial load, the effect of different titres needs to be considered, especially 
when assessing rifampicin susceptibility. This result then led to an increase of the MIC of 
rifampicin used in future experiments. 
Cells with an MGT of 69.3 hours were less susceptible to isoniazid and rifampicin compared to 
cells with the fastest doubling time (23.1 hours) at all concentrations up to 16 x MIC (section 
3.5). This shows a clear relationship between growth rate and susceptibility to antibiotics; the 
slower the doubling time the less effective an antibiotic is. This is probably due to rifampicin and 
isoniazid acting on cellular processes. It is interesting to see this effect in M. tuberculosis as it is 
naturally a slow growing bacterium; the reduction at even slower growth rates highlights the 
challenge in treating this disease. Both antibiotics showed a concentration independent killing 
effect and this was true at all growth rates for rifampicin and between 2-8 x MIC for isoniazid. 
This suggests that increasing the concentration of the antibiotic does not have any advantage, 
perhaps indicating that there is a sub-population of cells that are preferentially killed, the 
remaining cells appear recalcitrant to the antibiotic. Isoniazid took longer to affect the slow 
growing cells than rifampicin; the result of exposure for 24 hours did not reflect the result of 
exposure for 96 hours for the slowest growing cells. The slowest growing cells were shown to 
be least susceptible to isoniazid and rifampicin overall, however after 24 hours of exposure this 
population was the most susceptible. The slowest growing cells showed the most growth when 
grown in no drug, perhaps they had more nutrients remaining intracellularly and were able to 
actively divide with no lag phase, allowing isoniazid to act on these cells more so than the faster 
growing cells, which may have been in a metabolic lag (which was also seen in the cell density 
work). This result highlights the need to continue experiments such as this, with slow growing 
bacteria for longer than 24 hours of drug exposure as the growth ratio at 96 hours for isoniazid 
was contradictory to the 24 hour result for the very slow growing M. tuberculosis. The inclusion 
of this time-point has allowed analysis on the exposure times required to see the effect of the 
antibiotic. 
Growth phase also affected the efficacy of isoniazid and rifampicin, particularly for isoniazid. The 
longer the cells were in batch culture, the less susceptible they were to both antibiotics, which 
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followed a similar pattern to the effect of growth rate. This pattern was seen at sub-MIC levels 
of rifampicin but overall there was a less clear link between growth phase and susceptibility to 
rifampicin. This result could reflect the differing actions of isoniazid and rifampicin. Rifampicin 
targets RNA synthesis and so even if the cells are not dividing or are dormant they still have low 
levels of RNA synthesis and this process is still essential. Rifampicin also acts quickly against its 
target and is not reliant on conversion by bacterial enzymes to be effective. In contrast, isoniazid 
requires bacterial KatG to convert it to an active form and acts on the cell wall, this process 
would be perhaps more affected by a slowing or cessation of growth, less cell wall turnover 
would also weaken the effectiveness of isoniazid by reducing the available target site (Bardou et 
al., 1998; Petros C. Karakousis, Ernest P Williams and William R. Bishai, 2007). It has also been 
shown that cells from this culture and others accumulated an extracellular material (ECM) as 
time went on and there was an upregulation of LAM (lipoarabinomannan) (Bacon et al., 2014). 
Rifampicin is lipophilic and so is able to enter the M. tuberculosis cell wall even in times of ECM 
accumulation, this may be why there did not seem to be such a strong association of 
susceptibility to rifampicin to growth phase when compared to isoniazid; the accumulating ECM 
may have posed more of a barrier to isoniazid than rifampicin. This observation is supported by 
work showing that pyrazinamide, isoniazid and rifampicin have lower lesion concentrations than 
in plasma in vivo and isoniazid had the lowest coefficient of penetration in both healthy lung and 
lesions (Kjellsson et al., 2012). 
The difference between isoniazid and rifampicin activity was also seen in the day 65 (late 
stationary) and NRP cells, there was no significant difference in the response of these two cell 
populations when exposed to isoniazid but the day 65 cells were more susceptible to rifampicin 
than the NRP cells (section 3.6.2) . If there was no turnover of the cell wall and no division at late 
stationary phase and NRP phase the isoniazid would likely be ineffective. At day 65 (stationary 
phase) and in the NRP phase (day 277) there was still RNA synthesis occurring allowing rifampicin 
to act on those cells that were still viable but not necessarily dividing. Using this culture, 
transcriptomic analyses showed upregulation of gene expression in stationary phase and in the 
NRP phase (Bacon et al., 2014) demonstrating active RNA synthesis. One of those upregulated 
genes was mmr a multidrug efflux pump, revealing one of the possible mechanisms of drug 
tolerance of non-replicating M. tuberculosis to both isoniazid and rifampicin. 
The effect of isoniazid also highlighted that there was no difference in the response to isoniazid 
between the day 9 (exponential phase) and day 30 (early stationary phase) cells suggesting that 
they were in the same stationary phase of growth in terms of the amount of cell wall synthesis 
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but that the amount of RNA synthesis may be different between these two time points. It was 
shown that there was an induction of mycolic acid synthesis at day 30 (Bacon et al., 2014), this 
may have led to an increase in KatG activity which could have led to an accumulation of 
isonicotinic acid intracellularly. If enough isonicotinic acid was accumulating, the 
transmembrane pH difference may have been disrupted leading to diffusion of isonicotinic acid 
out if the M. tuberculosis cell (Bardou et al., 1998). This diffusion would lead to an apparent 
reduction in activity of isoniazid which may help to explain why the day 65 cells were less 
susceptible to isoniazid than previous time points despite an observed induction of mycolic acid 
synthesis. When a much higher concentration of isoniazid was used (64 x MIC) there was a large 
difference between the viability of the day 65 and NRP cells, a difference which had not been 
seen at lower concentrations of isoniazid, the day 65 cells were far more susceptible than the 
NRP cells. Increasing the concentration of isoniazid in the medium may have restored the 
concentration gradient with isonicotinic acid intracellularly allowing passive diffusion into the 
cell once more. 
It appears that cell density, growth rate and phase all affect the efficacy of antibiotics against M. 
tuberculosis. Generally, as cells become slower growing either through lack of nutrients (as seen 
in the cell density and growth phase work) or through a slower doubling time, they become less 
susceptible. These experiments have also served to highlight the differences between isoniazid 
and rifampicin, showing rifampicin to be quicker at killing but showing more discrimination 
between growth phases. Isoniazid appears effective against fast growing cells but does not 
affect late stationary cells differently to NRP phase cells. The evidence that these factors clearly 
affect antibiotic efficacy both in terms of the bacterial adaptation and the antibiotic mechanism 
of action, will aid in the interpretation of the isoniazid chemostat experiment results in the 
chapter 4. 
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Chapter 4. Effect of growth rate on the response of Mycobacterium tuberculosis 
to Isoniazid 
4.1 Introduction 
Isoniazid has been shown to prevent the progression of tuberculosis and prevent reactivation in 
people with a positive tuberculin skin test (TST) or interferon gamma release assay (IGRA) and 
no symptoms of active disease (Lobue and Menzies, 2010). Isoniazid is therefore an important 
therapeutic used at all stages of disease. Resistance and persistence to isoniazid therapy is a 
prevalent problem, globally in 2014 480,000 people developed multi-drug resistant TB (MDR-
TB), leading to 190,000 deaths  (WHO, 2015). 
It is thought that during isoniazid treatment distinct populations of bacilli are present; those in 
the lining of open cavities with an abundant supply of oxygen are probably growing at a fast rate 
whilst those in closed lesions deprived of oxygen are likely to be growing slowly. Previous studies 
that plotted the viable counts of M. tuberculosis obtained from the sputum of patients 
undergoing treatment with isoniazid showed an initial rapid kill followed by a slower killing 
(figure 4.1). This supports the theory that there is heterogeneity in the rate of growth of the 
initial population (D A Mitchison and Coates, 2004) 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.1 Viable counts of M. tuberculosis per ml sputum during the first month of treatment 
with regimens containing isoniazid (Taken from (D A Mitchison and Coates, 2004)) The solid 
and dashed lines overlaid show a suggested heterogeneity in the population with the solid 
line representing hypothesised fast growing bacilli and the dashed representing slow growing 
bacilli. 
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When the four drugs used to treat tuberculosis are combined (isoniazid, rifampicin, 
pyrazinamide and ethambutol) isoniazid has a high initial early bactericidal activity during the 
first 2 days of treatment (Jindani et al., 2003) when it is presumed that rapidly growing bacteria 
are killed. After 2 days, virtually all of the sterilising activity is due to rifampicin and other drugs 
in the regimen such as pyrazinamide and is not influenced by the continued presence of 
isoniazid; Leading to the hypothesis that the bactericidal success of isoniazid is influenced by the 
growth rate of the bacilli. The inclusion of isoniazid beyond the initial treatment phase is to 
prevent any reactivation of disease and prevent resistance to the other antibiotics in the regime. 
Continuous culture is the only culture system for bacteria that allows the growth rate (i.e. mean 
generation time) of the bacteria to be controlled via limitation and dilution rate of a key nutrient 
(section 1.6.2). Continuous culture was used to investigate the differences between M. 
tuberculosis growing at a slow growth rate or fast growth rate by analysing viable count data. 
Samples were also taken for sequencing and for gene expression studies to enable an analysis 
of the effect of growth rate on the response of M. tuberculosis to isoniazid 
The metabolism and cell composition of M. bovis BCG with mean generation times of 23.1 hours 
and 69.3 hours has been studied previously, with correlations in RNA content, ribosome 
production and proportions of lipids to the growth rate (D J Beste et al., 2005). These mean 
generation times represent a growth rate close to that seen in human disease and a rate that is 
3 times slower, representing a slow growing population. It is clear that there is an effect of 
growth rate on the physiology of the bacteria which also influences the response of M. 
tuberculosis to isoniazid, cells removed from continuous culture in Chapter 3 showed that 
isoniazid was less efficacious against cells that had been grown at slow growth rate. This 
difference was also seen when the effect of growth phase was investigated; early exponential 
cells sampled after two days of culture were more susceptible to isoniazid than those cultured 
for longer periods.  
By adding isoniazid directly to a continuous culture at a controlled growth rate and removing 
samples over a time-course, rather than removing cells and investigating susceptibility in small 
batch cultures as in Chapter 3, the response to isoniazid can be studied under reproducible 
defined and controlled conditions. This will allow the hypothesis to be tested that fast growing 
M. tuberculosis is preferentially killed by isoniazid and that slow growing bacilli are less 
susceptible to the effects of isoniazid and are the population most likely able to persist through 
drug treatment.  
101 
 
The specific objectives for this work were as follows: 
1. To model the growth characteristics of M. tuberculosis in the presence of isoniazid under 
fast and slow culture conditions 
 
2. To determine the effect of mean generation time  on isoniazid  susceptibility 
 
 
3. To characterise temporal changes in susceptibility to MIC levels of isoniazid during 
continuous culture at fast and slow growth rates. 
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4.2 Mycobacterium tuberculosis growing in continuous culture at a mean generation time of 
69.3 hours 
Mycobacterium tuberculosis was grown in continuous culture as described in section 2.2.3 with 
a dilution rate of  0.01 h-1 (mean generation time of 69.3 hours). Samples were removed from 
the cultures after each mean generation time through-out a steady-state period. Control 
cultures were run without the addition of isoniazid, to establish the viable count data, 
transcriptomic and antibiotic resistance of cultures in steady-state that were not exposed to 
antibiotic as a baseline for further experiments. Further cultures were established, once these 
cultures were confirmed to be in steady–state using readouts such as turbidity, pH and dissolved 
oxygen tension (section 2.2.2) isoniazid was added at 0.5 µg/ml (MIC) (section 2.2.3.5). The 
response to isoniazid was explored by studying the viability, gene expression changes and the 
development of isoniazid resistance (sections 2.2.2, 2.6, 2.3 and 2.5).  
4.2.1 Mycobacterium tuberculosis growing in continuous culture at a mean generation time of 
69.3 hours with the addition of MIC level of Isoniazid (0.5 µg/ml) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Viable count data from M. tuberculosis growing in continuous culture at a 
dilution rate of 0.01 h-1, a doubling time of 69.3 hrs. The cultures were in steady state 
with no isoniazid addition (S-No drug) and replicate cultures with 0.5 µg/ml isoniazid 
addition (Culture S1 and Culture S2) at 0 mean generations. The theoretical washout line 
is represented by the dotted diagonal line. Error bars represent the SEM (N=3) 
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The cultures in figure 4.2 were cultured for 3 to 5 mean generations to establish steady state at 
a dilution rate of 0.01 h-1 (MGT of 69.3 hours), once this steady state was established, isoniazid 
was added to both the medium reservoir and chemostat vessel at a concentration of 0.5 µg/ml 
(section 2.2.6), this was taken as the zero hour time-point. 
The total viable count (TVC) data in both cultures growing with a doubling time of 69.3 hours 
showed a loss of viability within the first few hours after drug addition, this loss of viability was 
demonstrated by a 1 log drop in the total viable count. The control culture that had not been 
exposed to isoniazid (S-No Drug figure 4.2) shows a maintenance of steady-state viability 
indicating isoniazid that was causing the decrease in cfu/ml in the drug treated cultures rather 
than an inability of M. tuberculosis to maintain a viable population at this growth rate in the 
chemostat system. The bactericidal effect observed seems to occur at different rates in the two 
slow growth cultures. In culture S2 (figure 4.2) there was a period of killing within the first 2 
mean generations that reduced viable cell numbers from 2.01x108 to 7x104 cfu/ml. Between 2 
mean generations and 4.5 mean generations there was another period of killing with a reduction 
in viable cell numbers to 1x103 cfu/ml, which represents the lowest viable count reading. This 
shows a loss of 99.997% of the viable population of M. tuberculosis. This is showing an increase 
in the rate of death (0.036 h-1) that is higher than the theoretical wash out of the culture, which 
is equivalent to a bacteriostatic responses therefore showing that an MIC level of isoniazid is 
bactericidal in our system (0.017 h-1). After 4.5 mean generations there was a rapid rise in 
viability in the culture in the presence of isoniazid. The value at 4.5 mean generations was close 
to limit of detection of the plating at this timepoint, it is possible that this result at 4.5 mean 
generations is anomalous, due to the fact that M. tuberculosis is not known to divide as quickly 
as indicated by these results, either in vivo or in vitro . This culture did not continue past 7 mean 
generations but it appeared that it was establishing and maintaining a population of cells at 1 x 
107 cfu/ml in the presence of isoniazid after the initial bactericidal kill.  
Culture S1 in figure 4.2 showed the same bactericidal kill over the initial hours after isoniazid 
addition at 0 mean generations, with a 99.75 % reduction in viable cells by 2 mean generations 
after isoniazid addition. This replicate culture reached a maximum titre after isoniazid addition 
of 6.3 x 107 cfu/ml at 12 mean generations, after a period of re-growth. This re-growth period 
from 2 mean generations onwards shows fluctuating viable counts, dropping to around 1 x 105 
cful/ml followed by an increase to 1 x 107 cfu/ml.  
The lowest viable count was higher in the replicate culture (S2) than the lowest viable count for 
the first culture (S1) and also occurs earlier on in culture.  
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Both cultures followed a pattern of rapid killing followed by re-growth of the population 
resulting in an establishment of M. tuberculosis growing in the presence of isoniazid; the culture 
that was continued until 18 mean generations (Culture S1 figure 4.2) showed maintenance of an 
apparently isoniazid-tolerant population. 
4.3 Mycobacterium tuberculosis growing in continuous culture at a mean generation time of 
23.1 hours 
Fast growing chemostat cultures were established (as described in section 4.2) with a dilution 
rate of 0.03 h-1 which equates to a mean generation time of 23.1 hours, a doubling time similar 
to the natural rate seen in vivo and in vitro and a rate that has been previously studied in 
mycobacteria ( Beste et al., 2005). Two steady-state cultures were set up and isoniazid added at 
a concentration of 0.5 µg/ml and a third culture was maintained in steady state with no isoniazid 
added to provide control data. 
4.3.1 Mycobacterium tuberculosis grown in continuous culture at a mean generation time of 
23.1 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
The viability data in figure 4.3 shows cultures with an imposed mean generation time of 23.1 
hours. In the absence of isoniazid there is maintenance of a viable population of exponentially 
Figure 4.3 Viable count data from M. tuberculosis growing in continuous culture at a dilution 
rate of 0.03 h-1, a doubling time of 69.3 hrs. The cultures were in steady state with no isoniazid 
addition (F-No drug) and replicate cultures with 0.5 µg/ml isoniazid addition (Culture F1 and 
Culture F2) at 0 mean generations. The theoretical washout line is represented by the dotted 
diagonal line. Error bars represent the SEM (N=3) 
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growing M. tuberculosis cells at 1 x 109 cfu/ml for the duration of the experiment (17 mean 
generations) 
The addition of isoniazid to the fast growing cultures in figure 4.3 resulted in an immediate 
decrease in viability at a rate greater than the theoretical washout indicating a bactericidal 
effect. This killing action appeared to last until 7 mean generations in both cultures which was 
in contrast to the slow growing experiments in figure 4.2 where the bactericidal effect appeared 
to cease earlier in the time-course. In the fast growing cultures there was maintenance of an 
exponentially growing population of M. tuberculosis at a titre of 1 x 105 cfu/ml for the duration 
of the cultures, in culture F1 in figure 4.3 this rose to 1 x 106 cfu/ml after 9 mean generations 
which was then maintained. In culture F2 there was a fluctuation between 1 x 105cfu/ml and 1 
x 106  cfu/ml over the last 20 mean generations of the experiment, this fluctuation was similar 
to the pattern in the slow growing culture, Culture S1 (figure 4.2). From these chemostat 
experiments it appears that the slow growing M. tuberculosis (MGT 69.3 hours) was rapidly killed 
after addition of isoniazid as seen in the slow growing experiment. The slow growing cells then 
re-established a population growing in the presence of isoniazid which reached a titre similar to 
the initial steady state level prior to isoniazid addition indicating an adaptation to the presence 
of isoniazid allowing re-growth. The fast growing M. tuberculosis maintained an exponentially 
growing population but at a lower titre than the initial titre, illustrating a difference between 
the slow and fast growing M. tuberculosis. 
4.4 Determination of changes in susceptibility to isoniazid of M. tuberculosis cultured in the 
chemostat using cell density 
 
To determine whether the susceptibility of the M. tuberculosis in the cultures represented in 
figures 4.2 and 4.3 changes over time, cell samples were removed as an inoculum for medium 
containing various levels of isoniazid. Using optical density provides a fast readout and allows 
the calculation of the MIC of isoniazid at various time points in the chemostat cultures, which 
may indicate whether the bacteria are adapting to the presence of antibiotic. 
Cells were removed from the chemostat and added to 25 mL universal tubes containing various 
levels of isoniazid were inoculated to a starting OD540nm of 0.05 as described in section 2.4.1, this 
method was followed with OD540nm measurements taken daily for at least 96 hours post 
inoculation and no TVC data was collected. The data has been represented as a growth ratio (the 
initial 0 hr OD540nm measurement / final OD540nm measurement) to allow the amount of growth 
to be plotted as one column, this ratio was then log10 transformed to create a scale that is easily 
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visible on one graph and allows reduction in turbidity (i.e. cell death) to be visualised with a 
negative value. 
A total viable count would be a more accurate measure of the viability of the cells, optical density 
measurements can only measure the density of a population of cells and cannot distinguish 
between live and dead cells, or changes to the cell wall which may alter the light absorption or 
scattering properties of the cell. Despite these limitations it is a widely used method and a 
relationship between optical density and viable counts has been demonstrated in M. 
tuberculosis (Peñuelas-Urquides et al., 2013). One of the major factors in using optical density is 
also the slow growing nature of M. tuberculosis causing a lengthy incubation time, optical 
density provides a result which can be virtually instant giving information on an experiment 
whilst it is still running.  
Control cultures with no isoniazid were included at each timepoint to visualise growth and to 
reduce the discussion on the variables that could have caused a reduction in optical density in 
the presence of isoniazid. Viable count data has been taken from these cultures also (figures 4.2 
and 4.3) and susceptibility data from before drug addition was also plated out (chapter 3) 
meaning that the conclusions from this work are not solely based on optical density data. 
4.4.1 Susceptibility of slow growing (MGT 69.3 hours) M. tuberculosis after chemostat culture 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 The changing susceptibility of M. tuberculosis cells after chemostat culture at a slow 
growth rate (MGT 69.3 hours). Cells were removed from the S-No Drug culture seen in Figure 
4.2 at the 0 mean generation timepoint after establishment of steady state. These growth ratio 
results were calculated after 96 hours of culture. 
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After 96 hours of culture in medium containing no isoniazid, M. tuberculosis removed from a 
slow growing chemostat grew, with the OD540nm reading increasing over 10-fold (figure 4.4). The 
M. tuberculosis also grew at the higher concentrations of isoniazid in the range tested with a 
marked drop off in growth at 0.25 µg/ml isoniazid. At levels of 0.5 µg/ml (MIC) to 4 µg/ml there 
was a doubling in the OD540nm reading at 96 hours compared with the reading from the 0 hour 
timepoint and this growth ratio was similar for all concentrations, showing a concentration 
independent pattern. At 8µg/ml there was very little growth with less than 10% increase in 
turbidity, this reading could have indicated no growth from the start of the experiment as the 
actual reading was only 0.005 of an increase, which is negligible especially when this is compared 
to the increases in turbidity seen at lower concentrations of isoniazid. 
This result could indicate that the MIC is higher than previously established at 0.5µg/ml although 
there is a 46% increase in killing between 0.25 µg/ml and 0.5 µg/ml. The original MIC 
experiments were carried out using cells from a fast growing chemostat, this result shows that 
the MIC of isoniazid is higher in slow growing M. tuberculosis even before isoniazid exposure 
and shows growth rate is a factor to be accounted for when determining MICs of antibiotics in 
continuous culture. 
4.4.1.2 Susceptibility of slow growing (MGT 69.3 hours) M. tuberculosis after chemostat 
culture in the presence of isoniazid 
Figure.4.5 The changing susceptibility of M. tuberculosis cells after chemostat culture in the 
presence of isoniazid (0.5 µg/ml) at a slow growth rate (MGT 69.3 hours). Cells were removed 
from culture S1 seen in figure 4.2 before isoniazid addition (a) and after 5 MG of isoniazid 
exposure (b) 
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At 3 mean generations post isoniazid exposure in the chemostat (figure 4.2) there was a marked 
difference in the profile of the response to isoniazid. When a sample was tested for drug 
susceptibility from a slow growing culture (culture S2 figure 4.2) growth was enhanced at all 
levels of isoniazid (figure 4.5b), indicating an adaptation to isoniazid by M. tuberculosis which 
was observed in culture S2 in figure 4.2.  
At 5 mean generations of exposure there were differing results (in figures 4.5c and 4.6b). The 
results do however reflect the difference in the slow growing chemostat cultures (figure 4.2). In 
culture S2 there was an increased rate of killing between 3 and 5 mean generations with the 
lowest viable count occurring at 5 mean generations (figure 4.2). The cells removed after 5 MGT 
in culture showed an increase in their susceptibility to isoniazid with a decrease in optical density 
Figure 4.6 The changing susceptibility of M. tuberculosis cells after chemostat culture in the 
presence of isoniazid (0.5 µg/ml) at a slow growth rate (MGT 69.3 hours). Cells were removed 
from culture S2 seen in figure 4.2 before isoniazid addition (a), after 3 MG of isoniazid 
exposure (b) and after 5 MG of isoniazid exposure (c)  
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at every concentration of isoniazid (figure 4.6c). The control (0 µg/ml isoniazid) showed the cells 
at this timepoint had the ability to grow; the growth of the control however was lower than in 
previous time points and gave an indication that the M. tuberculosis at 5 mean generations in 
culture S2 was perhaps compromised by the presence of isoniazid within the chemostat the 
sample was taken from (figure 4.2). After removal from the chemostat, cells were washed before 
the MIC experiments but the viability due to being cultured in the presence of isoniazid may 
have been affected. 
Figure 4.5b shows at 5 mean generations of exposure the cells in this experiment were able to 
grow in the presence of isoniazid at all concentrations; there is a decreased susceptibility to 
isoniazid in these cells which is in contrast to figure 4.6c. This reflects the maintenance of a large 
population of M. tuberculosis in the chemostat in culture S1 at 5 mean generations indicating in 
this slow growth experiment these cells were adapted earlier than the cells in culture S2 to the 
presence of isoniazid (figure 4.2) 
4.4.2 Susceptibility of fast growing (MGT 23.1 hours) M. tuberculosis after chemostat culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cells removed from the fast growth control culture (figure 4.3) grew well in levels of isoniazid 
up to 1 µg/ml (figure 4.7). There was a large reduction in the growth of M. tuberculosis after 0.5 
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Figure 4.7 The changing susceptibility of M. tuberculosis cells after chemostat 
culture at a fast growth rate (MGT 23.1 hours). Cells were removed from the 
F-No Drug culture seen in Figure 4.3 at the 0 mean generation timepoint after 
establishment of steady state. These growth ratio results were calculated 
after 96 hours of culture 
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µg/ml as has been seen in the results presented in section 4.4.1 and 4.4.1.2. There was a 
concentration independent effect between 1 µg/ml and 4 µg/ml with these concentrations 
showing between a 2.4 and 2.7 fold increase in optical density. The highest concentration of 
isoniazid used (8 µg/ml) showed some discrimination when compared to the lower 
concentrations with a 1.8 fold increase in growth but this was still higher than most of the results 
from the slow growing cultures at this concentration (with the exception of figure 4.5b) 
This result shows a decreased susceptibility in fast growing cells compared to the slow growth 
culture at the lower levels of isoniazid (figure 4.4) and a similar susceptibility profile for the two 
growth rates at concentrations at or above 1 µg/ml isoniazid. It appears that the MIC may be 
around 1 µg/ml for this fast growth culture, although there was a doubling in the OD540nm reading 
at this concentration of isoniazid this measurement was taken after 96 hours of culture, in effect 
showing a doubling time of 96 hours which is far from optimal for M. tuberculosis. 
 4.4.2.1 Susceptibility of fast growing (MGT 23.1 hours) M. tuberculosis after chemostat 
culture in the presence of isoniazid 
 
 
Fig.4.9 A series of graphs to show the changing susceptibility of M. tuberculosis cells  after chemostat culture in the 
presence of isoniazid (0.5 µg/ml) at a fast growth rate (MGT 23.1 hours). Cells were removed from the culture seen 
in Fig 4.4 before isoniazid addition (a) and after 3 MG of isoniazid exposure (b) 
Figure 4.8 The changing susceptibility of M. tuberculosis cells after chemostat culture in the 
presence of isoniazid (0.5 µg/ml) at a fast growth rate (MGT 23.1 hours). Cells were removed 
from culture F1 seen in figure 4.3 before isoniazid addition (a), and after 3 MG of isoniazid 
exposure (b)  
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The samples removed from the fast growing chemostats after 3 mean generations of isoniazid 
exposure showed a marked difference in the susceptibility of M. tuberculosis. There was a 
decrease in optical density at every concentration of isoniazid (figures 4.8b and 4.9b), indicating 
an increased susceptibility to isoniazid. At the timepoint in the culture the samples were 
removed from (3 mean generations) (Cultures F1 and F2 figures 4.3) the period of rapid 
bactericidal killing was coming to an end. Titres were at 1 x 106 cfu/ml (started at 1 x 108 cfu/ml) 
and 3 x 104 cfu/ml (started at 3 x 108 cfu/ml) respectively, with these figures illustrating the rapid 
bactericidal action of isoniazid in these chemostats. It appears at 3 mean generations the cells 
left in the chemostat were still highly susceptible to isoniazid and probably compromised as even 
a sub-MIC level (0.25 µg/ml) of isoniazid inhibited growth, this was reflected in the susceptibility 
results (figures 4.8b and Fig 4.9b). The cells do not appear to have adapted to the antibiotic 
presence in the chemostat culture at 3 mean generations. It is also of note that the control 
culture in figure 4.8b did not grow. It is likely this is due to the compromised nature of the cells 
not being able to withstand the re-inoculation and at a lower titre meaning perhaps there was 
not a sufficient population to establish in the susceptibility experiment.  
After 5 mean generations of isoniazid exposure (figure 4.8c), the cells had decreased in 
susceptibility when compared to 3 mean generations of exposure (figure 4.8b). There was a 5 
fold increase in the optical density across the concentration range to 4 µg/ml isoniazid, at and 
above 4 µg/ml there was still at least a doubling in optical density reading (figure 4.8b). This 
indicated that even though growth at these concentrations may be much slower, it is not 
inhibited altogether, showing an increase in MIC from around 0.5 µg/ml to greater than 8 µg/ml 
Figure 4.9 The changing susceptibility of M. tuberculosis cells after chemostat culture in the 
presence of isoniazid (0.5 µg/ml) at a fast growth rate (MGT 23.1 hours). Cells were removed 
from culture F2 seen in figure 4.3 before isoniazid addition (a), after 3 MG of isoniazid exposure 
(b)  
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isoniazid. At 5 mean generations in the continuous cultures with isoniazid added (Cultures F1 
and F2 figure 4.3) there was a very slight increase in viable count, indicating that it is this point 
at which the cells become adapted to the presence of isoniazid in the chemostat. After 5 mean 
generations of isoniazid exposure in both cultures there is a trend for an increase in viable cells 
and a cessation of overall killing with a population adapted to growth in the chemostat 
maintaining at a titre of around 1x 106 cfu/ml (figure 4.3) 
4.5 Discussion 
The results in this chapter confirm a difference in the response of M. tuberculosis to isoniazid 
based on growth rate. In continuous culture (section 4.2.1 and 4.3.1) after a period of 
bactericidal killing at both growth rates, the slow growing cells were able to re-establish a 
population at a high titre whereas the fast growing bacteria maintained a population at a lower 
titre. The bactericidal response seen at both growth rates has been observed previously with 
isoniazid exposure in a number of studies (de Steenwinkel et al., 2010; Gumbo et al., 2007; D A 
Mitchison and Coates, 2004; Paramasivan et al., 2005) This result also mimics the result seen in 
vivo, demonstrating rapid bactericidal kill in the first few days of treatment (figure 4.1 (D A 
Mitchison and Coates, 2004)). The results in this chapter have allowed a clear difference to be 
seen between growth rates by controlling mean generation time using continuous culture, 
whereas other studies have investigated the theory of differing growth rates of M. tuberculosis 
using metabolism based assays and growth phase in uncontrolled batch cultures (de 
Steenwinkel et al., 2010; Paramasivan et al., 2005) or stationary phase cells (Mitchison and 
Coates, 2004; Paramasivan et al., 2005). Studies using continuous culture controlling the growth 
rates at 23.1 and 69.3 hours, as in this study, have shown differences in metabolic flux, the 
genetic requirements and mechanisms for pyruvate dissimilation between slow and fast growing 
mycobacteria (Beste et al., 2007b; Beste et al., 2009, 2011) but has not investigated the effect 
of growth rate on the efficacy of antibiotics. 
The susceptibility results in this chapter show that the MIC of isoniazid is around the expected 
0.5 µg/ml for both the slow and fast growing cultures that have been exposed to isoniazid. The 
slow growing (MGT 69.3 hours) M. tuberculosis adapted to the presence of isoniazid faster than 
the fast growing (MGT 23.1 hours) M. tuberculosis with a decrease in susceptibility seen after 3 
mean generations of exposure in the slow growing bacteria compared to 5 mean generations of 
exposure in the fast growing M. tuberculosis.  
The difference in the rate of adaptation could be the reason for the different responses seen in 
the fast and slow growth chemostat cultures with the slow growing population re-establishing 
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a population more quickly and at a higher titre than the fast growing M. tuberculosis. The results 
in chapter 3 showed the slow growing cells were less susceptible to levels of isoniazid above the 
MIC when compared to the fast growing cells. This effect was apparent after just 24 hours of 
culture in isoniazid. At an MIC level of isoniazid the results indicated that the slow growing cells 
took longer to be affected by the isoniazid. The susceptibility results in this chapter showed a 
similar MIC prior to isoniazid exposure but this was based on turbidity as a quick read out rather 
than viable counts as seen in chapter 3 which is a more accurate measure of an antibiotic’s effect 
on viability. 
The substantial drop in cell biomass at both growth rates would have led to an excess of glycerol 
(the limiting carbon source) in the medium. This would have meant that there would be no 
longer carbon limited control of growth rate and provide an environment suitable for an 
increase in growth rate. Only the slow growing cells were able to increase their growth rate and 
re-establish cell titres close to original value before addition of isoniazid. It is possible that at a 
controlled mean generation time of 23.1 hours, the fast growing population that was established 
after the bactericidal kill was growing at close to the maximum growth rate of M. tuberculosis in 
this system (µmax). Previous work in the TB Research group at PHE, Porton Down determined 
that the mean generation time at µmax was close to 23.1 hours (data not shown). The fast growing 
cells would not have been able to grow any faster than this maximum growth rate and therefore 
not increase in biomass even in the presence of excess glycerol. The slow growing cells however 
would have had the opportunity to grow at or near the maximum growth rate because of the 
excess glycerol and increase their biomass as seen in the re-establishment of a high titre 
population.  
The excess glycerol allowing the slow growing cells to re-establish a population at a high titre in 
the presence if isoniazid helps to explain the differences between the two growth rates in 
response to isoniazid but the susceptibility results in this chapter and chapter 3 show that the 
slow growing cells are in general less susceptible to isoniazid. Data was collected from the 
chemostat cultures presented in this chapter on the mutation rate and mutant frequency 
(sections 5.2, 5.3 5.4), colonies that were able to grow on isoniazid containing medium were 
sequenced at loci of known isoniazid resistance genes (5.2.1, 5.3.1, 5.4.1) This will aim to 
determine whether the difference between the slow and fast growing bacteria is due to a 
genetic element or whether the slow growing bacteria are phenotypically adapted to isoniazid 
exposure underpinning a genotypic adaptation once exposed to isoniazid.  
 
114 
 
 
Chapter 5. Investigation into the genotypic responses of Mycobacterium 
tuberculosis to isoniazid at differing growth rates 
5.1 Introduction 
The results in Chapter 4 showed a difference in the response of M. tuberculosis to isoniazid 
based on growth rate. In order to investigate whether this was due to an increase in mutation 
rate, the mutant frequency and subsequently the mutant genotypes of M. tuberculosis were 
measured throughout the chemostat cultures presented in Chapter 4.  The differences in the 
responses could be due to a difference in mechanism of adaptation, for example, a phenotypic 
change such as changes in expression levels of key isoniazid related genes or a genotypic change, 
leading to selection of mutations in isoniazid resistance genes. It is often thought that the slow 
growth is a phenotypic persistence mechanism against antibiotic encounters (M. R. Brown et al., 
1990; Kussell et al., 2005) allowing a natural tolerance to many antibiotics. It may be that slowing 
the growth rate of M. tuberculosis even further using the chemostat may elucidate changes that 
explain the emergence of resistance and persistence in the face of isoniazid therapy that are not 
seen at the natural doubling time of around 17-24 hours. 
5.1.1 Determining mutation rate 
The methods for calculating mutation rates are dependent on the model of expansion of mutant 
clones originally described by Luria and Delbrück (Luria and Delbruck, 1943). During exponential 
growth, every cell has a low probability of sustaining a mutation during its lifetime and this 
probability is the mutation rate. The mutant frequency is simply the proportion of cells in a 
population that are a mutant, and this depends on factors such as population size or the time 
when the first mutation appeared (Couce and Blazquez, 2011). 
Mutant frequencies can be good indicators of the rate at which mutations are induced by DNA 
damaging agents but they are not adequate for investigating spontaneous mutations, this is 
because the population of mutants is composed of clones, each of which arose from a cell that 
sustained a mutation (Foster, 2006) . One of the disadvantages of averaged mutant frequencies 
is their low reproducibility (that is, the probability of repeated measurements displaying the 
same results under the same conditions) rather than their poor accuracy (Couce and Blazquez, 
2011). 
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 It is preferable to measure the mutation rate as the relationship between mutant frequency 
and the rate at which mutations occur is uncertain. If a mutation arises early in the culture 
period, then a large number of mutant progeny occur and this would be represented by a higher 
mutant frequency than if the mutation had occurred later in the culture (Pope et al., 2008). The 
exponential growth of a bacterial mutant population then leads to a low probability event 
occurring early during the growth of a population having huge consequences.  
In many experiments mutation rates are low and the number of bacteria that can be worked 
with is relatively small; in chemostat systems the number of bacteria is large (billions). This 
method is based on the idea of growing bacteria exponentially until probability dictates that a 
mutant will be present. This method is very accurate but is often referred to in the literature as 
complicated and time consuming (Foster, 2006; Snyder and Champness, 2007), this is because 
the culture needs to be sampled at multiple time points in order to gain the information that is 
required, something that is achievable within the chemostat system. If the number of mutants 
and total number of bacterial cells are known at each time point, then the mutation rate can be 
calculated from the slope of the line describing the relationship between the fraction of mutants 
against generation number based on the assumption that the higher the mutation rate the faster 
the proportion of mutants will increase. With the chemostat model of tuberculosis at two 
different growth rates established, it was decided that mutant accumulation would fit these 
studies well. 
5.1.2 Target genes for sequencing 
katG is a gene in Mycobacterium tuberculosis encoding a catalase peroxidise enzyme that 
activates isoniazid, also known as isonicotinylhydrazine (INH) (Zhang et al., 1992). The most 
common mutation in the M. tuberculosis katG gene correlating with resistance to isoniazid is a 
SNP at codon 315, resulting in a coding change from the wild type serine (AGC) to threonine 
(ACC). This mutation greatly reduces the affinity of wild type KatG for isoniazid whilst the enzyme 
maintains reasonably good steady state catalytic rates. Poor binding of the drug to the enzyme 
limits drug activation and brings about isoniazid resistance (Yu et al., 2003). Other coding 
changes have also been detected at this codon resulting in varying resistances and catalase-
peroxidase activity (Marttila et al., 1998; Ramaswamy and Musser, 1998). It has been 
summarised that 50-95% of isoniazid resistant strains are the result of mutations in the katG  
gene (Garza-Gonzalez et al., 2009) and between 75-90% of these are located in codon 315 
(Ramaswamy and Musser, 1998).  
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InhA is an enoyl-acyl carrier protein (ACP) reductase, this class of molecule catalyses the 
nicotinamide adenine dinucleotide (NADH)-dependent reduction of a growing fatty acid chain 
linked to ACP, this is an enzymatic activity that is common to all known fatty acid biosynthetic 
pathways. Mycobacteria utilise the products of InhA catalysis to create mycolic acids (Rozwarski 
et al., 1998). Mutations in the inhA gene account for 20-25% of isoniazid resistant strains (Garza-
Gonzalez et al., 2009; Ramaswamy and Musser, 1998) one such area of this gene is in the 
putative promoter region.  
These two regions were chosen to cover the largest frequency of mutations that have been 
found in clinical and previous research studies. Focussing on these regions allows a large number 
of colonies to be screened from multiple time points of cultures at different growth rates with 
and without exposure to isoniazid. 
 
The specific objectives for this work were as follows: 
1. To recover isoniazid-resistant mutants growing in the chemostat at slow and fast growth 
rates and measure the mutant frequency. 
 
2. To apply the mutant accumulation method to determine if there were any differences 
in the mutation rates between the slow and fast growing M. tuberculosis cultures. 
 
3. To sequence regions of genes known to be involved in isoniazid resistance to determine 
whether M. tuberculosis is adapting genotypically and/or phenotypically to the presence 
of isoniazid and whether slow and fast growing cells are adapting to isoniazid exposure 
via different mechanisms.  
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5.2. Mutant frequency and mutation rate to isoniazid in the absence of selection pressure 
To assess the mutation rate to isoniazid in the absence of selection pressure, chemostats were 
set up (Section 2.2.3) at fast and slow grow rates with no isoniazid added. The viable count data 
showing maintenance of steady state has already been presented in sections 4.2.1 and 4.3.1. 
Samples from these cultures were plated onto 2 X MIC (1 µg/ml) isoniazid to study mutant 
frequency and mutation rate. 
 
 
 
 
 
 
 
 
 
 
Mean generation Mutation rate of 
fast 
Mutation rate of 
slow 
1 2.47 x 10-6  
2 1.15 x 10-6  
4 2.64 x 10-8  
5  2.5 x 10-8 
7 2.5 x 10-7 5.19 x 10-9 
10 4.63 x 10-7 6.41 x 10-9 
12  2.05 x 10-8 
15 4.25 x 10-7  
18  9.92 x 10-9 
Figure 5.1 The viable count data for a fast growth (square symbols solid line) and slow growth 
culture (triangle symbols solid line). The lower half of the axis shows the mutant frequency 
data for the same fast (square symbols broken line) and the slow (triangle symbols broken 
line) growing cultures. The mutant frequency value of 1 x 10-10 has been plotted to indicate 
samples were plated but no colonies were isolated.  The table shows the mutation rate data; 
this was calculated using the pre-drug timepoint as a reference  
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The viable count data for both the fast and slow growth cultures in the absence of isoniazid is 
very similar as discussed in chapter 4. The mutant frequency and rate remain stable for the 
length of the culture and is equivalent to the natural mutation rate of M. tuberculosis to 
isoniazid (1 x 10-6 – 2 x 10-8) (Bergval et al., 2009; Riska et al., 2000)  This was also true of the 
slow growth culture after 5 mean generations of culture; before this time point there were no 
colonies isolated on 2 x MIC isoniazid from the culture.  This result could indicate a change in 
the slow growth population after 5 mean generations of culture in the chemostat, the result at 
5 mean generations and beyond is within the natural mutation rate and the reason for this 
variation has not been determined. Colonies from these cultures were picked and DNA extracted 
for pyrosequencing at katG codon 315 and the promoter region of inhA, two regions that are 
frequently mutated in isoniazid resistant strains of M. tuberculosis to determine whether any 
genetic changes were occurring in the absence of isoniazid 
5.2.1 Pyrosequencing of colonies isolated from fast and slow growth rate chemostat cultures 
have not been exposed to isoniazid 
This sequencing data represents the M. tuberculosis colonies that grew on 2 x MIC isoniazid (1 
µg/ml) after culture in the chemostats containing no isoniazid (figure 5.1) Colonies were 
sequenced using pyrosequencing at katG codon 315 and in the promoter region of inhA, the 
regions amplified and the method for pyrosequencing can be found in sections 2.7 and 2.8. 
The chemostat growing at a slow growth rate that had not been exposed to isoniazid to act as 
control data produced very few colonies that exhibited the ability to grow on 2 x MIC isoniazid. 
A very small number of colonies i.e.< 10, were recovered at 10, 12 and 16 mean generations 
after the experiment started but not analysed as the sample size was too small. The colonies 
that did grow were small and difficult to obtain DNA for PCR from and so there is no 
pyrosequencing data for this culture due to the lack of ability to grow on 2 x MIC isoniazid. 
The data available in figure 5.2 shows the fast growing M. tuberculosis population was 
comprised of a majority wildtype genotype at all time points (69.5% - 98%). The most variation 
in the genotype of the population was at 4 mean generations, 31% of the population tested 
were mutated at katG codon 315. The mutation rate throughout this culture was no higher than 
the natural rate and the emergence of these mutants in small numbers is to be expected. It is 
clear to see that of the colonies isolated from the fast growth chemostat with the ability to grow 
on 2 x MIC isoniazid, the majority were wild type at katG codon 315 (figure 5.2) indicating that 
these colonies are naturally able to grow on isoniazid likely due to a phenotypic adaptation.  
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All samples (from all growth rates and conditions) sequenced in the promoter region of inhA 
were wild type. 
There could be mutations at other isoniazid relevant loci but the probability of this is low as the 
70-80% of isoniazid resistant isolates have mutations in these loci (Rattan et al., 1998) 
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 Genotype AGC*  AAC AGA ACC ATC AGG Mix Total 
0  51 4 1 0 0 1 0 57 
2 82 0 1 0 0 1 0 84 
4 16 2 4 0 0 1 0 23 
10 57 1 0 0 0 0 0 58 
 14 34 2 0 0 0 0 0 36 
Figure 5.2 The genotype of the colonies recovered on 2 x MIC isoniazid isolated from a 
chemostat growing with a doubling time of 23.1 hours with no isoniazid present. The 
genotype shown is at katG codon 315 * denotes the wild type genotype. The total number of 
colonies sequenced is shown in the far right column. The graph is a visualisation of the data 
in the table as a percentage. 
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5.3 Mutant frequency and mutation rate to isoniazid of slow growing M. tuberculosis exposed 
to isoniazid  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean generation Mutation rate 
culture 1 
Mutation rate 
culture 2 
1 1.10E-03  
2 6.38E-03  
3 1.50E-03  
   
4  3.60E-06 
5 6.40E-03 7.48E-04 
7 9.07E-04 7.14E-03 
8  1.09E-03 
10  3.08E-04 
12  5.29E-04 
16  1.55E-02 
18  1.36E-03 
Figure 5.3 The viable count data for two biological replicate slow growth cultures with 
isoniazid added, Slow Growth 1 (SG1) (square symbols solid line) and Slow Growth 2 
(SG2) (triangle symbols solid line). The lower half of the axis shows the mutant frequency 
data for SG1 (square symbols broken line) and SG2 (triangle symbols broken line). The 
mutant frequency value of 1 x 10-10 has been plotted to indicate samples were plated 
but no colonies were isolated.  The table shows the mutation rate data, this was 
calculated using the pre-drug timepoint as a reference. 
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Both slow growth cultures showed an increase in the number of mutants up to 5 mean 
generations after isoniazid addition, the data shows culture SG1 maintained a stable mutation 
rate through this period – this pattern is due to the bactericidal action of isoniazid over the 
corresponding time period which can be seen in the TVC data (figure 5.3). The point at which 
the mutant frequency is at its highest corresponds to the lowest TVC in both slow growth 
cultures indicating that at these time points the population is comprised of M. tuberculosis with 
the ability to grow on 2 x MIC isoniazid; the mutation rate at these time points (5 and 7 mean 
generations) is very similar in both cultures (6.4 x 10-3 and 7.1 x 10-3 respectively). The overall 
trend of both slow growth cultures was an increase in the number of colonies able to grow on 
isoniazid followed by a plateau and maintenance of this population in the culture. In culture SG2 
no colonies were isolated on isoniazid until 4 mean generations after isoniazid addition to the 
chemostat. The corresponding TVC data shows less kill by isoniazid in the first 2 mean 
generations, this data could suggest the cells within this culture were using more phenotypic 
adaptation within the chemostat but this adaptation was not maintained when grown on solid 
medium containing isoniazid where the growth rate was not controlled. The slow growth control 
data also showed a lack of colonies able to grow on isoniazid until 4 mean generations and very 
few after this, indicating the slow growing culture is less able to grow on isoniazid naturally than 
the fast growth culture and perhaps takes time to adapt. 
Colonies that were isolated from these cultures on 2 x MIC isoniazid were sequenced at codon 
315 of katG and in the promoter region of inhA (sections 2.7 - 2.8) to determine whether any 
genetic mutation was present. 
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5.3.1 Pyrosequencing of colonies isolated from slow growth rate (69.3 hr MGT) chemostat 
cultures exposed to isoniazid 
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Genotype  AGC* AAC AGA ACC ATC AGG Mix Total 
Culture: Slow Growth 1 
1 9 1 0 0 0 0 0 10 
2 4 28 3 1 2 0 0 38 
3 9 7 1 0 0 0 0 17 
Culture: Slow Growth 2 
4 22 6 1 0 0 0 0 24 
7 8 36 3 17 18 0 12 94 
12 4 33 6 30 19 0 5 97 
 
Figure 5.4 The genotype of the colonies recovered on 2 x MIC isoniazid isolated from cultures 
SG1 and SG2 (figure 5.3). The genotype shown is at katG codon 315 * denotes the wild type 
genotype. The total number of colonies sequenced is shown in the far right column. The 
graphs below the table are a visualisation of the data in the table as a percentage. 
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The majority (90%) of the population in culture SG1 was wild type (AGC) codon 315 of katG after 
1 mean generation of culture with isoniazid (figure. 5.4). Similar proportions can be seen in the 
0 mean generation time point for the fast growth control (figure 5.2) indicating that no 
adaptation or selection had occurred due to the presence of isoniazid in SG1 at this point. The 
variety of mutations increased as did the proportion of the population that was mutated at katG 
codon Ser315 at 2 mean generations post isoniazid addition. This was at a point in the culture 
where there had been over a 3-log drop in viable cell number, suggesting the wild type cells 
were preferentially killed. It is worth noting that this data shows cells that are wild type at katG 
codon Ser315 but still had the ability to grown on isoniazid, showing the slow growing M. 
tuberculosis is using strategies other than mutation at this loci such as mutation at other loci or 
phenotypic adaptation. The dominant mutation throughout the sequencing data available for 
culture SG1 is katG codon Ser315 AGC>AAC and this mutation is also present throughout the data 
for SG2, this mutation does not outcompete any of the other mutations though. At the first 
timepoint mutants were recovered in culture SG2 there is a majority wild type population, as 
the mutant frequency and rate continue to increase (figure 5.3 SG2) so does the proportion of 
the population that is mutant, with a large variety in mutation seen, this population was then 
maintained. The viable count data between 7 and 12 mean generations shows an increase in 
number (figure 5.3 SG2) indicating that the mutant population was increasing in number with 
no fitness cost associated with mutation. 
It appears that both slow growing cultures were adapting genotypically to the presence of 
isoniazid and a pattern emerged in both cultures of a majority wild type population being 
replaced with a majority mutant population. One of the mutations occurring frequenctly 
through the timecourse was katG codon Ser315 AGC>AAC, resulting in a coding change to 
threonine. This mutation is the most common seen in clinical samples (Haas et al., 1997a; Heym, 
1997; Lipin et al., 2007; Musser et al., 1996). The AGC>AAC mutation results in a coding change 
to asparagine which has been seen in samples of MDR M. tuberculosis isolated in Africa as has 
the AGC>ATC mutation resulting in a change to isoleucine (Haas et al., 1997a).  
This variation not only shows the clinical relevance of these mutations and this model but also 
shows that all SNPs were maintained within the chemostat without one outcompeting the 
others. This may be that at a controlled MGT of 69.3 hours, any fitness cost is nullified due to an 
imposed slow growth rate. 
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5.4 Mutant frequency and mutation rate to isoniazid of fast growing M. tuberculosis exposed 
to isoniazid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean generation Mutation rate FG 1 Mutation rate FG 2 
1 2.28E-04  
3 6.33E-04  
6 1.85E-03 8.16E-03 
7 1.78E-03  
8  1.20E-03 
9  1.66E-04 
10  2.29E-03 
13  1.34E-02 
15 2.39E-02 2.46E-02 
16  1.02E-02 
17  1.21E-02 
23 1.89E-02  
Figure 5.5 The viable count data for two biological replicate fast growth cultures with isoniazid 
added. Fast Growth 1 (FG1) (square symbols solid line) and Fast Growth 2 (FG2) (triangle 
symbols solid line). The lower half of the axis shows the mutant frequency data for FG1 (square 
symbols broken line) and FG2 (triangle symbols broken line). The table shows the mutation 
rate data, this was calculated using the pre-drug timepoint as a reference. 
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Both fast growing cultures showed a steady increase in the number of colonies able to grow on 
2 x MIC isoniazid over the first 6 mean generations of isoniazid exposure. The mutation rate at 
this point was around 1 x 10-3 in both cultures, much higher than the natural reported mutation 
rate of M. tuberculosis to isoniazid. It was at this timepoint also that the viable count was 
approaching its lowest point, after 6 mean generations of exposure both cultures maintained a 
mutation rate around 1 x 10-2 and this heightened mutation rate to isoniazid was reflected in 
the high frequency of mutants (figure 5.5). The viable count remained stable from around 10 
mean generations post isoniazid exposure with no real increase in viable population from the 
lowest viable count after the initial bactericidal killing period. The slow growth cultures 
maintained a population at a higher titre (figure 5.3) than these fast growth cultures indicating 
that the fast growing M. tuberculosis were able to proliferate in the presence of isoniazid but 
may have incurred a fitness cost. The mutation rate was generally higher in the fast growing 
culture and there were more mutants certainly in the latter part of the time-course. The slow 
growing culture contained mutants with SNPs in katG codon Ser315 (figure 5.4). Colonies isolated 
on 2 x MIC isoniazid from the fast growing cultures were also sequenced at the same loci to 
determine whether any isoniazid resistant mutations could be found and whether the 
population also predominantly consisted of katG codon Ser315 mutations as with the slow 
growers (figure 5.4)  
5.4.1 Pyrosequencing of colonies isolated from fast growing M. tuberculosis exposed to 
isoniazid  
Throughout both fast growth cultures there were very few SNPs at katG codon 315 that arose. 
The population of fast growing M. tuberculosis in the chemostat remained wild type at katG 
codon 315 during continual isoniazid exposure. There were less mutants when isoniazid was 
present in the cultures than in the culture that was not exposed to isoniazid (figure 5.2) but the 
majority of the  population in both culture conditions was wild type at this loci.  
The colonies sequenced were isolated on 2 x MIC isoniazid and the population in the chemostat 
was clearly able to grow exponentially in the presence of isoniazid (figure 5.5) although not as 
successfully as the slow growing cultures (figure 5.3). This indicates that the fast growing M. 
tuberculosis were using a mechanism other than mutation at katG codon 315 or the promoter 
region of isoniazid. 
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Genotype  AGC* AAC AGA ACC ATC AGG Mix Total 
Culture: Fast Growth 1 
Pre-drug 12 0 0 0 0 0 0 12 
3 36 0 1 0 0 0 0 37 
6 28 0 0 0 0 0 0 28 
23 24 0 1 0 0 0 0 25 
Culture: Fast Growth 2 
Pre-drug 17 0 0 1 0 0 0 18 
6 60 0 0 0 0 0 0 60 
13 88 2 5 1 1 1 0 98 
Genotype 
Figure 5.6 The genotype of the colonies recovered on 2 x MIC isoniazid isolated from cultures 
FG1 and FG2. The genotype shown is at katG codon 315 * denotes the wild type genotype. 
The total number of colonies sequenced is shown in the far right column. The graphs below 
the table are a visualisation of the data in the table as a percentage. 
0
10
20
30
40
50
60
70
80
90
100
PD 6 13MGT
%
 p
o
p
u
la
ti
o
n
0
10
20
30
40
50
60
70
80
90
100
PD 3 6 23
Mix
AGG
ATC
ACC
AGA
AAC
MGT
%
P
o
p
u
la
ti
o
n
 
127 
 
5.5 Sanger sequencing of the katG gene from fast and slow growing Mycobacterium 
tuberculosis 
Sequencing of the katG gene after 13 MGT of exposure to isoniazid  (sequenced by Dr Irene 
Freire-Martin , Jeeves et al., 2015) was performed to confirm that nearly 90 % of fast growing 
colonies were wild type at katG codon 315 at this time-point (figure 5.6) (Jeeves et al., 2015). Of 
the 77 colonies sequenced that were wild type, 65 had alternative mutations in the katG gene 
(table 5.1), some of which have been seen previously and most of which were deleterious (Rouse 
et al. 1996; Ramaswamy et al. 2003;Heym et al. 1993; Haas et al. 1997a; Hazbón et al. 2006). 
Five of the colonies contained a double mutation in katG (table 5.2), some of which included a 
mutation in codon 315, most of the alternative mutations caused a frameshift upstream of katG 
codon 315. This work confirms that there were very few mutations at katG codon 315 in the fast 
growing population but a number of frameshift and deletion mutations within katG would have 
disrupted the function of katG entirely (Heym et al., 1995). 
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Mutation AA change 
G1C M1L 
T2C M1A 
G3A M1V 
G3C M1V 
G3T M1V 
3Gdel Frameshift 
7GAdel Frameshift 
18Ains Frameshift 
19Cins Frameshift 
G28T E10* 
54Cins Frameshift 
78GAAATACins Frameshift 
G91T E31* 
G113A W38* 
140Tins Frameshift 
G241T E81* 
G264T Q88H 
G2095A G699R 
295Gdel Frameshift 
G311A R104Q 
G320A W107* 
355Cins Frameshift 
G356C R119P 
G362A G121D 
367Gins Frameshift 
371Gdel Frameshift 
A413G N138S 
A425C D142A 
Mutations 
continued 
AA change 
continued 
G451T V151F 
G452A W198* 
[597Gins] 
Frameshift 
628Ains 
Frameshift 
633Gins 
Frameshift 
T685G Y229D 
[G944A] S315N 
[G944C] S315T 
[G944T] S315I 
C945G S315R 
[C945A] S315R 
A970C T324P 
G983T W328L 
1102Tins Frameshift 
C1153T R385W 
G1282C G428R 
G1282T G428W 
[G1283T] G428V 
{1317Gdel} Frameshift   
A1316G Q439R 
1559Cdel Frameshift 
1701Tins Frameshift 
G1795T G599* 
T1985G L662R 
T2002C W668R 
Table 5.1 Colonies picked from slow or fast growth cultures (Culture SG2 and Culture FG2) at 
12 or 13 MGT were subjected to Sanger sequencing. The notation used for each mutation is 
as follows: original nucleotide followed by the nucleotide number and finally the new 
nucleotide. The corresponding amino acid changes or effects at each position are also 
indicated. In cases where an amino acid alteration is indicated by an asterisk there was a 
truncation of the gene. The square brackets indicate that the mutation was found in both 
growth rates, curly brackets indicate a mutation in slow growth and no brackets indicate a 
mutation in fast growth. Taken from (Jeeves et al., 2015) 
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5.6 Susceptible colonies 
Colonies isolated from chemostats that were not exposed to antibiotic (either in the control 
culture from a pre-drug sample of the drugged cultures) were taken and cultured on isoniazid 
containing plates to determine their susceptibility. The aim was to pick a range of colonies from 
different growth rates however many of the colonies became contaminated, the results shown 
are from the slow growth no drug control.  
Those colonies that were susceptible i.e. did not grow on isoniazid were then sequenced to 
confirm a wild type genotype at katG codon 315 and in the promoter region of inhA. Of the 
colonies sequenced 100 % were wild type at both codons (table 5.3) 
Culture name  Alternative 
mutation- 
nucleotide position  
& (315 codon) 
No. of 
colonies 
with this 
mutation 
Amino acid change 
or effect 
SG2;12MGT 1317Gdel (ATC) 1 Frameshift (S315I) 
 G1283T (ATC) 1 G428V (S315I) 
 597Gins (AAC) 3 Frameshift (S315N) 
FG2; 13MGT A1316G & G1795T 1 Q439R & G599* 
 1559Cdel (AGA) 1 Frameshift (S315R) 
 597Gins (AAC) 1 Frameshift (S315N) 
 597Gins (AAC) 1 Frameshift (S315N) 
 355Cins & G264T 1 Frameshift & Q88H 
Table 5.2 Double nucleotide polymorphisms within the katG gene in colonies isolated 
from slow or fast growth cultures (Culture SG2 and Culture FG2) at 12 MGT or 13 MGT, 
respectively, were identified by Sanger sequencing. The notation used for each mutation 
is as follows: original nucleotide followed by the nucleotide number and finally the new 
nucleotide. Some of the katG codon Ser315 mutations will have shifted by a nucleotide 
because of a deletion (“del”) or insertion (“ins”) upstream of the katG codon Ser315. 
Corresponding amino acid changes or effects at each position are also indicated. In cases 
where an amino acid alteration is indicated by an asterisk there was a truncation of the 
gene. Taken from (Jeeves et al., 2015) 
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5.7 Discussion 
Both cultures demonstrated equivalent mutation rates which reflected previous findings 
showing little differences in the mutation rates of active latent and reactivated disease samples 
from non-human primates (Ford et al., 2011). Mutation rates in latent infection in humans have 
however been reported to be lower than in actively replicating samples, these mutation rates 
were calculated by sequencing the outbreak and control strains recovered during the study 
(Colangeli et al., 2014). The slow growing cultures seemed less able to grow on isoniazid initially 
(the first 4 mean generations) in both the control and drugged cultures. The mutant frequency 
increased as the TVC declined and the pyrosequencing shows a genetically adapted population 
with a variety of SNPs at katG codon 315.  
The SNPs seen were clinically relevant mutations in response to isoniazid and have been 
reported previously (Haas et al., 1997a; Hazbón et al., 2006; Lipin et al., 2007), this high 
percentage of mutations at codon 315 of katG and the occurrence of different non-synonymous 
substitutions demonstrate the importance of this codon for the development of isoniazid 
resistance (Haas et al., 1997b), further strengthening the reasoning for the choice of this loci for 
analysis. The slow and fast growth mutants were wild type in the promoter region sequenced of 
inhA but it has been shown that inhA promoter mutations are inversely associated with 
mutations in katG (Hazbón et al., 2006). Resistance to isoniazid via inhA promoter mutations is 
due to over-expression of inhA.  However, this is an unlikely to occur as a primary mutation as 
expression of inhA has been shown to be tightly regulated (Banerjee et al., 1994). Therefore 
Mean 
Generation 
Time 
Days after 
inoculation 
No. of 
colonies 
Susceptible (1 
µg/ml isoniazid) 
katG codon 
315 
inhA 
promoter 
region 
69.3 31 5 Yes Wild Type 
 41 10 Yes 
 43 3 Yes 
 51 8 Yes 
 53 4 Yes 
Table 5.3 Colonies sequenced at katG codon 315 after being determined susceptible to 2 x 
MIC (1 µg/ml) isonazid.  
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overexpression could be too much of an energy cost to the bacterium and so katG mutations 
are likely to be selected for over inhA promoter mutations. 
The fast growth cultures that were not exposed to isoniazid showed a similar result to the 
drugged cultures in that M. tuberculosis at this growth rate appeared to be phenotypically 
adapted when katG codon 315 sequencing results were analysed (figure 5.2). Further 
sequencing was done on these colonies and showed that the majority of the resistant colonies 
that were wild type at katG codon 315 had mutations elsewhere within the katG gene (Jeeves 
et al., 2015). Many of these mutations resulted in frameshifts or deletions that would have 
disrupted the function of katG entirely. 
The previous results in Chapters 3 and 4 showed the slow growing M. tuberculosis adapted 
quicker and earlier to isoniazid exposure in terms of the viable count and susceptibility  and it 
was thought this was due to a natural phenotypic adaptation. The results in this chapter indicate 
that the slow growing M. tuberculosis was adapting genotypically at katG codon 315. A  mutation 
that occurs with increasing frequency the more drug resistant an isolate becomes (Hazbón et 
al., 2006) and because of catalase peroxidase activity retention, confers a high level of resistance  
(Somoskovi et al., 2001). The quicker adaptation of the slow growers compared with the fast 
growers could be due to the retention of KatG activity compared to the loss of KatG function the 
fast growers would have encountered. The slow growth rate conditions could have been 
selecting against the maintenance of mutants with alternative sites of mutation and loss of KatG 
activity. The fast growing population with disrupted KatG activity did survive through isoniazid 
treatment, indicating there was a requirement for a functional KatG in the slow growers but not 
in the fast growing population.  The dependency on a functional KatG in the slow growers could 
be due to a need to protect against the additive effects of free radical isoniazid intermediates 
(Wengenack and Rusnak, 2001) and increased exposure to free radicals through a longer 
replicative lifespan. In vivo During infection, an important part of human immune defences is 
the production of anti-microbial oxygen and nitrogen radicals by phagocytes, a functioning KatG 
is essential in the oxidative stress network of M. tuberculosis (Nambi et al., 2015).  
Fitness is the capability of a genotype or individual cell to survive and reproduce, genetic 
mutations associated with antibiotic resistance have been shown to reduce the fitness of a 
bacteria (Andersson and Hughes, 2010). One such consequences of a reduction in fitness is a 
reduction in the growth rate of an organism (Lenski, 1998; Schulz zur Wiesch et al., 2010). The 
imposed slow growth rate in culture may have been slow enough to nullify any fitness cost 
caused by mutations in katG codon 315. The increased growth rate in the slow growing cultures 
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after the initial bactericidal kill is likely to have still been slower than the fast growth rate which 
was close to µmax in our system otherwise we would start to see a more diverse range of katG 
mutations (as seen in the fast growth) starting to accumulate. 
Transcriptomic analyses were performed (in Chapter 6) from RNA samples removed from the 
slow and fast cultures described in this chapter. The transcriptomics analyses (Chapter 6) aimed 
to determine any differences in phenotypic adaptation between the two growth rates and 
whether there was upregulation of any genes in response to the differing mutations in katG. In 
populations with a defective KatG, upregulation of ahpC could compensate for the loss of 
oxidative stress response, these compensatory mutations have been described previously 
(Sherman et al., 1996). Phenotypic adaptation to antibiotic exposure can include upregulation 
of efflux pumps which has been described previously in response to isoniazid exposure (Gupta 
et al., 2010; Jiang et al., 2008). It will also be interesting to determine the differences in 
transcriptomic profiles between fast and slow growth before isoniazid exposure. 
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Chapter 6. Transcriptomic analysis of fast and slow growing Mycobacterium 
tuberculosis exposed to isoniazid 
6.1 Introduction 
Results have been presented in chapters 4 and 5 showing the differing responses of M. 
tuberculosis to the presence of isoniazid in the chemostat based on doubling time. Slow growing 
(69h MGT) bacilli appear to be adapting to the effects of isoniazid exposure by mutation of katG 
codon 315 as shown by the pyrosequencing results in chapter 5. The fast growing bacilli (23h 
MGT) did not appear to be adapting at either katG codon 315 or in the region of the promoter 
that controls inhA expression levels but did show mutations in other regions of the katG gene.  
Both growth rates resulted in a population of bacteria surviving through drug exposure (MIC 
levels of 0.5 µg/ml) in continuous culture but the mechanisms that were used to achieve this 
appear to be different. Resistance is a term usually preserved for bacteria that have a genetic 
adaptation to the presence of antibiotic and can be identified using sequencing methods. 
Persisters are a population of bacteria able to survive antibiotic exposure but are formed 
through a number of independent parallel mechanisms (Lewis, 2008), these include phenotypic 
mechanisms such as transcriptional regulation. Persisters are generally classed as phenotypic 
variants of the wild type (Keren et al, 2011) meaning that sequencing methods will not identify 
any differences in these cells to the wild type in traditional antibiotic resistance loci.  
In order to investigate phenotypic adaptation, RNA was extracted from the continuous culture 
systems as described in (section 2.6) to compare the expression profiles of the slow and fast 
growing M. tuberculosis in the presence of isoniazid. Genome wide expression analysis using 
microarray provides a powerful means to study the adaptive survival strategies of bacteria in 
response to a variety of stress conditions (Bacon and Marsh, 2007; Karakousis et al., 2008; 
Kendall et al., 2004). These strategies include regulatory changes resulting in changes to the 
physiology of the bacterium. Regulatory adaptations inform the bacterium as to the genomic 
changes that maximises the chance of adaptation and evolutionary success (Ryall et al., 2012). 
A regulatory change in genes involved in a DNA repair mechanism could lead to a change in 
mutation rate. A downregulation in DNA repair could result in mutations, such as single 
nucleotide polymorphisms (SNPs), these could confer an advantageous phenotype which is then 
selected for.  
Previous studies investigating transcriptional responses of M. tuberculosis in a variety of 
environments gives an indication of the groups of genes that may be important in the 
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interpretation of the results in chapters 4 and 5. In a previous study looking at the gene 
expression of both slow and fast growing Mycobacteria it was found that expression of genes 
belonging to the PE and PPE families, insertion sequence (IS) elements and genes associated 
with biosynthesis of the cell envelope were significantly up-regulated in the slow growing 
bacteria whereas genes involved in the synthesis and modification of macromolecules were 
down-regulated (Beste et al., 2007b). Some of these genes could also alter the response of the 
bacterium to isoniazid. Isoniazid regulatory genes (IRGs) have found to be up-regulated in M. 
tuberculosis in the mid-exponential phase of growth (Karakousis et al., 2008) , comparable to 
the fast growth rate in the experiments in this thesis. These IRGs include genes of the FASII 
operon, genes involved in mycolate transfer and fatty acid β-oxidation and genes involved in the 
detoxification of the toxic consequences of isoniazid and antibiotic efflux (Wilson et al., 1999) 
Another interesting group of genes that are important for growth through isoniazid exposure 
are those that are involved in the conversion of isoniazid from its pro-drug to active form, for 
example differential expression of ndh can contribute to isoniazid resistance in isolates that do 
not contain mutations in katG, inhA or kasA (Karakousis et al., 2008) In general, lack of IRG 
expression by organisms following exposure to isoniazid correlated with reduction in drug 
activity. 
By comparing the gene expression profiles of the fast and slow growth M. tuberculosis exposed 
to isoniazid, a list of significantly up or down regulated genes was produced with the hypothesis 
that fast and slow growing M. tuberculosis were persisting through isoniazid treatment using 
differing mechanisms. The slow growers were accumulating mutations in katG codon 315 and 
the fast growers accumulating mutations disrupting the function of KatG. The transcriptomic 
data was interrogated with the aim of determining whether additional mechanisms to survive 
isoniazid exposure, such as compensatory regulation was occurring in these populations. 
The specific objectives of this work were as follows: 
 To identify genes involved in phenotypic adaptation to isoniazid and whether these 
differ between slow and fast growing M. tuberculosis 
 
 To investigate whether there is evidence of compensatory regulation of genes in the fast 
growth experiments to compensate for a defective KatG due to mutation. 
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6.2 The effect of isoniazid addition on gene expression in M. tuberculosis 
M. tuberculosis grown in the chemostat shows a differing response to isoniazid, based on growth 
rate (figure 6.1). Samples were taken for RNA before isoniazid was added to the steady-state 
cultures and then at 1 MGT and 2 MGT post-isoniazid addition. This study focused on the 
transcriptional changes occurring at 2 MGT because this was a point at which the profiles of the 
cultures began to differ from each other in their response to isoniazid exposure.  
 
Figure 6.1 Total Viable Counts of Mycobacterium tuberculosis H37Rv in response to isoniazid in 
a continuous culture.  
The total RNA collected was then hybridised to a custom designed tiling array from Agilent with 
180 x coverage of the Mycobacterium tuberculosis H37Rv genome (section 2.7). The gene 
expression intensity values for cultures with or without drug exposure were normalised and 
analysed using GeneSpring software. Firstly, quantile normalisation was applied across the 
combined slow and fast datasets, followed by an averaging of the expression levels of all the 
probes for each open reading frame. 
Significance analyses were applied to find genes that were significantly differentially expressed 
between fast and slow growth rates either in the absence or absence of isoniazid by adopting a 
pairwise comparison method using 2-way ANOVA with a Benjamini-Hochberg correction 
(P=0.05) A further filter was applied to select genes with at least a two-fold change in gene 
expression. All microarray processing, statistics, PCR validation and compilation of gene lists 
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were performed by Dr Rose Jeeves at Public Health England, Porton Down. Full geneand can be 
found in (Jeeves et al., 2015). 
 
 
 
There were 164 genes up-regulated in the slow growing culture alone between 0 and 2 mean 
generations (figure 6.2), the number uniquely up-regulated in the fast growing culture is almost 
half this amount (73).  When looking at down-regulated genes the opposite result is true with 
101 genes in the fast growth culture alone down-regulated over time, more than double the 
number in the slow growth culture alone (41). There was a tendency towards up-regulation of 
the genes differentially expressed in both slow and fast cultures (140) when compared to the 
shared down-regulated genes (89). 
6.2.1 Differentially expressed genes in both fast and slow growing Mycobacterium 
tuberculosis 
This data describes genes that were significantly differentially expressed in both slow and fast 
growing M. tuberculosis over time after the addition of isoniazid, representing expression in 
response to isoniazid addition, independent of growth rate. Lists of differentially expressed 
genes, which were filtered as described in section 6.2, were submitted to the DAVID Functional 
Figure 6.2 Venn diagram depicting the number of genes differentially regulated between 0 and 
2 mean generation times from isoniazid addition in fast and slow growth rate continuous 
cultures.  
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Annotation Bioinformatics tool (http:// david.abcc.ncifcrf.gov/) (Huang et al., 2009a, 2009b) to 
identify statistically significantly enriched functional groups of genes. Gene functions were 
identified by Uniprot accession number and significant percentage enrichment was identified 
using a Benjamini multiple testing correction. The data discussed is from samples taken after 2 
mean generations of isoniazid exposure compared to expression levels prior to isoniazid 
addition when the cultures were in steady-state. 
There were 89 genes that were down-regulated over the course of 2 mean generations in both 
the fast and slow growth cultures. There were several major functional groups of genes 
identified using DAVID analysis. Genes involved in aerobic respiration were down-regulated and 
these included a group of NADH dehydrogenases of complex I (Rv3145-6, Rv3148-9, Rv3151-3, 
Rv3155-7) which catalyse the transfer of electrons. Downregulation of this regulon results in less 
free NADH within the cell, which would slow the catalysis of isoniazid pro-drug, indicating that 
this was a general response to the presence of isoniazid.  Essential ATP synthases (Rv1307-10) 
were also down-regulated under both growth conditions and have been previously shown to be 
down-regulated under stress conditions (Betts et al., 2002), this correlates with the presence of 
isoniazid as it would be expected that aerobic respiration would be down-regulated in the 
presence of a bactericidal antibiotic due to cell death, which can be seen in the viable count data 
in Chapter 4.  
Alongside these aerobic respiration genes was the down-regulation of secreted proteins Rv2780 
and Rv1886c. Rv2780 encodes for Ald, which is a secreted L-alanine dehydrogenase, this protein 
is thought to be linked to cell wall synthesis as alanine is an important constituent of 
peptidoglycan. Rv1886c encodes secreted antigen FbpB (also known as antigen 85-b) and this 
protein is involved in cell wall mycolation and possesses activity required for the biogenesis of 
‘cord factor’, a dominant structure necessary for maintaining cell wall integrity. In addition to 
these cell wall related genes, two cell division genes were also down regulated Rv2147c and 
Rv2150c encoding SepF and FtsZ respectively. Polymerisation of Fts into a circular structure at 
mid-cell, the Z ring, initiates cytokinesis in bacteria. This Z ring functions as a scaffold for a group 
of conserved proteins that execute the synthesis of the division septum. SepF is one of these 
proteins and is an essential part of cell division (Hamoen et al., 2006). The down-regulation of 
these groups of genes suggests a reduction in cell wall metabolism and cell division in both fast 
and slow growing mycobacteria in the presence of isoniazid.  
There were 141 genes up-regulated in the cultures in response to isoniazid. Rv3181c and Rv1561 
encode for the VapB45 antitoxin and VapC11 toxin respectively. Toxin-antitoxin (TA) systems 
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have been implicated in the formation of persister cells leading to antibiotic tolerance in an 
otherwise susceptible population (Keren et al., 2011). The VapBC TA systems are a member of 
the largest TA systems in M. tuberculosis and are thought to be associated with ribonuclease 
function and have been shown to block translation and mRNA cleavage in M. smegmatis 
(Robson et al., 2009). Transient activation of these mRNAses  may allow the bacteria to adapt to 
stress not only by inhibiting replication but also by degrading existing transcripts allowing a rapid 
change in the metabolic program of the bacteria (Ramage et al., 2009). It appears that both the 
fast and slow growing bacteria have responded to the stress of isoniazid addition by trying to 
quickly adapt to the environment through regulation of TA systems, of which there are a high 
number in M. tuberculosis. 
Another possible adaptation that can be seen in this expression data was the up-regulation of 
Rv3065 (mmr) which encodes for a multi-drug efflux pump. Bacterial efflux pumps are 
membrane proteins that are capable of actively transporting a broad range of substrates 
including drugs, from the cytoplasm to the exterior of the cell.  Increased expression of efflux 
pump genes confers a low-level resistant phenotype and mmr has been shown to be 
overexpressed in strains of M. tuberculosis exposed to isoniazid (Machado et al., 2012; 
Rodrigues et al., 2012).  
The increase in expression of mmr in both the slow and fast growing cultures over the first two 
mean generations of this experiment showed a response to the presence of isoniazid which 
allowed the possibility of continued replication enabling the chance of a mutation conferring 
drug resistance to occur. 
6.3 The effect of growth rate on gene expression in Mycobacterium tuberculosis 
6.3.1 Gene expression prior to isoniazid addition 
In the absence of antibiotic, the expression profiles of the slow and fast cultures were very 
similar with only 7 genes being differentially expressed (Table 6.1). This is a small number of 
genes that are different between the cultures when compared to work in M. bovis (BCG), which 
found 84 genes exclusively required for slow growth (Beste et al., 2009). An important group of 
genes that may have been expected to be more highly expressed in the fast growing cultures 
would be ribosomal related genes, as evidence of growth rate mediated regulation of ribosome 
biosynthesis has been presented also in M. bovis (BCG) (Beste et al., 2005). 
Four of these were more highly expressed in the fast growing culture when compared to slow 
growing culture (Rv1592c, Rv0196, Rv2429 and Rv2428) and 3 genes were more highly 
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expressed in the slow growing culture (Rv2638, Rv3572, Rv3089) compared to the fast growing 
culture data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fast growing cultures show a higher level of expression of ahpC and ahpD (Rv2428 and 
Rv2429) which encode an alkyl hydroperoxide reductase. In  M. tuberculosis, OxyR, the central 
regulator of bacterial oxidative and nitrosative stress responses is inactive (Deretic et al., 1995). 
Despite this loss, several other oxidative stress response genes are preserved. One of the genes 
under the control of OxyR is ahpC which is suggested to protect mycobacteria from the 
deleterious effects of the combinatorial products of reactive oxygen and nitrogen intermediates 
(Pagán-Ramos et al., 2006). KatG is the only peroxide inducible gene in M. tuberculosis in the 
absence of functional OxyR. It has been shown that in the absence of KatG, (for example due to 
mutation), overexpression of the ahpC gene occurs, AhpC can act as an antioxidant; protecting 
DNA and other proteins from oxidative stress (Chauhan and Mande, 2002). Levels of AhpC are 
low in wild type M. tuberculosis. Increased expression of ahpC could perturb peroxidative  
Higher expression in Fast cultures 
Gene Description P-value 
(Growth Rate) 
Rv1592c-S Probable inactive lipase 0.007014 
Rv0196-S Uncharacterized HTH-type transcriptional regulator 0.006672 
Rv2429-S Alkyl hydroperoxide reductase AhpD  0.006672 
Rv2428-S Alkyl hydroperoxide reductase subunit C AhpC 0.006528 
 Higher expression in Slow cultures 
Gene Description P-value 
(Growth Rate) 
Rv2638-S SpoIIAA family protein 0.001306 
Rv3572-S Putative uncharacterized protein 0.007448 
Rv3089-S Fadd13 possible Fatty Acid-CoA-Ligase 0.007014 
Table 6.1 Genes found to be differentially expressed in slow and fast growing M. tuberculosis 
in chemostat culture before addition of isoniazid. These results are from 2 replicates with an 
ANOVA performed from the larger data set. 
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homeostasis that mycobacteria try to maintain (Heym et al., 1997) leading to a reduction in the 
requirement for KatG activity. A clinical isolate has been studied that possessed an upregulated 
promoter region of ahpC and it is thought this could compensate for any loss of KatG activity 
(O’Sullivan, McHugh, et al., 2008). If the fast growing M. tuberculosis in this experiment was 
expressing ahpC at a level higher than the slow growing M. tuberculosis then perhaps the 
requirement for katG expression was reduced, this could lead to less isoniazid being converted 
to pro-drug and apparent resistant/persistent phenotype without a mutation.  
6.3.2 Differential gene expression specific to fast growing Mycobacterium tuberculosis in the 
presence of isoniazid 
There were 101 genes uniquely down-regulated in the fast growing M. tuberculosis over the 
course of the first 2 mean generations of the experiment post isoniazid-addition (figure 6.2). 
Most of these down-regulated genes were classed as oxidoreductases, including dyhydrofolate 
reductase, cytochrome P450 and aldehyde dehydrogenase, which are essential genes involved 
in processes such as glycolysis, oxidative phosphorylation, and amino acid metabolism. The 
presence of isoniazid appears to be causing a down-regulation of the essential metabolism of 
the cell, which is reflected in figure 6.1 by the decline in titre over the first 2 mean generations 
of isoniazid exposure. Another group of genes up-regulated in the presence of isoniazid were 
lipoproteins, which have a functional role in the transport of nutrients through the cell wall. The 
role of lipoproteins in the adaptation to antibiotic exposure is still unclear but two of these genes 
were up-regulated in a previous study upon isoniazid exposure (Waddell et al., 2004). 
Membrane proteins including genes encoding DNA translocases such as ftsK and ftsW, both 
involved in cell division were also down-regulated over time. 
Term P-Value Genes Fold Enrichment Benjamini 
correction 
fatty acid 
metabolism 
0.000294 Rv0905-S, Rv2930-S 29.87058824 0.014001601 
lipid metabolism 0.000393 Rv0905-S, Rv2930-S 27.15508021 0.009389622 
antibiotic 
resistance 
0.001705 Rv1846c-S, Rv0667-S 16.59477124 0.0269263 
Table 6.2 Results from the DAVID Functional Annotation Bioinformatics tool (http:// 
david.abcc.ncifcrf.gov/) showing statistically significantly enriched groups of genes in the fast 
growing (MGT 23.1 hours) M. tuberculosis. Significant percentage enrichment was identified 
using a benjamini multiple testing correction. 
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The results of the DAVID analysis described  how groups of genes that were enriched only in the 
fast growing M. tuberculosis at 2 mean generations (table 6.2); the viable count data (figure 6.1) 
suggested this was the timepoint at which the two growth rates began to differ in their 
responses to isoniazid. 
Genes involved in fatty acid metabolism and lipid metabolism were enriched 30 fold and 27 fold 
respectively in the fast growing M. tuberculosis. Gene Rv2930 (fadD26) is involved in phthiocerol 
dimycocerosate (DIM) biosynthesis, which is a major cell wall lipid of the tubercle bacillus. It is a 
highly apolar wax and with the exception of one species of mycobacteria, all DIM containing 
species are pathogenic, leading to the idea that DIM is implicated in virulence (Brennan, 2003). 
Mutants without DIM have been shown to be more permeable and hypersensitive to antibiotics 
(Camacho et al., 2001; J. Yu et al., 2012) and so the enrichment of genes in the fast growth when 
compared to slow growth involved in fatty acid and lipid metabolism, including DIM 
biosynthesis, in the presence of isoniazid could indicate a defence mechanism against entry of 
isoniazid into the cell by trying to maintain the cell wall and the natural low permeability of the 
mycobacterial cell wall. This is an indication of a phenotypic adaptation by the fast growing 
mycobacteria. There was also a 17 fold enrichment of genes classified to be involved in antibiotic 
resistance. Rv1846c encodes BlaI which is a transcriptional repressor, BlaC governs β-lactamase 
production in response to beta-lactam treatment and causes de-repression of the BlaI regulon 
and up-regulation of ATP synthase transcription, indicating a potential regulatory loop between 
cell wall integrity and ATP production (Sala et al., 2009). Gene, Rv0607 encodes for RpoB which 
catalyses the transcription of DNA to RNA, rpoB is the site of mutations that confer resistance to 
the rifamycin antibacterial agents, such as rifampicin. Mutations in rpoB that confer resistance 
to rifamycins do so by altering residues of the rifampicin binding site on RNA polymerase  
(Campbell et al., 2001).  
6.3.3 Differential gene expression specific to slow growing Mycobacterium tuberculosis in the 
presence of isoniazid 
There were more than double the number of genes upregulated over 2 mean generations in the 
slow growing M. tuberculosis when compared to the fast growing M. tuberculosis. Two toxins, 
part of a TA system, VapC24 and VapC39 were both upregulated in slow growth. There were TA 
genes up-regulated in both the fast and slow growth (section 6.2.1) (VapB45 antitoxin, VapC11 
toxin). The additional up-regulation of toxins in the slow growing bacteria perhaps indicates a 
more varied and more prominent role of TA systems in this population. As a result of 
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bioinformatics analysis of M. tuberculosis, 38 potential toxins (23 VapC homologues) were 
identified (Pandey and Gerdes, 2005). It was also found that M. leprae appears to have lost all 
functional toxin genes and this is thought to be due to the unchanging nature of the niche M. 
leprae occupies in the human host, as opposed to the free-living slow growing M. tuberculosis 
(Pandey and Gerdes, 2005).  
At 2 mean generations of culture in isoniazid, NADH dehydrogenases and oxidoreductases were 
enriched in slow growth indicating a possible increase in metabolism and a response to oxidative 
stress. The expression of putative transposases (Rv1199c, Rv3348and Rv3844) was also up-
regulated in slow growth cultures. Insertion-sequence (IS) elements are known to be segments 
of bacterial DNA that can move from one position on a chromosome to a different position on 
the same chromosome or on a different chromosome. When IS elements appear in the middle 
of genes, they interrupt the coding sequence and inactivate the expression of that gene. Owing 
to their size and in some cases the presence of transcription and translation termination signals, 
IS elements can also block the expression of other genes in the same operon if those genes are 
downstream from the promoter of the operon (Griffiths AJF, Miller JH, Suzuki DT, 2000). 
Transposition, mediated by transposases, is known to account for some of the genetic diversity 
in mycobacteria as this event can cause mutation and IS6110, a Mycobacterium tuberculosis 
complex species-specific insertion element, is used in DNA fingerprinting of M. tuberculosis 
strains (Thorne et al., 2011). 
There were very few down-regulated genes in the slow growth culture, genes involved in mycolic 
acid biosynthesis were down-regulated including Rv0469 (umaA a probable mycolic acid 
synthase), this could be a response to the presence of isoniazid and a slowing of cell division. 
6.3.4 Differential expression of ahpC in fast and slow growing M. tuberculosis 
The expression profiles of the slow and fast growing M. tuberculosis prior to addition of isoniazid 
were very similar, indicating differing growth rate does not cause major expression changes. This 
is in contrast to other work using these growth rates in chemostats where 84 genes were 
exclusively required for slow growth (Beste et al., 2009). The main difference was the significant 
enrichment in expression of ahpC and ahpD in the fast growing culture and not the slow. It 
appears the fast growing M. tuberculosis has a natural higher expression of the alkyl 
hydroperoxide reductase which is an important oxidative stress response gene. The fast growing 
M. tuberculosis in these results was used to model the actively growing state of the bacteria as 
opposed to the slow growing M. tuberculosis which is likely to be the state the bacteria are in 
when entering the latent phase of the disease once infection has been established in the host. 
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These actively growing cells may have a disposition to increased ahpC expression to combat the 
increased threat of oxidative stress caused by free radical attack. Actively growing cells are more 
likely to encounter hyperoxic environments, for example in the airway after infection or in the 
sputum prior to expulsion, which can lead to the production of reactive oxygen species. The 
immune system of the host also relies on the production of oxygen radicals to kill pathogens and 
it is likely that it is actively growing M. tuberculosis cells in a newly infected host that encounter 
these defences. A natural increased expression of ahpC in fast growing M. tuberculosis would 
indicate the phenotypic ability to survive these environments of likely free radical attack, this 
could also contribute to the greater involvement of phenotypic resistance seen in the fast 
growing cultures (section 5.3.1.2). Expression levels of ahpC following isoniazid exposure 
increased in both growth rates but were higher in the slow growing bacteria by 2 mean 
generations compared to the fast growers, the differential expression of ahpC was confirmed 
using qRT-PCR as can be seen in figure 6.3.  
 
 
 
 
 
 
 
 
 
 
 
It has been hypothesised that M. tuberculosis maintains a peroxidative homeostasis (Heym et 
al., 1997) that is maintained via regulation of ahpC and katG. An increase in ahpC expression 
following exposure to isoniazid may be due to katG being sequestered by isoniazid. The increase 
in expression of ahpC in the slow growing bacteria could be to compensate for partial loss of 
function of KatG, compromised by the mutations seen in katG codon 315 in section 5.3.1 The 
Figure 6.3 Relative expression levels, as confirmed by qRT-PCR, of the ahpC gene of M. 
tuberculosis in fast and slow growing cultures across 2 mean generations of isoniazid 
exposure. Data provided by Dr Rose Jeeves. 
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mutants in the fast growing population (section 5.4.1) are likely to have a more compromised 
KatG, the increase in expression of ahpC could compensate for some of this but it may be that 
the increase in efflux pump expression may be another compensatory response to the loss of 
KatG function. 
6.4 Antisense RNA 
In this study, tiling arrays were used as a means of investigating expression. These arrays are 
high density arrays composed of oligonucleotide probes that span the entire genome of an 
organism. This is particularly useful as they do not require a fully annotated genome and 
provides an unbiased approach to interrogate the genome for areas of novel non-protein coding 
RNA (Yazaki et al., 2007) 
Antisense RNA (asRNA) is a single stranded RNA that is complementary to a messenger RNA 
(mRNA) strand transcribed within a cell. asRNA provides a mechanism of gene expression 
regulation through transcriptional interference. The use of tiling arrays has revealed 
unexpectedly large numbers of closely spaced promoters, dramatically increasing the potential 
for transcriptional interference through a number if methods, including; collision of two 
divergently elongating RNA polymerase complexes, occlusion of the promoters by an already 
elongating RNA polymerase and removal of bound RNA polymerase by the collision of an already 
elongating RNA polymerase complex. An RNA duplex can also generate a specific processing site, 
which may lead to a translationally inactive mRNA (Georg and Hess, 2011) 
A full analysis and interpretation of the asRNA data is outside of the scope of this study but there 
were some results of note. There was a general up-regulation of asRNA expression in both the 
fast and slow growth cultures over the first two mean generations of culture in the presence of 
isoniazid. In the slow growing M. tuberculosis however, 71% of the total significantly up-
regulated genes were antisense compared to 42% in the fast growth. This indicates that perhaps 
the slow growing bacteria are using antisense RNA as a level of transcriptional regulation more 
than the fast growing M. tuberculosis. 
6.5 Discussion 
In response to isoniazid, in both fast and slow growing M .tuberculosis, there was a down-
regulation in aerobic respiration and core metabolic processes, which is in agreement with 
previous results obtained in a nutrient starvation model (Betts et al., 2002). Cell wall 
constituents and genes involved in cell wall mycolation along with cell division genes were also 
down-regulated. Isoniazid acts by inhibiting mycolic acid synthesis and requires NADH to form 
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an intermediary complex; by down-regulating respiration including NADH pathways, there may 
be less free NADH in the cell which could slow the catalysis of isoniazid pro-drug to its active 
form. 
There appears to be a general stress response indicated by the up-regulation of toxin-antitoxin 
(TA) systems and two TA genes were up-regulated suggesting a response to isoniazid. TA systems 
allow a rapid change in the metabolic program of the bacteria (Ramage et al., 2009) and have 
been implicated in persistence (Lewis, 2012). It has been suggested in M. tuberculosis that RelE 
toxins are involved in determining the fraction of drug tolerant persisters in vitro and this 
overexpression was drug specific (Singh et al., 2010) although this result could not be replicated 
in vivo. The upregulation of TA systems also indicates an adaptation to a changing environment, 
whether that be isoniazid exposure or the changing host conditions, M. tuberculosis has a large 
number of TA systems allowing this adaptation (Pandey and Gerdes, 2005) possibly faciliting the 
maintenance or generation of persister cells. 
Further evidence of a stress response was seen with the up-regulation of a multidrug efflux 
pump (mmr), this has been attributed to emergence of high level resistance. In previous studies, 
overexpression of mmr, showed no effect on the MIC of isoniazid against M. tuberculosis in 
response (Rodrigues et al., 2013). It is thought the overexpression of mmr and other efflux 
pumps may be due to a general stress response caused by exposure to isoniazid and would also 
serve to transport any other bacterial metabolites either derived from isoniazid itself or 
generated in response to isoniazid-induced damage. It has also been suggested that sub-
therapeutic antibiotic stress induces efflux pumps in mycobacteria and this is the first step in 
acquiring higher level resistance (Schmalstieg et al., 2012). The efflux pump induction allows 
protection from the antibiotic allowing replication and increasing the chances of mutation as 
part of the stochastic process. The induction of efflux pumps preceding emergence of high level 
resistance is thought to be part of the same process and not two independent events. 
There was a general trend of antisense up-regulation in both fast and slow growing M. 
tuberculosis. With the advent of new technologies the analysis of transcription of individual cells 
is possible. It has become clear that transcription is not a continuous smooth process and is 
irregular with periods of inactivity followed by strong periods of activity know as transcriptional 
bursting. This phenomenon  may occur under new environmental conditions and has been 
shown to lead to significantly higher intrinsic ‘noise’ in asRNA based regulation than in 
transcription factor based regulation (Mehta et al., 2008). This ‘noise’ is due to random 
fluctuations in gene expression and can establish cell-to-cell differences in an isogenic 
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population of bacteria (Casadesús and Low, 2013). This could increase the phenotypic 
heterogeneity of cells within a population and antisense expression is associated with genes of 
larger expression variability. Small RNAs also allow cells to respond rapidly to large changes in 
input signals, such as environmental conditions, which suggests a niche for these RNAs in 
allowing cells to transition quickly between different states (Mehta et al., 2008), this is often 
why genes involved in the stress response or environment specific genes are often enriched for 
in antisense expression (Xu et al., 2011).  
6.5.1 Fast Growth 
Genes enriched at 2 mean generations on their function only in fast growth also included genes 
involved in fatty acid and lipid metabolism including DIM biosynthesis genes. It has been shown 
that mutants without DIM are more permeable to antibiotics (Camacho et al., 2001) so 
enrichment of these genes shows a phenotypic adaptation by the fast growing mycobacteria by 
maintaining the cell wall and its natural low permeability. This enrichment, occurring only in the 
fast growing bacteria could indicate this population is suffering more cell wall damage in the 
presence of isoniazid. Lipoproteins were also enriched and these non-covalently linked lipids 
have also been implicated in contributing to the virulence of some mycobacterial species, 
enrichment of these genes in the fast growth may indicate a response to isoniazid that involves 
an increase in virulence, perhaps as a method of survival.  
Genes involved in antibiotic resistance indicate a shift to an up-regulation in cell metabolism, 
Rv1846c (BlaI) could be present as a response to cell wall damage caused by the isoniazid 
resulting in up-regulation of ATP synthase. The presence of rpoB on the list could be less to do 
with its links to rifampicin resistance but more to the essential role it plays in transcription, 
indicating that the fast growing cells are responding to the presence of isoniazid by altering 
transcription and ATP synthesis. 
A multi-drug efflux pump (mmr) was upregulated in both fast and slow growing M. tuberculosis 
which appears to be a general stress response. The fast growing bacteria also upregulated efpA 
an efflux pump which has been shown to be involved in isoniazid efflux (M. Wilson et al., 1999). 
This additional method of isoniazid efflux could indicate a gene that allows a phenotypic 
adaptation and a means of persistence in the fast growing bacteria. 
6.5.2 Slow Growth 
In the slow growing M. tuberculosis there was more upregulation of genes, including toxin-
antitoxin genes, this could indicate a more varied gene regulation pattern in this population in 
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response to isoniazid and alternative phenotypic adaptation which could lead to generation of 
persisters. Of the genes upregulated, 71% were antisense, indicating that the slow growers are 
using an alternative gene expression regulation system that is able to fine tune transcription 
regulation. Transcription factors often control regulons consisting of many genes and operon 
structures are generally transcribed as one unit; asRNA implements adjustment of mRNA 
amounts from genes within an operon (Georg and Hess, 2011). Putative transposases were 
upregulated in the slow growth cultures, showing another possible variation in gene expression 
control methods. Transposons can also cause genetic mutation and in general, the more 
transposition, the more genetic instability occurs. Transposition has been shown to occur more 
readily from transcriptionally active locations, a stable strain may develop more rapid variation 
due to transposition into an active site (Wall et al., 1999). There were more than double the 
number of genes upregulated between 0 and 2 mean generations in the slow growing cultures 
compared to the fast, indicating the slow growing M. tuberculosis could be more susceptible to 
genetic change due to more transposition because of the increased number of transcriptionally 
active locations. 
6.5.4 Conclusions 
It appears that the fast growing M. tuberculosis in this experiment are adapting by increasing 
fatty acid and lipid metabolism as has been seen previously when microarrays  were performed 
on exponentially growing M. tuberculosis exposed to isoniazid (Wilson et al., 1999). Along with 
the upregulation of efpA involved in isoniazid efflux this suggests a number of phenotypic 
adaptations by the fast growing bacteria. An up-regulation of ahpC at 2 mean generations of 
isoniazid exposure could be a mechanism to manage the toxic consequences of any isoniazid 
activation and compensate for loss of KatG function in those mutants with disruptive mutations 
in katG.    
The transcriptomic results suggest the main difference between the growth rates is the method 
of transcriptional regulation. The slow growers have a more varied and fine-tuned response 
involving antisense RNA and toxin-antitoxin systems; this combined with the up-regulation of 
mobile genetic elements could provide an environment for the surviving bacteria to be more 
suited to the niche environment and able to respond to the changing conditions more quickly, 
whilst accumulating advantageous genetic mutations within katG codon 315. The upregulation 
of TA systems at both growth rates indicates a mechanism to allow formation of persisters 
(Lewis, 2012) and adapt to changing environments (Pandey and Gerdes, 2005) the fast growing 
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mycobacteria appear to have capitalised on this with phenotypic adaptations along with the 
deleterious mutations in KatG. 
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Chapter 7. Discussion 
This study set out to investigate growth rate differences in M. tuberculosis and the effect these 
phenotypic states may have on antibiotic efficacy. It has been discussed previously that the 
environment in which bacteria grow is not always optimal for the action of an antibiotic (Udekwu 
et al., 2009). In vitro studies have demonstrated that the number of persister cells in a 
population is directly proportional to the number of stationary phase cells inoculated into the 
culture (Balaban et al., 2004). Also, decreasing the growth rate of E. coli in continuous culture 
has been shown to increase the fraction of persister cells (Sufya et al., 2003). Growth rate is the 
change in cell number per unit time and growth phase refers to the metabolic state of the 
bacterium and a population could have a slower growth rate but still be in the exponential phase 
of growth.  These two factors are not synonymous and are both effective indicators of the fitness 
of a population and also give clues to adaptive techniques.  Reduced growth rate has been 
hypothesised to be responsible for antibiotic tolerance (Baek et al., 2011) , almost all antibiotics 
preferentially kill rapidly replicating bacteria so the slowing of metabolic processes such as cell 
wall synthesis and RNA transcription results in a reduction in antibiotic target. In many infectious 
diseases including tuberculosis, the quantity of bacteria can far exceed standard MIC testing 
inoculums and so antibiotic concentrations derived from these tests may be insufficient. 
Understanding how these factors can influence the effectiveness of an antibiotic treatment is 
essential. Titres in vivo are far higher than those tested clinically and poor treatment outcome 
that is based on low titre susceptibility testing could be contributing to the tuberculosis burden 
and not reflecting the true pharmacokinetics of the antibiotic in situ (Udekwu et al., 2009). 
Continuous culture has allowed cell density effects to be investigated because of the ability to 
grow and maintain high titre populations of bacteria in a controlled and defined environment 
over a timecourse. The effectiveness of an antibiotic can be investigated in an environment 
which reflects in vivo conditions; more so than in a small scale flask culture. 
7.1 Cell density influences antimicrobial efficacy 
Cell density experiments (section 3.3) highlighted rifampicin’s ineffectiveness at titres ranging 
from 105 cfu/ml to 107 cfu/ml; titres  that are clinically relevant (De Groote et al, 2011; Ordway 
et al, 2010; Sharpe et al, 2009, 2010b) and found in vivo during infection. Rifampicin was more 
effective at lower titres that are often used as an MIC testing standard (105 cfu/ml) (Udekwu et 
al., 2009) (figure 3.8). Isoniazid was shown to be effective at higher cell densities than rifampicin 
but still showed reduced killing at high cell densities (figure 3.5) which has been seen previously 
(Davey and Barza, 1987; Gilbert et al., 1987; LaPlante and Rybak, 2004; Udekwu et al., 2009). In 
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vitro  data using Staphylococcus aureus showed that in low titre populations the  antibiotic was 
at the MIC or higher for the full timecourse. In high titre populations the concentration of 
antibiotic was effectively diluted by the number of cells, showing high titre inoculums to have a 
significant impact on the efficacies of nafcillin and vancomycin (LaPlante and Rybak, 2004). It 
was also noted in (Udekwu et al., 2009) that the cell density effect differed depending on the 
mode of action of the antibiotic. At a high bacilli titre the nutrients are depleted by bacterial 
growth faster than in a comparably low titre culture, this reduction would lead to a reduction in 
the growth rate of the population which could slow the action of antibiotics, this was 
demonstrated in Streptococcus pyogenes in stationary phase when penicillin binding proteins 1 
and 4 were undetectable in a high inoculum therefore leading to the primary targets being 
absent (Stevens et al., 1993). For isoniazid at a high cell density it could be that a reduced growth 
rate leads to a reduction in mycolic acids due to a slowing of cell division and therefore a 
reduction in target for isoniazid. Uptake of isoniazid is via passive diffusion and a disruption in 
proton motive force or reduction in available ATP does not affect this; it has been shown that 
KatG activity is the limiting factor in isoniazid activity so when growth rate is decreased due to 
nutrient limitation the activity of KatG and subsequent conversion of the isoniazid pro-drug will 
also decrease (Bardou et al., 1998).   
The effectiveness of rifampicin has been shown to be concentration dependent (T Gumbo et al., 
2007) and time dependent (de Steenwinkel et al., 2010; Jayaram et al., 2003) intracellularly. An 
increase in the concentration of bacilli would effectively lower the concentration of rifampicin 
available per cell and perhaps lead to less effectiveness at a higher cell density. Rifampicin does 
not require conversion to an active form unlike isoniazid so once within the cell the amount of 
time required to act is shorter possibly leading to quicker depletion extracellularly due to passive 
diffusion based on the concentration gradient.  
As well as demonstrating a cell density effect this work also served to demonstrate the 
differences in modes of action of rifampicin and isoniazid and also introduced the ideas of 
growth rate and phase affecting antibiotic efficacy. 
7.2 Slow growing M. tuberculosis is better adapted to antimicrobial exposure 
It has generally been accepted that the slower the doubling time of a bacterium the less 
bactericidal kill is afforded by an antibiotic (Brown and Williams, 1985; Brown et al., 1990; 
Gilbert and Brown, 1978; Sufya et al., 2003). This was seen in this study with isoniazid and 
rifampicin and appeared independent of drug concentration. This was important as doubling 
times in bacterial infections have been shown to be slower than batch culture in vitro 
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experiments (Cozens et al., 1986) To study this slow growth phenotype is important in order to 
determine antibiotic efficacy at more relevant growth rates. The requirement for a multi-drug 
approach to treatment of tuberculosis disease was also modelled in section 3.5 as the different 
efficacies of isoniazid and rifampicin were revealed. Isoniazid appeared more slow acting than 
rifampicin as the results from the very slow growing bacteria after 24 hours of exposure were 
not reflective of the amount of action after 96 hours of isoniazid exposure (figures 3.9 and 3.10). 
These initial experiments served to highlight the importance of considering bacterial 
physiological factors such as growth rate and phase in the design of new tuberculosis therapies 
and in the design of experiments aiming to model their action in infection. The requirement for 
new antimicrobials that are effective against all growth rates has also been highlighted as the 
efficacy of the two frontline antibiotics for tuberculosis treatment dramatically decreased with 
slowing growth rate. Bedaquiline belongs to a novel class of antibiotics, which are bactericidal 
against slow growing and non-replicating mycobacteria (Lakshmanan and Xavier, 2013), 
targeting the mycobacterial ATP synthase (de Jonge et al., 2007). This new drug has been 
incorporated into the treatment regime although due to adverse effects is seen as a treatment 
for use for patients with MDR-TB with no other treatment options (Worley and Estrada, 2014), 
there is obviously still a need for new therapies 
7.3 Effect of growth rate on the activity of isoniazid 
The study was then continued (chapter 4) using isoniazid as it is one of the frontline therapies 
used for both active infections and latent infections (Centers for Disease Control and Prevention, 
2003). Previous studies have shown that the decrease in the M. tuberculosis population in 
sputum during therapy was biphasic, showing isoniazid caused a rapid bacillary decrease during 
the first two days (Jindani et al., 2003; Mitchison, 1979). The theory from this previous work was 
that the bi-phasic kill was due to depletion of exponentially growing organisms and it was the 
growth rate of the population that determined the effectiveness of the antibiotic. An 
understanding of the action of isoniazid on different populations and the emergence of 
resistance is still important information that could inform the usage of this antimicrobial. 
The observation that growth rate led to a reduction in effectiveness of isoniazid was further 
modelled and investigated by adding isoniazid directly to continuous cultures with controlled 
doubling times (sections 4.2.1 and 4.3.1). It has previously been demonstrated that the biphasic 
killing of tuberculosis by isoniazid was accounted for by emergence of resistance, due to a 
heterologous population (Gumbo et al., 2007),  the cessation of early bactericidal kill by isoniazid 
corresponded with the drug resistant isolates in exponential growth exceeding the population 
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of susceptible cells. This study in Gumbo et al used the Hollow Fibre Model which allows 
pharmacokinetic and pharmacodynamic (pk-pd) studies of drugs with the absorption and 
elimination kinetics of the drug being closely controlled (Cadwell, 2012). This model does not 
control the doubling time of the bacteria and although a very valuable model the continuous 
culture experiments in this study were focussed on the effect of growth rate.  By using 
continuous culture, the organisms were maintained in exponential phase so the effect of the 
growth rate can be studied to determine whether it has an effect on the emergence of 
resistance. This population can then be interrogated and the different aspects such as mutation 
rate and phenotypic adaptation investigated. 
7.4 Slow growing M. tuberculosis is adapted to isoniazid with mutations in KatG codon 315 
It was hypothesised that the difference in the responses of slow and fast growing M. tuberculosis 
to isoniazid were due to different mechanisms of adaption.  The fast growing bacteria were 
adapting less successfully than the slow growing M. tuberculosis and it was thought this was due 
to a natural phenotypic adaptation brought about by slow growth rate. The chemostat culture 
result (sections 4.2 and 4.3) confirmed that growth rate has an impact on isoniazid activity; the 
slow growing mycobacteria were able to increase their growth rate and re-establish a high titre 
population after an initial period (2-3 MGT) of bactericidal kill whereas the faster growing 
mycobacteria maintained a lower titre population after the same magnitude of bactericidal kill. 
An increase in growth rate occurred after bactericidal kill, the reduction of the steady state 
population in the chemostat will have led to an increase of the carbon source, glycerol, allowing 
for growth rates higher than the imposed dilution rate. The slow growing bacteria may have 
been able to take advantage of this in the presence of isoniazid more so than the fast growers 
as the imposed fast growth rate (23.1 hour MGT) was close to µmax in this system. 
When the mechanism behind this relationship was investigated it was found that the two growth 
rates had very similar mutation rates, agreeing with work from other authors (Ford et al., 2011). 
The reason behind the ability of M. tuberculosis to grow in the presence of isoniazid was 
however different depending on growth rate. The majority of the mutant population recovered 
from the slow growing population of M. tuberculosis was mutated at the clinically relevant 
codon 315 of katG whereas only a small number of the fast growers possessed this mutation, 
the majority of the mutations in the fast growers were elsewhere in katG. This mutation at katG 
codon 315 did not appear to be imposing a fitness cost at the controlled doubling time of 69.3 
hours as the culture was able to grow and maintain a very high titre population within the 
chemostat.  Pyrosequencing of isoniazid relevant codons of katG and inhA allowed a rapid 
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method to screen for SNPs that may be contributing to the ability of M. tuberculosis to grow on 
isoniazid. The range of non-synonymous substitutions found in codon 315 of katG highlighted 
the importance of this gene and regions high in non-synonymous mutations have been shown 
to be strongly associated with antibiotic resistance (Shekar et al., 2014). This heteroresistance 
has also been demonstrated in clinical samples (Rinder et al., 2001). The absence of any SNPs in 
the region of inhA sequenced was in agreement with an observation that mutations in this gene 
are inversely associated with mutations in katG (Banerjee et al., 1994) as inhA over-expression 
may be at significant cost to the bacterium.  
The presence of katG codon 315 mutations predominantly in the slow growing population 
suggests that this was a mutation selected for during slow growth. It could be that this mutation 
does incur a fitness cost, perhaps the reduction in catalase activity and ability to tolerate 
oxidative stress, reducing the growth rate of the bacterium. This fitness cost may have reduced 
the ability of M. tuberculosis to grow at the faster doubling time but the slower doubling time 
of 69 hours may have been sufficient to nullify the fitness cost. The majority of mutations in the 
slow growers were in this codon of katG and not dispersed throughout the gene as in the fast 
growers. In contrast to the slow growing bacteria the fast growing M. tuberculosis was more 
susceptible to the concentrations of isoniazid above the MIC. The pyrosequencing results 
showed genetically wild type regions of katG codon 315 and the promoter region of inhA, the 
two regions that were sequenced were chosen because the frequency of mutations occurs in 
these regions at 70-80 %, in this study they have served to highlight the difference between 
growth rates. More recently, work done by Dr Irene Freire-Martin,  has shown that 65 out of 77 
isoniazid-resistant colonies that were wild type in KatG codon 315 isolated from the fast growing 
population (after 12-13 MGT) contained mutations elsewhere within the katG gene (Jeeves et 
al 2015) (section 5.4.1). This suggests that the KatG codon 315 mutation was selected for by 
slow growth and perhaps other alternative more deleterious mutations throughout the gene 
were lost (selected against), indicating that slow growing M. tuberculosis requires a functional 
KatG.  
7.5 Slow growing M. tuberculosis has more varied transcriptional regulation  
The continuous culture experiments also allowed RNA to be collected for transcriptomic 
analyses (chapter 6), which showed that there was more gene upregulation in general in the 
slow growing bacteria, including toxin-antitoxin genes, possibly serving as an alternative 
mechanism of transcription regulation. Further evidence for alternative regulation was the high 
ratio of upregulated antisense RNA, a mechanism enabling bacteria to rapidly adapt to changing 
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environmental conditions (Mehta et al., 2008). Antisense RNAs along with other non-coding RNA 
based mechanisms have been discovered through the use of high density tiling arrays and RNA 
sequencing (RNA-seq). In Mycobacterium tuberculosis 65 % of the genes have an antisense 
component corresponding to >10% of the coding transcript during exponential growth and this 
increases to >90% in stationary phase, the extent of this antisense transcription suggests that it 
may represent a common component of gene regulation in M. tuberculosis (Arnvig and Young, 
2012) and also other bacterial species such as Helicobacter pylori, Salmonella enterica and 
Pseudomonas aeruginosa to name a few (Sesto et al., 2012). Successful pathogenesis relies on 
the ability to adapt to unfavourable environments and to thrive in environments suited to 
bacteria replication, accumulation and detection of sRNAs linked to different stress regulons can 
inform on the response of the bacteria to these environments and support rational targeting of 
improved therapies (Arnvig and Young, 2012).  
In a study of the genetic requirements of fast and slow growth in mycobacteria it was shown 
that transcriptional regulators were responsible for control of growth rate, many of which have 
been implicated in virulence and persistence (Beste et al., 2009). The slow growing mycobacteria 
from the chemostats in this thesis adapted to isoniazid exposure via upregulation of methods of 
transcriptional regulation (section 6.4) such as antisense RNA and toxin-anti-toxin (TA) genes. 
TA systems allow a rapid change in the metabolic program of the bacteria (Ramage et al., 2009) 
and have been implicated in persistence (Lewis, 2012). Non-coding RNA in M. tuberculosis has 
been shown to have an association with genes implicated in pathogenesis and riboregulation 
may also be involved in the generation of persister cells (Arnvig and Young, 2012) perhaps it is 
this sub-population that are the most well adapted to virulence and persistence in vivo, a 
strategy that has been highlighted previously (Beste et al., 2007a). This transcriptional data 
along with the clinically relevant SNPs seen in katG codon 315 indicate that the slow growing 
population in this study are perhaps the most clinically relevant in terms of adaptation to the 
host environment and their response to isoniazid exposure. The chemostat has proven to be a 
method allowing isolation of clinically relevant populations of M. tuberculosis that can be 
thoroughly investigated over a timecourse at the high titres often seen in in vivo. 
7.6 Fast growing M. tuberculosis adapts with phenotypic adaptation along with more varied 
katG mutation 
Many of the mutations (frameshifts and deletions) found in the fast growers entirely disrupted 
the function of KatG, suggesting that a functional katG encoded catalase peroxidise is a 
requirement for slow growth but not fast growth. The transcriptomic data (sections 6.2.1 and 
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6.3.2) showed enrichment of gene expression involved in increasing the strength of the cell wall 
(fadD26, echA6), this could be a response due to the fast growing cells undergoing more cell wall 
damage by isoniazid or it could be an adaptation to decrease the permeability of the cell wall, 
making the entry of the isoniazid pro-drug more difficult. Further evidence for a phenotypic 
adaptation was upregulation  efflux pumps (mmr, efpA)  which have been shown to be involved 
in isoniazid efflux (Wilson et al., 1999) and efflux pump mediated resistance has also been 
demonstrated in M. tuberculosis (Gumbo et al., 2007). The faster growth rate imposed may itself 
have been advantageous in that the turnover of cell wall may have been fast enough to diminish 
some of the effect of isoniazid, the fast growers may have been more susceptible than the slow 
growers but were still able to adapt and maintain a population in the presence of isoniazid. Efflux 
pump mediated resistance may be transient and it is thought that this mechanism appears to 
serve only as a ‘stepping stone’ to high level resistance (Trauner et al., 2014). To fully investigate 
the role of efflux pumps in this population, an efflux pump inhibitor such as reserpine could be 
introduced as has been done to elucidate the mechanism of efflux pump mediated drug 
tolerance of M. tuberculosis previously (Colangeli et al., 2005). The possible loss of KatG function 
in the fast growers with frameshift/deletion mutations would prevent the conversion of the 
isoniazid pro-drug and lead to a mechanism of resistance, the combination of this strategy along 
with efflux pump upregulation and cell wall strengthening allowed the fast growers to persist 
through isoniazid exposure. The loss of KatG function would leave this population open to 
oxidative attack and perhaps this is the reason that the slow growing population was able to 
thrive rather than persist; they retained the catalase peroxidise activity of KatG enabling them 
to withstand oxidative attack.  
At both growth rates expression of ahpC and ahpD (alkyl hydroperoxide reductase subunits C 
and D) increased over time which could be hypothesised to be compensating for reduction or 
elimination of the function of KatG caused by mutation. The majority of the slow growing 
population had mutations at KatG codon 315 which as discussed earlier leads to lack of isoniazid 
activation but maintains some catalase peroxidise activity. At 2 mean generations after exposure 
transcription of ahpC was higher in slow growth than fast growth, this combination of a partially 
functional katG with ahpC may have given the slow growers an effective mechanism to combat 
oxidative attack. Mutations in ahpC have been detected in isolates with katG mutations and it 
has been suggested that changes to the ahpC promoter are not casually involved in isoniazid 
resistance, rather they act as compensatory mutations occurring as a consequence of reduction 
or loss of catalase peroxidase activity (Sherman et al 1996).  
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7.7 Future studies 
Isoniazid resistant mutants have also been shown to revert to wild type in the absence of 
selection pressure (Richardson et al., 2009). Further work in plating of the colonies isolated in 
the presence of antibiotic onto medium containing no antibiotic may show reversion to a wild 
type phenotype. Replacing the medium in the continuous culture with medium containing no 
antibiotic would also allow measurement of the changes to the population at a phenotypic and 
genotypic level and further add to the understanding of the nature of the resistance of both the 
slow and fast growing populations.  
Whole genome sequencing would determine whether there are any compensatory mutations 
for loss of KatG function in the fast growers and would allow other key isoniazid resistance genes 
such as inhA (Vilcheze et al., 2006) and ahpC (Seifert et al., 2015; Sherman et al., 1996) be 
visualised. Determining whether the fast growing populations have mutations in isoniazid 
resistance genes or in previously unidentified areas of the genome may highlight an alternative 
mechanism of resistance or indeed an epistatic relationship with the detected mutations. In 
many bacterial strains compensatory evolution has been shown to mitigate fitness costs 
associated with drug resistance mutations and it has been seen in rifampicin resistant isolates 
of M. tuberculosis (Borrell and Gagneux, 2009; Eldholm et al., 2015). Interrogation of the whole 
genome would give an unbiased read-out of mutation rates and compensatory mutations. 
Future work that would further elucidate the methods used by differing growth rate populations 
of M. tuberculosis would involve a investigating a range of drug concentrations within the 
chemostat, to look at the populations that would arise with a fluctuating level of isoniazid, 
similar to the exposure in vivo in patients treated for tuberculosis. It would also be interesting 
to model combinations of antibiotics within the chemostat to further elucidate the differing 
effects of isoniazid and rifampicin on M. tuberculosis and how they might work synergistically to 
clear specific populations of bacteria. This would be useful to model in both batch and 
continuous cultures to investigate the effects of growth phase and look at growth rate also.   
Continuous culture could also be powerful tool for characterising clinical mutants, it would be 
interesting to characterise clinically relevant mutations at different growth rates in the presence 
of single and combination therapy. This could help inform under what conditions these mutants 
arise, whether they thrive at a slow growth rate, in a particular environment such as low pH 
which has been demonstrated to be permissive to a wide range of mutations in rpoB causing 
resistance to rifampicin (Jenkins et al., 2009) or if a certain threshold of antibiotic concentration 
causes increased mutation. The ability to model and replicate clinical mutations strengthens the 
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chemostat model for investigating mechanisms of antibiotic persistence and resistance in 
clinically relevant bacterial strains. Using M. tuberculosis that has been isolated directly from 
patients may help characterise the effect of genetic background on resistance phenotypes as it 
has been shown that the genetic background of a strain of M. tuberculosis can influence the 
capacity of transmission even in strains with the same resistance mutations (Fenner et al., 2012) 
7.8 Conclusion 
The main aim of this thesis was to establish whether persisting populations of M. tuberculosis in 
the presence of antibiotic had adapted differently due to growth rate and whether the 
adaptation seen was due to phenotypic or genotypic mechanisms. Susceptibility profiles of M. 
tuberculosis did show a difference based on growth rate with the slower growing cells generally 
more recalcitrant to the effect of an antibiotic.  
 The reduced susceptibility of the slow growing bacteria appears to be due to specific 
genetic mutation at katG codon 315 and differing transcriptional regulation.  
o Any fitness cost associated with mutations in katG codon 315 were nullified 
initially by the imposed slow growth rate, it is possible that there was a large 
enough mutant population to survive even when the growth rate increased due 
to excess glycerol.  The slow growers may have been conserving energy by fine 
tuning transcriptional regulation as a stress response which may have led to 
increased genetic heterogeneity and could have served as a mechanism of 
survival for M. tuberculosis in the presence of isoniazid  
 Efflux pump upregulation and maintenance of KatG activity may help to explain the 
success of the fast growing population. 
o  The upregulation of efflux pumps in the fast growing population in this study 
could be an indication of how the higher level resistance occurs. Efflux pump 
mediated resistance can be transitional and a stepping stone for a higher level 
resistance by allowing mutants to establish a population. In vivo, the faster 
growing bacteria with efflux pump mediated resistance could facilitate a slower 
growing population to emerge with a genetic mutation; the genetic mutation in 
the slow growing population appears more specific and retains KatG activity 
perhaps explaining the success of this population in the presence of isoniazid. 
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